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Abstract 
Adoptive immunotherapy with genetically-engineered T-cells is showing 
promise in a clinical setting. However, this approach is limited by the 
requirement to generate autologous, patient-derived, T-cells, which is both 
costly and time-consuming. To address this, a methodology which would allow 
the generation of allogeneic universal T-cells would be highly beneficial. In this 
project, I have attempted to develop a protocol by which the following T-cell 
modifications will be introduced: (1) a chimeric antigen receptor (CAR), (2) a 
sort-suicide gene, (3) human leukocyte antigen (HLA) knock-down, (4) T cell 
receptor (TCR) knock-down (5) natural killer (NK) cell inhibition. Various 
strategies have been tested to attempt these modifications. Firstly, I knocked 
down HLA Class I by using two viral proteins, US11 and infected cell protein 
(ICP)-47, which give knock-down of 88% and 91% of HLA Class I expression 
respectively when tested in donor peripheral blood mononuclear cells 
(PBMCs). In a mixed lymphocyte reaction (MLR) with HLA mis-matched 
donors, US11 has clearly been shown to reduce the proliferation of effector 
PBMCs. To address rejection of HLA negative cells by NK cells, HLA-G has 
been cloned and expressed in cell lines and donor PBMCs to mimic the 
expression of HLA-G by trophoblast cells in the uterus and by certain cancers. 
TCR knock-down has been demonstrated in PBMCs, and CD52 knock-down 
has been achieved in a cell line by using DNA-editing transcription activator-
like effector nucleases (TALENs). A CAR can be introduced to redirect the T-
cells and a sort-suicide gene can be used to select modified cells and also 
provide a mechanism to deplete therapeutic cells in case of an adverse event. 
Some of these strategies have been combined with each other, with limited 
success.  
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1.1 Cancer 
 
Cancer is one of the most common causes of death globally, with one in four 
deaths in the US being due to cancer. In 2005, there were 7.6million deaths 
as a result of cancer, projected to rise to 11.4million by 2030 (Gavhane et al. 
2011). In the US, in 2014 alone, it is estimated that there will be over 1.6million 
new cases, and over half a million deaths from the top ten types of cancer. 
The lifetime probability of being diagnosed with an invasive cancer is 44% for 
men and 38% for women (Siegel et al. 2014). As treatments for other diseases 
improve and more people survive, cancer becomes a more prevalent disease 
and cause of death.  
Research and treatment of cancer stretches back for a couple hundred years, 
with Ephraim McDowell recorded as removing an ovarian tumour by surgery 
in 1809. Surgery was the main form of cancer treatment for almost a century 
until the era of radiation treatment that began in 1895 with the work of 
Roentgen and Pierre and Marie Curie. The cellular origin of cancer was 
discovered by Virchow in 1863. Chromosomal mutations in cancer were 
discovered by Boveri in 1914 and the National Cancer Institute (NCI) was set 
up in 1937. By the 1950s, only a third of cancers could be cured by the use of 
surgery, radiation or a combination of the two. Chemotherapy became 
available in the mid-1970s and now forms part of a three-pronged approach to 
tackling cancer. Despite the vast amount of research into cancer, its causes, 
symptoms and treatment, the relative survival rate only reached 68% in 2005, 
and some cancers are still as lethal as they were nearly 50years ago (DeVita 
& Rosenberg 2012). As with radiation and surgery though, chemotherapy is 
reaching the point where improvements in survival are difficult to achieve, and 
other avenues of treatment are being discovered. The most recent 
development is the use of monoclonal antibodies as targeted therapies, 
specifically targeting cancer-associated antigens. These have been shown to 
be highly effective when cancers express molecules differentially to healthy 
cells.  
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1.1.1 Solid Cancers 
 
Solid tumours are abnormal masses of tissue that can be benign or malignant. 
Examples are sarcoma, arising from bone or muscle tissue, lymphoma, 
originating from lymphoid tissue, spleen or thymus and carcinoma, deriving 
from epithelial or glandular cells. As stated earlier, the main treatments for 
these types of cancers are surgery, radiation, chemotherapy and monoclonal 
antibodies. The main difference between solid cancers and healthy tissue is 
the vasculature of the tumour, with tumour vascular environments often 
containing distended capillaries with slow blood flow and leaky walls, leading 
to hypoxic conditions (Brown & Giaccia 1998). Discussed below are the 
obstacles to treatment of solid tumours and strategies that have been 
employed to overcome them. 
 
1.1.2 Resistance to targeted small molecules 
 
Chemotherapy has been the main method of treatment for over 50years, and 
has been shown to be effective for some cancers. The drawback is the high 
levels of toxicity associated with this treatment. Drugs used in chemotherapy 
often have debilitating side-effects, such as nausea, hair loss and tiredness 
(Love et al. 1989). When targeting the tumour cells, small molecules are not 
usually completely effective. As a result, there are tumour cells that are 
resistant to the small molecule, and therefore, once treatment is stopped, 
these cells recommence proliferating and cause a relapse in the patient. The 
same small molecule is therefore ineffective for a second treatment as the cells 
are all resistant to it. One example of standard chemotherapeutic treatment is 
that used for diffuse large B cell lymphoma. This treatment is comprised of 
cyclophosphamide, doxorubicin, vincristine and prednisone (collectively 
known as the CHOP regimen). Due to tumour resistance, this has a low 
complete response rate of 40-50% and three-year survival rates of 35-40% in 
elderly patients (Coiffier et al. 2002). Trying to add further cytotoxic drugs has 
not proved successful, as they require the doses of cyclophosphamide and 
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doxorubicin to be reduced, as well as having a higher level of associated 
toxicity (Fisher et al. 1993). As most patients diagnosed with diffuse large B 
cell lymphoma are elderly, any increase in drug toxicity is not well tolerated, 
and it appears that this therapy, used alone, is close to reaching the limit of its 
effectiveness. 
Another obstacle to the use of small targeted molecules is the tumour 
microenvironment, which is often poorly vascularised and hypoxic. There are 
usually two types of blood vessels in the tumour – those around which the 
tumour formed initially, and those that have been generated as a result of 
neovascularisation caused by the tumour cells. As such, treatment of patients 
with solid tumours has had most success with antibodies that target antigens 
such as VEGF and EGFR (Scott et al. 2012). VEGF in particular has stood out 
as being promising as a target for anti-angiogenic treatment in tumours, either 
on its own, or in combination with molecules such as foetal liver kinase (Flk)-
1 (W. S. Lee et al. 2015). 
As well as the hypoxic environment, the poorly organised vasculature causes 
an increase in interstitial fluid pressure and an absence of fully functional 
lymphatics. The extracellular matrix (ECM) is also composed in such a way as 
to slow down movement of molecules within the tumour. This causes a 
reduction in the extracellular pH, again inhibiting efficacy of small molecule 
therapy. All of these factors combined together result in a limitation of small 
molecule distribution to tumour cells and often limit treatment to cells that are 
on the exterior of the tumour, or the cells closest to the vessels perfusing the 
tumour environment (Minchinton & Tannock 2006). Clearly solid tumours are 
difficult to treat and there are multiple obstacles standing in the way of an 
effective treatment, and whilst small molecules can be effective in certain 
cancer subtypes, they are very much limited as a general cancer treatment. 
 
1.2 Immunotherapy 
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A fairly recent development in tumour therapy has been the use of 
immunotherapy. This is designed to manipulate the patient’s own immune 
system and to augment the response elicited against tumour cells. Most 
commonly, autologous T cells are removed from a patient, and can be 
genetically modified to target cancer cells, or cancer-specific T cells can be 
expanded ex vivo before being reinfused to the patient. This has been shown 
to be successful in certain cancers, including melanoma, but requires 
immunogenic tumours in order to have tumour-reactive T cells to expand 
initially (Rosenberg et al. 2004). Other studies have shown that genetic 
manipulation by the introduction of native TCR or CAR transgenes can be 
successful at achieving tumour regression (Abad et al. 2008; Pule et al. 2008). 
Other cell types have been used in immunotherapy (Table 1), but T cells are 
the most studied and are effective at both cell killing and development of 
memory. Outlined below are some of the methods that have been used to 
exploit this recent avenue of cancer treatment. 
Table 1 – Cell types that have been used in immunotherapy 
Cell Type Advantages of cell type Reference 
B Cells 
Antibody factories, able to produce 
large quantities of fully human 
antibodies against target. 
Moutai et al. 2014 
Dendritic 
Cells 
Integral cells in modulating immune 
response. 
Most efficient cell type at 
processing and presenting 
antigens. 
Palucka & Banchereau 
2013  
Schuler et al. 2003 
NK cells 
Recognise multiple ligands that can 
induce a cytotoxic response. 
Short lifespan, do not require 
suicide mechanism. 
Ames & Murphy 2014 
Jewett et al. 2012 
T cells 
Potent killing mechanisms when 
activated by specific antigens. Able 
to develop memory and interact 
with other immune cell types. 
Kalos & June 2013  
Han et al. 2013 
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1.2.1 Check point inhibition 
 
The immune system is a surveillance system that constantly ‘scans’ and 
monitors the homeostasis of the body. Within this system, immune cells are 
either activated by foreign or ‘abnormal’ molecules, or they are inhibited by 
recognition of checkpoint molecules. By removing or inhibiting some of these 
checkpoint molecules, the immune system can be activated so that it does 
respond to tumour cells that might otherwise evade recognition.  
Two molecules that are involved as T cell checkpoint molecules are cytotoxic 
T-lymphocyte-associated antigen 4 (CTLA4) and programmed death protein 1 
(PD1). CTLA4 is exclusively expressed on T cells and interacts with the CD80 
and CD86 on antigen presenting cells (APCs), competing with the activatory 
CD28 molecule. CTLA4 dampens the T cell activation signal as well as 
providing inhibitory signals to the T cell (Linsley et al. 1994; Riley et al. 2002; 
Sharma et al. 2011). The importance of CTLA4 as an inhibitory molecule are 
clearly demonstrated in CTLA4 knockout mice, which display lethal systemic 
immune hyperactivation (Waterhouse et al. 1995). From this, it was discovered 
that partial blockade of CTLA4 was able to achieve anti-tumour responses 
when anti-CTLA4 antibodies were used in mice (Leach et al. 1996). This led 
to the development of ipilimumab, a monoclonal antibody, which showed a 3.5 
month survival benefit for patients with advanced melanoma compared to 
standard treatment without ipilimumab (Hodi et al. 2010).  
PD1 is involved in limiting the activity of T cells in peripheral tissues during 
inflammatory responses and in autoimmunity (Ishida et al. 1992; Keir et al. 
2006; Nishimura et al. 2001). PD1 expression is stimulated when T cells are 
activated, and inhibits kinases that are involved in T cell activation by the SHP2 
phosphatase (Freeman et al. 2000). This is predicted to alter the duration of 
synapse formation, potentially reducing the overall activation signal (Fife et al. 
2009). In contrast to CTLA4, PD1 is more widely expressed on B cells and NK 
cells, which also limits their lytic capabilities. Therefore, blockade of PD1 would 
likely affect B cell and NK cell activation also (Terme et al. 2011; Pardoll 2012). 
When testing anti-PD1 antibodies in Phase I clinical trials, initial results are 
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promising, with a mixture of mixed, partial and complete responses (Brahmer 
et al. 2010). There are other checkpoints that are yet to be, or currently 
undergoing, investigation. To broaden targets for treatment, it is also possible 
to target both the ligand-receptor pair of molecules. This has been 
demonstrated with PD1 and its ligand programmed death ligand (PDL)-1, 
where both receptor and ligand antibodies have been developed and tested in 
separate clinical trials with some clinical responses shown (Brahmer & Pardoll 
2013). In recent months, several clinical trials have published data for anti PD1 
therapies, including nivolumab, pembrolizumab and pidilizumab. These have 
all shown positive data, where overall response rates (ORRs) and/or overall 
survival (OS) rates have increased when treating patients with metastatic 
melanoma or advanced melanoma (Sznol et al. 2013; Ribas et al. 2013; Atkins 
et al. 2014). Both nivolumab and pembrolizumab were granted FDA approval 
in the last quarter of 2014 (Homet Moreno et al. 2015).   
 
1.2.2 Tumour infiltrating lymphocytes 
 
Tumour infiltrating lymphocytes (TILs) are white blood cells found in tumours. 
They comprise of various subtypes of lymphocytes, but are known to contain 
tumour-reactive T cells (Holmes 1985; Dudley et al. 2008). It is possible to 
extract these TILs and to expand them ex vivo before giving them back to the 
patient. The protocol for this requires isolation of TILs from patient biopsies 
followed by progressive selection of tumour-reactive cells using high levels of 
IL-2 and other cell culture techniques (June 2007). Success has been shown 
in the use of TILs to treat metastatic melanoma, with partial and mixed 
responses obtained. Thirteen patients were pre-conditioned with the 
immunosuppressive drug combination of cyclophosphamide and fludarabine, 
followed by treatment with TILs. Six patients had partial responses; four had 
mixed responses (Dudley et al. 2002). Importantly, prolonged engraftment was 
demonstrated compared to patients who did not receive pre-conditioning 
therapy, demonstrating the efficacy of combination treatments contrasted to 
single strategy therapies. A recent study has also shown the efficacy of TILs 
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in generating tumour responses against cervical cancer, where T cell 
populations were chosen based on oncoprotein reactivity, T cell growth rate 
and CD8+ T cell number. Three of seven patients demonstrated tumour 
responses; two demonstrated complete and ongoing tumour regression at 
three and nine months after treatment (Hinrichs et al. 2013). 
There are drawbacks to this therapy though. Less than 50% of biopsies yield 
usable T cell populations and the T cell expansion protocol is both cytokine-
intensive and takes up to six weeks (Pedrazzoli et al. 2012; Dudley et al. 
2003). In the study by Hinrichs et al. (2013), adverse events were seen due to 
the toxicities of the preparatory immunosuppressive treatment and the IL-2 
administered alongside the TILs. Administration of TILs, therefore, seems to 
carry risks of toxicity as wells as taking a long period of time to generate them 
in the first place.  
More recently, instead of a therapy, TILs have been used as an indicator of 
therapeutic success of other treatments. The presence of TILs indicates an 
immune system that is primed to react to the tumour and is easier to trigger 
using therapeutic regimens compared to an immune system that contains low 
or no TILs. It has been suggested that TILs could be used as part of a 
prognostic analysis in squamous cell carcinomas of the head and neck 
(SCCHN), oropharyngeal squamous cell carcinoma (OSCC), triple negative 
breast cancer (TNBC) and predictive for the effects of trastuzumab in early 
breast cancer (Jones 2014; Loi et al. 2014; Adams et al. 2014).  
 
1.2.3 T cell receptor transfer 
 
TCR transfer was developed to overcome some of the shortcomings of TILs. 
By having a transgenic TCR ready to introduce to donor or autologous T cells, 
any T cells can be extracted and modified quickly, with protocols as short as 
two to three days possible depending on the method of gene transfer used. 
Use of transgenic TCRs also allows for the use of TCRs that are not normally 
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found in the endogenous TCR repertoire, providing a wider range of targets 
than possible with therapies such as TILs (Schumacher 2002).  
The first co-transfer of α and β chains from a TCR to confer specificity against 
an antigen by polyclonal T cells was performed by Dembić et al. (1986). The 
main restriction on the use of TCRs is on the HLA typing. Since HLA-A2 is the 
most common HLA type in the Caucasian population and HLA-A24 is the most 
common HLA type in the Japanese population, TCRs restricted to these HLA 
molecules have been widely investigated (Casucci et al. 2012). Abad et al. 
(2008) have shown, in developing a murine melanoma model, that transgenic 
expression of a TCR specific for a cancer antigen can also be used as a 
method of therapy. Since then, a study has shown that autologous 
lymphocytes that express a TCR against a tumour-associated antigen (TAA) 
are able to mediate tumour regression (Rosenberg et al. 2008). TCRs have 
also been generated against the WT1 antigen, the minor histocompatibility 
antigens HA-1 and HA-2, melanoma antigen recognized by T cells (MART)-1, 
glycoprotein (gp)-100, NY-ESO-1 and p53 (Xue et al. 2010; Mommaas et al. 
2005; Morgan et al. 2006). 
Another limitation of TCR transfer is the risk of the α and β chains cross-pairing 
with endogenous TCR chains, leading to exogenous-endogenous TCR chain 
pairing. This could result in a lower avidity for the target of choice, as well as 
having the potential to create auto-reactive TCRs, which has been 
demonstrated in a mouse model with lethal cytokine-driven toxicity (Bendle et 
al. 2010). This risk can be minimised by strategies such as the use of codon 
optimisation, small interfering ribonucleic acid (siRNA) to reduce endogenous 
TCR expression or introducing a cysteine pair to the transgenic TCR (Kuball 
et al. 2007; Okamoto et al. 2009; Schumacher 2002).  
 
1.2.4 Chimeric antigen receptor transfer 
 
CARs, in comparison to chemotherapy, radiotherapy and mAbs, are a 
relatively recent development. They comprise the heavy (VH) and light (VL) 
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variable fragments from an antibody, joined by a short linker, to form a single 
chain variable fragment (scFv). This is attached to a spacer region to protrude 
the molecule from the cell surface. This is attached to a transmembrane 
domain (TMD), which is then subsequently attached to one or more 
intracellular activation domains. These may be immunoreceptor tyrosine-
based inhibition motifs (ITIMs) or immunoreceptor tyrosine-based activation 
motif (ITAMs) depending on what intracellular signalling pathway is being 
activated or inhibited. First generation CARs contained one intracellular 
signalling domain, with second generation CARs containing one additional 
costimulatory domain, and third generation CARs containing two costimulatory 
domains. First generation CARs showed limited efficacy, but lacked in vivo 
persistence and activity. Second and third generation CARs have been 
created to resolve these issues, and many different combinations of 
intracellular costimulatory domains are in clinical trials, which will help 
determine the most effective combination (Dotti et al. 2009). Most commonly 
used are the CD3ζ, CD28, OX40 and 41BB intracellular signalling domains. 
These constructs are introduced into T cells through the use of viral carriers, 
and then are used to re-direct the antigen specificity of the T cell (Willemsen 
et al. 2004).  
CARs are able to target cell surface antigens without needing major 
histocompatibility complex (MHC) recognition (Sadelain et al. 2009). As such, 
they are able to modify most subsets of T cells with ease, leading to increased 
persistence and improved development of memory (Curran et al. 2012). In 
addition, they are not restricted to recognition of protein-derived peptides, they 
can recognise every cell surface molecule on a target cell, including nonprotein 
structures such as gangliosides and carbohydrate antigens (Mezzanzanica et 
al. 1998).  
One clinical trial in 2008 was able to modify Epstein-Barr virus (EBV)-specific 
cytotoxic lymphocytes (CTLs) with an anti-GD2 CAR. The stimulation provided 
by the EBV-CTLs, along with the anti-GD2 CAR, resulted in enhanced activity 
and persistence of the transferred cells, and tumour regression was shown in 
half of the patients treated (Pule et al. 2008). A more recent clinical trial has 
shown that anti-CD19 CARs, generated using a 10day protocol, have been 
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successful at mediating five complete remissions and six partial remissions 
out of fourteen patients receiving pre-conditioning therapy followed by CAR 
infusion, without the addition of exogenous IL-2 (Kochenderfer et al. 2013). A 
recent clinical trial into the treatment of ALL has shown high levels of efficacy 
as a result of autologous aCD19-CAR-modified T cells, with complete 
remission (CR) demonstrated in 90% of patients. Durable remissions were 
seen for up to 24months, and treatment showed efficacy even amongst 
patients who had undergone failed stem-cell transplantation (Maude, Frey, et 
al. 2014). This clearly shows the vast potential of CAR-mediated therapy and 
its benefits of high affinity molecules, lack of HLA restriction, reduced toxicity, 
shortened cell manipulation time, and functional efficacy in vivo. 
 
1.3 Other cancer therapies 
 
Current treatments for B cell malignancies include chemotherapy, 
radiotherapy, monoclonal antibodies and CAR therapy. Combination therapy 
of two or more of these strategies often proves to increase the efficacy of the 
treatment, but care has to be taken to ensure that the effects of toxicity do not 
outweigh the benefits achieved through combination therapy. The combination 
of trastuzumab, paclitaxel and carboplatin treatment for women with HER-2–
overexpressing metastatic breast cancer (MBC) was evaluated in a phase III 
clinical trial and demonstrated to increase ORR and PFS in patients who were 
treated in this trial (Robert et al. 2006). So while individual therapies on their 
own have limitations, the combination of the therapies described below still 
has potential to ensure that cancerous cells can be targeted from as many 
directions as possible. There are multiple molecules that have been selected 
for targeted therapy of B cell malignancies, including CD20, CD23 and CD52, 
mainly using monoclonal antibodies (mAbs) (Schnaiter & Stilgenbauer 2010). 
CD19 and CD20 are expressed on B cell lineage cells, CD23 on follicular B 
cells and CD52 on mature lymphocytes. Currently, the main antigen targeted 
by various therapies is CD19. 
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1.3.1 Radiotherapy 
 
Another form of cancer therapy is to use radiotherapy to destroy cancerous 
cells by inducing deoxyribonucleic acid (DNA) damage. The main drawback 
with this treatment is that there is no discrimination between healthy cells and 
cancerous cells if ionizing radiation is used. Chronic lymphocytic leukaemia 
(CLL) is very sensitive to radiotherapy in the early stages of disease (I-II). Most 
patients, however, are diagnosed with stage III-IV disease, which is much 
more resistant (Jóhannsson et al. 2002). Total body irradiation (TBI) has been 
a common treatment, but has not been shown to be any more effective than 
chemotherapy. Radiotherapy has commonly been used to treat breast cancer, 
and has been shown to be effective, but has increased risks of cardiac and 
pulmonary toxicity, amongst other side effects (Brown et al. 2015). There are 
also limitations on the size of tumours that can be treated with radiotherapy. 
In an investigation into the incidence of adverse radiation effects after radiation 
therapy for brain metastases, risk increased rapidly with an increased size of 
lesion and tumour, demonstrating another limitation of this type of treatment 
(Sneed et al. 2015).  
 
1.3.2 Monoclonal antibodies 
 
Monoclonal antibodies (mAbs) are commonly derived from antibody-producing 
hybridoma cells. A study in 1976 demonstrated that antibodies could be 
produced against any antigen and this was followed by the ability to fuse 
antibody-producing cells from mice with myeloma cells to create hybridomas 
(Klinman et al. 1977; Köhler & Milstein 1975). Over time, more mAbs have 
been discovered and developed, and if derived from a non-humanised 
platform, they can now be modified and humanised through genetic 
engineering to be 95% human (O’Mahony & Bishop 2006). mAbs can also be 
isolated from donors who have been exposed to high levels of antigens, such 
as nursery workers, who have been shown to have high titres of viral-specific 
B cells as a result of exposure (Chan-Hui 2013). Animal models can be 
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generated that produce fully human antibodies, using technology developed 
by companies such as Kymab Ltd., who have mice with a fully human antibody 
repertoire (Lee et al. 2014). These mAbs can be conjugated or unconjugated 
to another molecule. Unconjugated antibodies carry out their effects through 
complement-dependent cytotoxicity (CDC) or antibody-dependent cellular 
cytotoxicity (ADCC), by blocking receptor-ligand interactions or by inducing 
cellular death. Conjugated antibodies are used as carriers for various 
molecules, including radioactive isotopes, as mentioned in the previous 
section, in order to deliver them to the antigen of choice. It is also possible to 
conjugate toxins, which can then be internalised and carry out their effects.  
In the treatment of B cell malignancies, multiple mAbs have been used, 
including ibritumomab, rituximab and alemtuzumab. In order to choose the 
best antigen to target, a mAb needs to meet three main criteria. Firstly, it needs 
to be almost exclusively expressed on the cell of choice, to reduce or prevent 
the risk of on target, off-site toxicity. Ideally, the antigen also needs to be a 
molecule that has constant surface expression levels to ensure effective 
depletion of the target cells. Finally, the antigen should not have soluble forms 
otherwise the mAb will have further off-site activity and reduce the 
effectiveness of treatment. 
Rituximab targets the CD20 antigen. It is a combination of the murine variable 
regions from the ibritumomab, with the human immunoglobulin (Ig)-G1 
constant regions (Golay et al. 2000). It works through CDC, ADCC, inhibiting 
proliferation, inducing apoptosis and sensitising cells to chemotherapeutic 
agents (Demidem et al. 1997). In 1998, it was the first mAb approved by the 
FDA for use in cancer treatment. A study by McLaughlin et al. (1998) showed 
an overall response rate (ORR) of 48%, with 42% partial remissions (PR) and 
6% complete remissions (CR). A small percentage of patients remained in 
remission that was unmaintained for more than five years.  
Alemtuzumab is a humanised IgG1 mAb that targets CD52, which is 
expressed on mature B cells and T cells as well as spermatozoa. Most B cell 
neoplasms express the CD52 antigen, including B cell CLL. Alemtuzumab 
mediates its effects by ADCC and CDC. In comparison to rituximab, 
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alemtuzumab does not require complement activation in order to deplete 
CD52-expressing cells (Golay et al. 2002). As a result, it is not as effective as 
rituximab if using cell lysis as the outcome. It has been combined with 
rituximab in clinical trials, and has been shown to be useful in the control of 
graft-versus-host-disease (GvHD) after allogeneic haematopoietic stem cell 
transplantation (HSCT) (Kottaridis et al. 2000).  
 
1.3.3 Recombinant immunotoxins 
 
Recombinant immunotoxins (RITs) are fusion proteins, where the cell-binding 
protein of a bacterial toxin has been replaced by the variable fragment (Fv) of 
a mAb. The heavy and light chains from an antibody are linked together by a 
flexible peptide linker or they are stabilised by a disulphide-bond. This is then 
fused to the immunotoxin of choice and then cloned into an expression vector. 
Proteins are expressed and prepared in inclusion bodies, which are then used 
to treat target cells. This results in being able to use the toxicity of a bacterial 
toxin and the targeting of an antibody to target cancer cells. The toxins used 
can be very potent and they can kill cells that are otherwise resistant to 
chemotherapy (Pastan & Ho 2010). One toxin, Pseudomonas exotoxin A 
(PEA), has been in clinical trials with CD22 and CD25 targeting Fvs, as well 
as mesothelin-expressing solid tumours (Kreitman et al. 2001; Kreitman et al. 
2000; Hassan et al. 2007).  
 
1.3.4 Radioimmunotherapy 
 
Combining radiotherapy with mAbs has proven to give higher response rates 
than using them individually. To try and reduce off-target effects, recent 
treatments have attached a radioactive isotope to an antibody targeted to a 
cancer antigen to develop radioimmunotherapy as a combination treatment 
(Witzig et al. 2002). This treatment uses the antibody as a carrier molecule to 
distribute the radioactive isotope to the cancerous cells. It requires an antibody 
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that targets an antigen that is specific to the cancer cells. As a result, much of 
the ionising radiation will be received by the cancerous cells, but there will still 
be some damage caused to healthy cells as the antibody travels through the 
body to the target site. 
Ibritumomab is a murine mAb which targets the CD20 antigen, which is 
expressed by all B cell lineage cells, but not on early progenitor lymphocytes 
(O’Mahony & Bishop 2006). CD20 is stably expressed on the cell surface and 
is not prevalent as a soluble molecule, making it a good candidate for B cell 
targeting. Ibritumomab tiuxetan was the first radiolabelled mAb to be approved 
by the US Food and Drug Administration (FDA) in 2002 for therapeutic use, 
using yittrium 90 (90Y) as the radioisotope. In a study by Knox et al. (1996), 
patients were pre-treated with unconjugated ibritumomab before being treated 
with up to 50mCi of labelled mAb. This resulted in minimal haematological 
toxicity and promising clinical responses. Progression-free survival (PFS) was 
72% for 3-29+ months and 78% PFS for doses of up to 40mCi. When 
compared to rituximab, the ORR was higher (80% compared to 56% for 
rituximab), and the CRs were higher (30% compared to 16% for rituximab) 
(Witzig et al. 2002). 
 
1.4 Creation of a universal T cell 
 
Although there has been much recent progress in the treatment of cancer, 
patients can go on to develop a chemotherapy-resistant disease. Older 
patients suffering from acute lymphocytic leukaemia (ALL) also have a low 
chance of survival, although this is not the case for children treated with T cells 
expressing a CD19 CAR (D. W. Lee et al. 2015). Single therapy is reaching 
the limit of its effectiveness and combination therapy has been shown to be 
more effective in the treatment of malignancies and in providing sustained 
protection against relapse. Adoptive immunotherapy is an attractive avenue to 
explore in order to develop these treatments further in malignancies such as 
CLL and ALL. 
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Adoptive immunotherapy with genetically engineered T-cells is showing much 
promise. Adoptive immunotherapy is the use of immune cells to elicit an 
immune response against a target; in this case, cancerous cells. Theoretically, 
creating a cell-based product is the least toxic treatment that can be developed 
as its aim is to closely mimic the mechanisms of action of the immune system. 
In a healthy individual, T cells move through the body scanning for MHC-
peptide complexes that activate their TCRs. In the case of infection, peptides 
are recognised as being foreign, allowing an immune response to be activated. 
In the case of cancer, the affected cells predominantly express self-peptides 
or down-regulate MHC expression, and are therefore unlikely to be recognised 
by T cells or APCs. There are some tumour-reactive T cells that are most likely 
activated by tumour-associated antigens (TAAs) presented by APCs, and 
adoptive immunotherapy aims to either augment this immune response or 
provide cells that can mimic this (Restifo et al. 2012). 
 
1.4.1 Steps required in creating a universal T cell 
 
At present, a bespoke therapeutic T-cell product has to be made for each 
patient either from autologous cells, or in some protocols which involve HSCT, 
from an allogeneic donor. Using autologous cells has problems: patients may 
not have healthy, readily-available T cells to isolate and transduce, especially 
if they are immuno-compromised, usually as a result of disease or 
lymphodepletion. This includes the additional risk of obtaining and engineering 
malignant cells, potentially increasing the persistence of the related 
malignancy in the patient. This method also requires a different cell product to 
be made for every patient (Abken et al. 1998). It can take several weeks for T 
cells extraction, in vitro manipulation and clinical preparation of the cells before 
they can be administered back to the patient. From an allogeneic donor, cells 
are more likely to be disease-free, but have the obstacle of HLA-restriction, 
the risk of GvHD, along with the possible need for immunosuppression 
(Vonderheide & June 2014). Cell numbers required for these therapies vary 
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depending on cell source and efficacy, but typically range from 106-108/kg 
(Drobyski et al. 1993; Grupp et al. 2013; Doubrovina et al. 2012). 
Adoptive cell therapy (ACT) has already shown promise in clinical situations 
for infections and malignancies. Graft versus leukaemia (GvL) has been 
shown in HSCT (Randolph et al. 2004), tumour-infiltrating lymphocytes have 
been used against metastatic melanoma (Rosenberg et al. 1988), and a 
clinical trial into neuroblastoma has shown that ACT can reconstitute EBV 
immunity following HSCT (Dudley & Rosenberg 2003). Despite this, it is 
relatively difficult to generate an effective, homogenous therapeutic T cell 
product using traditional methods of selection and expansion. The problem 
with using these methods is that cell viability drops off very rapidly once they 
have been removed from the in vivo context. Having to carry out multiple 
rounds of selection on this product then means that the cell product is non-
homogenous and the quantity of healthy, re-directed cells is minimal. Gene 
therapy opens several other possibilities for incorporation of various elements, 
such as resistance genes, homing genes and suicide genes to allow for 
sorting, engrafting and selective deletion of therapeutic cell products (Grignani 
et al. 1998). It also allows the use of integrating and non-integrating vectors to 
re-direct cell products, which are relatively straight-forward to generate and 
introduce into cells. 
Gene therapy is not without its own drawbacks.  By transferring T cells in an 
allogeneic setting, there is the risk of GvHD, caused by the endogenous TCR 
expressed on the therapeutic cells, along with the rejection of the therapeutic 
cells via the recognition of mis-matched HLA (major and minor), by the 
recipient’s immune system. CARs have the risk of being immunogenic, with 
anti-CAR antibody responses observed, ranging in severity (Sadelain et al. 
2009). The CAR may also cause some toxic off-target effects, so target 
selection has to be robust. The method of genetic integration used also comes 
with some associated problems. Retroviral and lentiviral vectors are the two 
most common integrating methods used in gene therapy. They do carry with 
them the danger of insertional mutagenesis, which can potentially cause the 
initiation of leukaemia, although this risk is minimal (Uren et al. 2005). The 
advantage of these vectors is that they have a relatively large packaging 
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capacity, meaning that it is possible to incorporate multiple elements into one 
vector. In recent years, the development of third generation CARs, along with 
research into suicide genes and the discovery of new potential cancer targets, 
has allowed the potential of ACT to grow. Combined with improvements in 
methods of gene delivery, ACT has now become a realistic alternative to drug 
development. 
 
1.4.2 Obstacles to creating a universal T cell 
 
In order to create a universal T cell, several obstacles need to be overcome. 
These include GvHD caused by allogeneic T cells, NK-mediated null cell killing 
of HLA-null T cells, host immune response to allogeneic cells, re-direction of 
the T cell towards a TAA, selection of modified cells to create a homogenous 
cell product and a mechanism to deplete therapeutic cells in case of severe 
adverse events, including GvHD. These all involve the assembly and testing 
of constructs aimed at resolving these issues, which is the aim of this project. 
 
1.4.3 Graft-versus-Host Disease 
 
Since the 1950s, stem cell transplantation (SCT) has been investigated as a 
treatment for patients following radiotherapy or chemotherapy. Before this, it 
was known that while aiming to achieve haematopoietic recovery, 
transplantation of splenocytes from noncongenic donor strains caused severe 
illness in mice and guinea pigs, displaying weight loss, diarrhoea and a 
hunched posture (Lorenz et al. 1951). Since, it has become clear that this is 
due to an immune-mediated activity (Wolf et al. 2012). Pre-conditioning before 
SCT is used to treat malignancy and to suppress the immune system of the 
recipient to prevent graft rejection. Allogeneic SCT involves using cells from 
matched or mis-matched donors and provide an additional graft-versus-
tumour (GvT) effect in some cases. In GvHD, immunocompetent donor cells 
recognise host cells as foreign. Therefore, the greater the HLA mis-match 
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between donor and recipient, the greater risk there is of GvHD (Hymes et al. 
2012).  
GvHD can be classified as being either acute or chronic. Acute GvHD has 
been traditionally defined by the onset of symptoms within the first 100days of 
a transplant, with chronic GvHD defined as showing symptoms more than 
100days post-transplant. With the development of transplant protocols and 
varying conditioning regimens, there has been a need to revisit these 
definitions. Acute GvHD may present after 100days and in patients treated 
with donor lymphocyte infusions (DLIs), symptoms of acute and chronic GvHD 
can be present together (Filipovich et al. 2005). Complications in diagnosis 
arise from the need to eliminate other causes for symptoms, such as infections 
and drug toxicities.  
Animal models have been used to gain a clearer understanding of the 
pathophysiology of acute GvHD. From these models, a three-stage process 
has been derived. Firstly, tissue damage, as a result of conditioning 
chemotherapy or radiotherapy, occurs. This leads to a release of inflammatory 
cytokines. Secondly, from the graft, mature lymphocytes enter into this 
environment, leading to their activation and proliferation upon encountering 
host and donor APCs. Thirdly, alloreactive T cells proliferate into cytotoxic T 
cells that cause tissue damage and further cytokine release (Ferrara et al. 
2009).  
The pathophysiology of chronic GvHD is much harder to understand due to a 
lack of suitable animal models that replicate the complex conditions. The 
current models are often based on autoimmune disease models, which involve 
isolated organ involvement as opposed to the multi-system effects of GvHD. 
It is known that GvHD has an abundance of detectable autoantibodies, 
including antinuclear, double-stranded DNA and smooth-muscle antibodies 
(Quaranta et al. 1999).  This is a similar scenario to that found in classic 
autoimmune diseases such as systemic lupus erythematosus and rheumatoid 
arthritis (Ippolito et al. 2011; Song & Kang 2010). 
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1.4.4 Host immune response 
 
In the case of SCT, HSCT or solid organ transplant, host T cells recognise the 
foreign HLA peptides expressed on donor cells, causing an immune response. 
The large HLA locus encodes genes for Class I, II and III MHC, which are 
responsible for presenting intracellular antigens (Class I), extracellular 
antigens (Class II)  and activation of the complement system (Class III) (Hewitt 
2003; Neefjes et al. 2011; Carroll et al. 1984). Recognition of foreign HLA by 
the recipient would trigger an immune response and destruction of the 
therapeutic T cells, negating any potential therapeutic effect that they may 
have had. 
There are two main mechanisms by which this occurs. Firstly, ‘direct’ 
allorecognition, where T cells are activated by intact HLA molecules on donor 
APCs. Secondly, there is ‘indirect’ allorecognition, where T cells recognise 
foreign peptides that have been presented on self APCs. This indirect 
recognition is the same mechanism used in response to a viral or bacterial 
infection. The mechanism of direct recognition is specific for allogeneic 
transplants. Semi-direct recognition is also believed to be involved, where 
intact donor MHC molecules are transferred from donor cells to recipient 
dendritic cells (Podestà et al. 2015; Bolton & Bradley 2015). 
Direct allorecognition is most likely to occur early after transplantation. Host 
helper T cells get into contact with donor APCs. This process takes 
precedence over indirect recognition at this stage due to the large number of 
T cells that recognise unprocessed foreign MHC-peptide complexes (Douillard 
et al. 1999; Auchincloss Jr & Sultan 1996; Benichou & Thomson 2009). A 
study by Benichou et al. (1999) demonstrated that over 90% of the response 
by T cells was directed to intact MHC molecules, while T cells going by the 
indirect recognition pathway were below 10%.  
Later on after the elimination of donor APCs (mainly dendritic cells), the 
balance shifts from direct to indirect allorecognition. The recipient APCs 
infiltrate the donor graft and process allo-antigens (Harris et al. 1999; Ali et al. 
2013). Studies have demonstrated that peptides derived from MHC molecules 
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make up a substantial portion of the naturally processed antigens that are 
presented by APCs (Shoskes & Wood 1994; Breman et al. 2014). This was 
further demonstrated when MHC Class I knock-out mice were shown to be 
able to reject skin grafts from MHC Class II knock-out mice. The recipient mice 
lacked CD8+ cytotoxic T cells capable of direct MHC Class I recognition, but 
did have CD4+ helper T cells that were stimulated indirectly by antigen 
presented in the context of MHC Class II molecules on APCs (Auchincloss et 
al. 1993).  
Since helper T cells mainly recognise antigen presented on MHC Class II 
molecules, and cytotoxic T cells recognise antigen presented on MHC Class I 
molecules, it has been postulated that if the mis-match between donor and 
recipient is mainly based on HLA Class I, then the cytotoxic T cell response 
will be stronger and the direct allorecognition pathway will be dominant; 
conversely, if the mis-match is mainly in the HLA Class II alleles, then the 
helper T cell response will be stronger and the indirect allorecognition will play 
a larger role in the allograft rejection (Slavcev 2001).  
 
1.4.5 Natural Killer cell-mediated killing of HLA class I null cells 
 
NK cells have a range of activating and inhibitory receptors, with relevant ITAM 
or ITIM domains, to enable a range of functions. Receptors with ITAMs include 
the killer-cell immunoglobulin-like receptor (KIR)-2/3DS family, CD16 and 
CD94. Receptors with ITIMs include the KIR2/3DL family, NKG2A and T cell 
immunoreceptor with Ig and ITIM domains (TIGIT). There are still further 
receptors with unknown ligands and functions (Bryceson et al. 2011). 
Originally thought to be large granular lymphocytes, NK cells are now known 
to be of a separate lineage (Vivier et al. 2008). They have cytotoxic capabilities 
through the use of perforin-dependent cell killing and they are also able to 
produce cytokines (Trinchieri 1989). They patrol the body scanning for 
activating antigens, or for self-MHC molecules that will prevent activation and 
inhibit release of lytic granules. If they interact with a cell that is not expressing 
a HLA Class I molecule (a ‘null’ cell), they will be activated. This seems to be 
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a fairly robust mechanism, especially as various cancers down-regulate HLA 
Class I, including acute myeloid leukaemia (AML), ALL and CLL, yet these 
tumours manage to avoid NK cell killing through the expression of a non-
classical HLA molecule, HLA-G (Menier et al. 2008; Nückel et al. 2005; Mizuno 
et al. 2000; Poláková et al. 2003). There are also some healthy cells that do 
not HLA Class I molecules, but avoid NK cell killing, including trophoblasts, 
which express HLA-G (Hunt & Langat 2009; Schust et al. 1998). NK cells are 
also activated by upregulation of activating ligands, which interact with the 
NKG2D receptor. Cancerous cells are also able to suppress expression of 
these ligands also (Eisele et al. 2006; Mincheva-Nilsson & Baranov 2014). 
There are two main subsets of NK cells, CD56dim CD16+ and CD56bright CD16+ 
NK cells. The CD56dim CD16+ NK cells make up around 90% of the NK cells 
in peripheral blood and the spleen. These cells express perforin, are cytotoxic 
and produce interferon (IFN)-γ upon encountering tumour cells (Anfossi et al. 
2006). The CD56bright CD16+ NK cells lack perforin and are mainly located in 
lymph nodes and tonsils and primarily express cytokines, including IFNγ upon 
stimulation with IL-12, IL-15 and IL-18 (Ferlazzo & Münz 2004; Cooper et al. 
2001).  
NK cell recognition is a complex process that involves a combination of 
activating and inhibitory interactions. The integration of these interactions and 
the subsequent signals determine on whether the NK cell detaches or whether 
it responds (Lanier 2005). As explained above, this response can be to 
produce cytokines, or to cause polarisation of lytic granules to the 
immunological synapse, which are then released onto the membrane of the 
target cell. NK cells differ from naïve T cells in that they are prepared to 
respond with prestored cytokines, lytic granules and granzymes, all of which 
can be released within minutes (Stetson et al. 2003). NK cells have a vast 
array of receptors, of which only a few ligands are well characterised. As a 
result, the complete mechanisms of NK cell action are not fully known, 
including how NK cells interact with other cells of the immune system during 
immune responses, the detachment of NK cells to allow serial killing to 
progress, and how activation thresholds are determined (Lanier 2005; 
Bryceson et al. 2011). 
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1.4.6 Re-direction of T cells 
 
In T cell immunotherapy, there are two main routes to obtain T cells that are 
specific for a TAA. Firstly, T cells can be extracted and exposed to the TAA. 
This will cause tumour-specific T cells to divide and multiply. The drawback to 
this is that it is time-consuming, costly and causes the T cells to age, reducing 
their efficacy when reinfused. Secondly, gene transfer techniques can be used 
to introduce native TCRs (nTCRs) or CARs. These molecules target a specific 
TAA and cause the modified T cell to activate upon interaction with their target. 
This technique is quicker and enables all modified T cells to be reinfused.  
TCRs are heavily expressed on T cells, each having been selected during 
differentiation of immune cells to react to foreign peptides and to allow 
tolerance of self-peptides. The huge variability in specificity caused by random 
splicing of the variable regions, forming the basis of the immune system. This 
is obviously beneficial in terms of health, but when using adoptive transfer of 
allogeneic cells, it can be a complex barrier to negotiate. nTCRs are MHC-
restricted molecules, and are therefore limited to recognising antigens in the 
context of HLA molecules, either expressed on the tumour cell surface or on 
APCs. In contrast, CARs are not MHC-restricted, and can respond to tumour 
cells that have often down-regulated their MHC expression. As a result, this 
technology has the capability to recognise any cell surface molecule, including 
glycolipids, carbohydrates or soluble ligands. CARs are unable to access 
intracellular antigens though, and they are limited to using characterised 
antibodies. 
The first effective use of nTCRs being used to target a TAA was demonstrated 
when using complementary DNA (cDNA) for a TCR specific for the m9-27 
peptide of MART1 to target melanomas. Human donor peripheral blood T 
lymphocytes (PBLs) were engineered with this cDNA, and CD8+ T cells 
generated from HLA-A2+ donors were shown to lyse HLA-A2+ melanoma cells 
in vitro (Clay et al. 1999). As previously mentioned, this strategy needs to be 
in the context of MHC-peptide complexes, and therefore, if used in an 
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allogeneic context, patient blood-typing needs to be carried out to find a 
matched donor. Also, for effective stimulation of an immune response, both 
CD4+ and CD8+ TCRs would need to be introduced. There is also the risk of 
forming hybrid TCRs with one chain from the introduced TCR dimerising with 
one chain from the endogenous TCR, leading to unknown off-target activity 
and potential autoimmune disease (Sadelain et al. 2003).  
CARs have been developed as an alternative to nTCRs. CARs combine 
antigen specificity and a signalling domain in one molecule, performing the 
task of the TCR and CD3 complex. A CAR is made up of a targeting molecule, 
such as a scFv, peptide, cytokine, toxin or other moiety, protruded from the 
cell surface by a spacer, which may be a molecule such as the CD8 stalk. A 
TMD then links the extracellular ectodomain to the intracellular signalling 
molecules, which include the CD28 co-stimulatory molecule, the CD3ζ 
signalling domain and other signalling moieties, depending on the engineer 
(Altvater et al. 2010). Ligand binding to the CAR initiates phosphorylation of 
the ITAMs, leading to activation of the intracellular signalling cascade and T 
cell activation. In vivo efficacy of CAR-modified cells has been shown for 
various cancer antigens, including tumour-associated glycoprotein (TAG)-72, 
folate-binding protein (FBP) and human epidermal growth factor receptor 
(HER)-2 (Sadelain et al. 2003). Human PBLs targeted to the CD19 antigen 
have also demonstrated elimination of Burkitt’s lymphomas after adoptive 
transfer to severe combined immunodeficiency (SCID) mice (Brentjens et al. 
2002). Along with a wider range of potential targets and the lack of MHC 
restriction, CARs are not at risk of forming hybrid TCRs. CARs do have 
limitations though, including being restricted to surface-bound molecules, a 
need to be characterised fully to determine the strength of activation after 
ligand binding, and their potential for immunogenicity (Sadelain et al. 2003; 
Hombach et al. 2001; Beecham et al. 2000).  
 
1.4.7 Selection of genetically engineered cells 
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When introducing genetic modifications into cells, there will be some cells that 
are successfully modified and some that will remain unmodified. If this mix of 
cells is used in immunotherapy, the efficacy of the treatment will be reduced, 
and there is a risk of unknown side effects and toxicities. Therefore, cells that 
have been genetically modified need to be selected to create a homogenous 
cell product. Traditionally, this has been done by fluorescence activated cell 
sorting (FACS), based on marker gene expression such as green fluorescent 
protein (GFP) and blue fluorescent protein (BFP), or by using antibiotic 
selection to select cells based on their expression of a resistance gene.  
Antibiotic, or drug, selection has been used to allow for selection of cells that 
express the desired vector; one which includes the relevant resistance gene. 
After integration of the vector into the cell, usually by viral transduction, cells 
are positively selected by being cultured in the relevant antibiotic or drug 
(Kawahara et al. 2003). The drawback of this method is if the conditions used 
in the selection are incorrect, then this can lead to the killing of the desired 
population or to the survival of the unmodified population (Brielmeier et al. 
1998). Selection of cells in this way also leads to impaired growth of the 
selected population. A study by Kim et al. (1998) demonstrated that the growth 
rate of cells grown in methotrexate (MTX) was reduced compared to cells 
grown in antibiotic-free medium. 
Selection of cells, based on fluorescent marker genes or antibodies, uses 
FACS to select cells. Cells can be selected based on size, fluorescence or on 
cell surface marker expression. Fluorescence is based on the expression of a 
fluorescent marker gene, such as BFP and GFP, or by using an antibody, 
conjugated to a fluorophore, bound to the surface of a cell. Cell surface marker 
expression was used to sort ex vivo expanded T regulatory cells, using 
multiple cell surface markers to sort a specific cell population (Trzonkowski et 
al. 2009). Cells are placed into a stream of fluid that restricts them to a flow 
that is one cell wide. The nozzle of the machine vibrates, causing the stream 
to break up into droplets that each contain a single cell. A laser interrogates 
each cell to determine fluorescence and a charge is applied to the cell. 
Electromagnets cause the droplet with the charged cell to be deflected into a 
reservoir, and cells are sorted (Herzenberg et al. 1976). This is a very robust 
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method, but the cells need to be in a single cell suspension for successful 
sorting to occur. This makes it more of a challenge to sort adherent cells or 
cells from solid tissue. Another drawback is the speed of cell sorting when 
using FACS machines. For clinical trials or experiments involving model 
organisms, large numbers of cells are usually required. This requires large 
numbers of cells which take a long time to be sorted, leading to questions over 
the quality of cells that have been out of optimal growth conditions for many 
hours. The sterility of the FACS machine also needs to be maintained between 
each cell sort to prevent cross-contamination (Cammareri et al. 2008). 
A fairly recent innovation in cell sorting is magnetic cell sorting (MACS). To do 
this, antibodies attached to magnetic beads are used. Cells are incubated with 
the antibody-bead conjugate and then passed through a column attached to a 
magnet. Cells that have the antibody-bead conjugate attached are retained in 
the column, and unlabelled cells pass through. Once the column has been 
washed with buffer, the column is removed from the magnet and the labelled 
cells are eluted. The remaining magnetic beads are biodegradable and 
degrade in culture. This allows for quick, sterile sorting of cells based on the 
expression of a cell surface marker (Cammareri et al. 2008). Again, this 
method works optimally with cells in a single cell suspension, and the choice 
of selection marker needs to be careful, for example, selecting NK cells using 
anti-CD56 beads may activate the NK cells, or select NKT cells as well. 
  
1.4.8 Mechanism for the depletion of therapeutic cells 
 
Genetic engineering of T cells with TCRs or CARs has expanded the range of 
malignancies that can be treated using ACT. Extensive modification of T cells 
by viral gene transfer could have the potential to alter their activation status 
and in vivo survival. The enhanced capacity to engraft and to persist in vivo 
longer than previous treatments using peptides or chemotherapeutic agents 
has previously been demonstrated (Louis et al. 2011). GvHD and other 
toxicities have been demonstrated in previous studies involving genetically 
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engineered T cells and further toxicities have been suggested in animal 
models (Morgan et al. 2010; Brentjens et al. 2010; Bendle et al. 2010).  
Cell-based therapy also carries the risk of over-activating the immune 
response of the recipient. As a result, there needs to be a mechanism by which 
therapeutic cells can be selectively removed from the patient to prevent the 
development of serious adverse events (SAEs). This can be done through the 
use of mAbs or drugs that specifically target a molecule expressed solely on 
the therapeutic cells. Including a marker protein in the genetic modification of 
therapeutic cells is one way of introducing a ‘suicide’ gene.  
Several mechanisms for providing this safety method have been investigated, 
including the herpes simplex virus thymidine kinase (HSV-TK), an inducible 
caspase 9 (iCasp9), CD20 and the mutated human thymidilate kinase 
(mTMPK) enzyme (Marin et al. 2012). HSV-TK functions as a suicide gene 
because it confers sensitivity to ganciclovir; demonstrated both in vitro and in 
vivo (Tiberghien et al. 1994; Moolten et al. 1990). In a trial carried out by Bonini 
et al. (1997), using HSV-TK as a suicide gene was shown to be effective when 
adding ganciclovir to patients suffering from acute GvHD. In one patient, who 
was suffering from chronic GvHD, full sensitivity to ganciclovir was not 
demonstrated; transduced cells that were isolated ex vivo from the patient 
were shown to have unmodified sensitivity, suggesting that in vivo resistance 
can be conferred to genetically modified cells. Use of ganciclovir as a suicide 
gene also prevents patients with cytomegalovirus infections from receiving 
these cells. 
iCasp9 was constructed by fusing a modified FK506 binding protein (FKBP)  
domain to the proteolytic domain of caspase 9 (Straathof et al. 2005). This 
molecule is non-immunogenic as it is derived from human molecules, except 
from one single amino acid substitution in the FKBP. In one study, in patients 
who developed GvHD, upon administration of a dimerising drug (AP103), 
apoptosis was induced and cells expressing the construct were eliminated. 
90% elimination of modified T cells occurred within 30minutes of 
administration (Di Stasi et al. 2011). Another advantage over using HSV-TK 
as a suicide gene is that iCasp9 is not virus-derived. As a result, this should 
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prevent development of any memory T cells specific for the junctional 
sequences between the molecules in iCasp9, reducing the chance of the host 
immune system eliminating the modified T cells (Straathof et al. 2005). 
mTMPK is a molecule that has been mutated to have a higher affinity for its 
substrate, the prodrug 3'-azido-3'-deoxythymidine-monophosphate (AZT-MP). 
By increasing the AZT concentrations, the rate of conversion of AZT-MP to 
AZT-triphosphate (AZT-TP) is increased, resulting in increased intracellular 
AZT-TP, which is cytotoxic (Sato et al. 2007). When tested alongside other 
suicide strategies, including CD20, HSV-TK and iCasp9, though, mTMPK is 
not as effective (Marin et al. 2012). 
Use of CD20 as a suicide gene allows for elimination of CD20-expressing cells 
using the anti-CD20 mAb, rituximab. The main disadvantage of using this as 
a suicide mechanism is that it leads to the depletion of the patient’s B cells as 
well as the genetically modified cells. In addition, modified cells cannot be used 
if the patient is undergoing rituximab treatment. Despite this, CD20 is 
promising as a suicide gene as the molecule allows for the sorting of modified 
cells and has also been shown to be non-immunogenic. Furthermore, the anti-
CD20 mAb, rituximab, has been used previously in the treatment of B cell 
lymphomas and its role in the lysis of cells, through complement activation, 
has been well-characterised (Serafini et al. 2004).  
  
1.4.9 Genomic manipulation to create a universal T cell 
 
Gene modifications can be transferred into T cells via a variety of methods, 
split into three main categories – physical, chemical or biological. Physical 
methods include electroporation, ultrasound and biolistic particle delivery 
(Niidome & Huang 2002). Chemical methods use delivery agents such as 
calcium phosphate, polyethylenimine (PEI), and liposomes (Nishikawa & 
Huang 2001). Biological methods include viral vectors and transposons. 
Physical and chemical methods can be very efficient, but they are also 
transient, and stable integration and expression is only achieved in a small 
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number of cells (Sorrell & Kolb 2005). Electroporation, for example, requires 
applying an electric current to cells in order to allow entry of DNA into the cell. 
This disrupts the membrane and creates nm-scale holes in the membrane, 
through which the DNA can enter the cell. The drawback of this is that overall 
cell viability after electroporation drops and conditions have to be 
experimentally optimised for each cell line tested in order to achieve the most 
efficient protocol and increase cell viability. 
As T cells have a rapid proliferation rate, it is vital to achieve gene transfer that 
is efficient and long-lasting. Currently, the best way to do this is to use retroviral 
or lentiviral vectors, which allow for stable and sustained expression of the 
transgene, as well as efficient integration into the genome. Retroviruses are 
able to insert their genome, containing the transgene of choice, into a distinct 
nucleotide sequence at non-specific sites throughout the host genome. 
Multiple studies have demonstrated the efficiency of retroviral integration into 
T cells, with most of these using Maloney murine leukaemia virus (SFG) 
derived vectors. Transduction efficiencies with these vectors can be 80-90% 
(Quintás-Cardama et al. 2007). 
The issue of epigenetic silencing is one that affects retroviral integration, 
although it does not affect lentivirus, which appears to avoid this issue (Pannell 
& Ellis 2001). In addition, the integration site of the virus into the host genome 
cannot normally be predicted. As a result, integration may occur in a site that 
downregulates transgene expression, or integration may modulate activity of 
host genes at the integration site, potentially having damaging effects. Hacein-
Bey-Abina et al. (2003) demonstrated this in two patients who developed 
leukaemia after having retroviral vector-based treatment for X-linked SCID (X-
SCID). Genome analysis showed that the retrovirus had integrated near to the 
LIM domain only (LMO)-2 proto-oncogene promoter, leading to abnormal 
regulation and expression of LMO2. Site-specific integration of transgenes 
would therefore be an advantage, and is something that is achievable by other 
strategies, including zinc finger nucleases (ZFNs), meganucleases (MNs) and 
TALENs.  
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Due to the adverse events previously experienced, research focused on the 
safety of viral vectors. The long terminal repeats (LTRs), included in the 
vectors, contain elements that regulate and promote gene expression. LTRs 
contain enhancer and promoter regions and the transcription start and 
termination sites (Uren et al. 2005). This restricts efficient viral expression to 
the environments that match the conditions set by the viral LTRs. The Moloney 
MLV has tropism for T cells and B cells, which accounts for the high 
transduction efficiency that has been shown with this viral vector in previous T 
cell studies (Erkeland et al. 2003; Erkeland et al. 2004). Other efforts to 
improve retroviral safety include making the vectors self-inactivating (SIN) and 
to modify the promoter sequences to prevent read-through by improving the 
messenger ribonucleic acid (mRNA) termination and polyadenylation 
(Schambach et al. 2007). Retroviral gene therapy using the MLV vector has 
been successfully achieved in multiple animal models and clinical trials and it 
is this vector that is used in this project.  
 
1.5 Safety 
 
The main safety considerations in this project are the possibility of 
allorejection, GvHD, on-target off-site activity and SAEs. Some of the 
strategies tested in this project were designed to overcome these obstacles, 
and some of these potential risks were unable to be tested in this system, 
although they have been evaluated in other studies. Toxicity is the main issue 
to solve as, regardless of the efficacy of the therapeutic cells, if the toxicity is 
above acceptable thresholds, regulatory approval will be refused. These 
issues and potential solutions are discussed in the following sections. 
 
1.5.1 Tumour lysis syndrome 
 
Tumour lysis syndrome (TLS) is an unwanted side-effect of some effective 
therapies. It occurs when the contents of tumour cells are released into the 
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bloodstream, often as a result of tumour cell death that is caused by 
chemotherapy or immunotherapy. Due to this huge release of intracellular 
contents, the body’s homeostatic systems and waste removal are quickly 
overloaded. This leads to electrolyte imbalances such as hyperuricemia, 
hyperkalaemia, hyperphosphatemia, and hypocalcaemia (Dhanraj & Biswajit 
2014). These complications can lead to severe clinical consequences, 
including acute kidney injury, cardiac arrhythmias, pulmonary oedema, fluid 
overload, seizures, and death (Abu-Alfa & Younes 2010). 
TLS occurs very soon after initiation of chemotherapy, within the first week. It 
most commonly occurs in patients suffering from haematological 
malignancies, especially those with high tumour loads. A model has been 
proposed in order to stratify patients with high, intermediate or low risks of TLS 
depending on the type of cancer present, the white blood cell (WBC) count 
and the type of therapy to be initiated. Patients with rapidly proliferating, 
therapy-sensitive tumours are among those at a higher risk of developing TLS 
(Coiffier et al. 2008).  
When treating patients with universal T cells, the efficacy of the cells will need 
to be assessed in order to determine the risk of causing TLS. If the CAR 
expressed on the T cells is highly specific with a high affinity, it may cause 
rapid tumour cell lysis leading to TLS. Careful selection needs to be made to 
determine the optimal antibody affinity and efficacy. The relationship between 
antibody affinity and in vivo efficacy is an unclear one, with one example 
showing this. A study made on a panel of ERBB2 scFvs showed that those 
with a threshold affinity (Kd) of 10-7 to 10-8 M allowed specific localisation to 
the tumour. Uptake of the scFvs reached a plateau at a Kd of 10-9 to 10-11 M. 
From this panel, the scFv with the lowest affinity showed the optimal ability to 
distribute throughout the tumour. On the other hand, the scFv with the highest 
affinity localised mainly to the perivascular region of the tumour (Adams et al. 
1998; Adams et al. 2001). Therefore, it can be seen that there needs to be a 
balance between affinity and tumour localisation in order to provide the most 
effective outcome, whilst also minimising the risk of inducing TLS. This is a 
key consideration needed when selecting the binding moieties of CARs to 
introduce into the therapeutic T cells. 
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1.5.2 Cytokine release syndrome 
 
Cytokine release syndrome (CRS) is caused by a sudden increase in 
cytokines as a result of T cell engagement and proliferation. Mild CRS is the 
most common form prevalent in patients undergoing immunotherapy, with flu-
like symptoms, fevers and myalgias. Severe CRS however, is characterised 
by symptoms including hypotension, pulmonary oedema, vascular leak and 
severe inflammatory syndrome, leading to multiple organ failure and possible 
death (Maude, Barrett, et al. 2014). Within these CRS categories, there is often 
large variability between patients, as the degree of cytokine elevation may not 
necessarily correlate to the severity of CRS or the response to therapy. Some 
patients display clinical symptoms that are not reflected in the sample analysis, 
and some sample analysis may suggest severe CRS yet the patient does not 
display the expected clinical symptoms (Klinger et al. 2012). 
Clearly, the use of therapeutic T cells is designed to result in a degree of 
cytokine release. The difficulty is being able to manage the level of cytokine 
release and to be able to suppress it in case CRS develops. Corticosteroids 
are one of the main options for CRS management, having been shown to be 
effective in T cell activation, GvHD and inflammatory disorders (Martin et al. 
2012). However, the use of steroids may result in a reduction in efficacy as 
previously seen (Porter et al. 2011). 
Another approach may be to target the cytokines released during CRS. 
Regulators of innate and cell-mediated immunity include IL-6, IL-10 and IFNγ. 
IL-10 is a negative regulator and therefore not an ideal target for CRS 
treatment. Similarly, IFNy is released after T cell engagement, and is required 
for efficacy. IL-6 is an inflammatory cytokine involved in multiple processes 
including immune responses, bone and lipid metabolism (Mihara et al. 2012). 
Levels of IL-6 reach an apex during maximal T cell proliferation, and blockade 
of IL-6 by tocilizumab has been shown to reverse severe CRS in patients 
undergoing CAR T cell or blinatumomab treatment (Grupp et al. 2013; 
Teachey et al. 2013). There are other cytokines that could be targeted, 
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including MCP-1, MIP1B, IL2-R, IL1-R, IL-33, IL-13, IL-31 and TNFα, and 
some of these are currently being tested (Maude, Barrett, et al. 2014). Clearly 
there is a balance that needs to be found between efficacy and management 
of toxicity; reducing the risk of CRS induction whilst maintaining the highest 
possible efficacy. 
 
1.5.3 Haemophagocytic lymphohistiocytosis 
 
Haemophagocytic lymphohistiocytosis is characterised by fever, 
hepatosplenomegaly and cytopenia. It contains two main conditions, familial 
haemophagocytic lymphohistiocytosis (FHL) and secondary 
haemophagocytic lymphohistiocytosis (SHLH). FHL is an inherited disease, 
but SHLH can affect any age, and also subside spontaneously (Henter et al. 
2002). Poorly controlled NK cells fail to stimulate apoptosis of activated cells, 
leading to a persistent inflammatory state, characterised by IL-6 and TNFα 
(Perez et al. 1984).  
Secondary HLH has the same symptoms as primary HLH, but is caused by an 
activation of the immune system by underlying illness. If a reduction in HLH 
symptoms is not achieved by treatment of the underlying illness, then 
immunosuppressive chemotherapy is used, following the HLH-2004 protocol 
(Keith et al. 2012). This protocol involves the use of dexamethasone, VP-16, 
cyclosporine A, introthecal methotrexate and corticosteroids in order to reduce 
and alleviate the symptoms of secondary HLH (Henter et al. 2007). In many 
ways, it is similar to macrophage activation syndrome (MAS), which most 
commonly occurs in infants. Secondary HLH is an issue that will need to be 
taken into consideration for patients who are being treated and have 
underlying illnesses that may trigger HLH.  
 
1.5.4 On-target, off-site activity 
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Tumour cells often display cell surface markers that are the same as, or very 
similar to healthy, non-cancerous cells. Some markers are down-regulated to 
prevent immune surveillance recognising the tumour cells, and others are up-
regulated to block the induction of death signals. As previously stated, the 
selection of tumour target needs to be performed carefully. The molecule 
targeted by a CAR may be expressed on multiple cell types, some of which 
are healthy, others cancerous. Taking CD20 as an example, this is normally 
expressed on B cells, but is also expressed in B cell lymphomas. Targeting 
the CD20 molecule means that all of the B cells are targeted, not just the 
cancerous ones. Some previous work has been done to augment the 
expression of CD20 on tumour cells in order to increase killing with aCD20 
antibodies. This study showed that IL-4, TNFα and GM-CSF caused an up-
regulation of CD20 antigen expression (Venugopal et al. 2000). 
Another example would be the NY-ESO-1 protein, which is in a class of 
cancer-testis (CT) antigens, which are expressed by some tumour types, but 
also in the testis. For TCR-modified T cells, the testis is not vulnerable to these 
T cells as the germ cells do not express MHC molecules (Morgan 2013). The 
NY-ESO-1 protein has been successfully targeted in ACT clinical trials, where 
objective clinical responses were observed in four of six patients with synovial 
cell carcinoma and five of eleven patients with melanoma tumours expressing 
the NY-ESO-1 antigen (Robbins et al. 2011).  
A final example is CD44, which is expressed widely in haematological and 
epithelial tumours. The CD44v6 isoform has been demonstrated to be 
expressed on the majority of AML and multiple myeloma (MM) tumour cells. A 
CAR targeting CD44v6 was developed and shown to inhibit tumour formation 
of AML and MM cells in xenograft models. What was also discovered was that 
CD44v6 is also expressed on keratinocytes and circulating monocytes. 
Keratinocytes were not recognised by the aCD44v6 CAR, but monocytes 
were, causing monocytopenia in the animal models tested. As a result, this 
study added an iCasp9 suicide gene to the therapy, allowing for depletion of 
the therapeutic cells in order to manage long term monocytopenia (Casucci, 
Robilant, et al. 2013). This is a very clear example of on-target, off-site toxicity. 
In many cases, it may be unavoidable, but with correct planning of therapy and 
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detailed analysis of the target, severe effects can be planned for and 
prevented, or responded to quickly. 
 
1.6 Project Aims 
 
The aim of this project is to investigate ways in which these strategies can be 
collated in order to develop a universal cell product (third party), where one T-
cell pool could be used to treat many patients. This would allow many more 
patients to be treated and for treatment to be commenced in a shorter time 
frame. The main two barriers to this are: (1) rejection of the adoptively 
transferred allogeneic T-cells by the host immune response (alloreactivity); (2) 
rejection of the host by the adoptively transferred T-cells, causing GvHD. The 
first barrier can theoretically be overcome by knock-down of HLA in adoptively-
transferred allogeneic T-cells. This may result in an additional obstacle of NK-
mediated null cell deletion. This may be overcome with HLA-G expression, 
mimicking the situation of trophoblast invasion in pregnancy (Rouas-Freiss, 
Gonçalves, et al. 1997; Rouas-Freiss, Marchal, et al. 1997). This was 
demonstrated by a lack of cell killing by the T cell leukaemia NK-like YT2C2 
clone when interacting with a HLA-negative cell line (K562), expressing HLA-
G1 and HLA-G2 (Rouas-Freiss, Marchal, et al. 1997). GvHD can be overcome 
by TCR knockdown and re-directing the T-cell specificity using a CAR. A sort-
suicide gene can be introduced to allow clinical grade sorting of the modified 
cells, and as a mechanism by which modified cells can be depleted from the 
patient in case of adverse events.  
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Chapter Two: Materials 
and Methods 
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2.1 Materials 
2.1.1 Reagents 
2.1.1.1 General reagents and chemicals 
 
14ml Falcon round-bottom tube  BD   352006  
(methyl-3H) Thymidine    Perkin Elmer  NET027001MC  
51Chromium labelled sodium chromate  Perkin Elmer  NEZ030002MC  
Agarose     Bioline  BIO-41025 
Boric acid     VWR International 20185.360 
Bovine Serum Albumin (BSA)  Sigma-Aldrich A7906  
Carbenicillin     VWR International 69101-3 
Ethidium Bromide    BDH Chemicals 443922U  
Ethylenediaminetetraacetic acid (EDTA) Disodium salt   
      VWR International 20302.260 
Electroporation Cuvettes, 2mm gap BTX   45-0125 
Filtermat     Perkin Elmer  1450-421  
Glycerol     Sigma-Aldrich  G5516 
Haemocytometer    Hirschmann Laborgeraete GmbH 
         8100103 
LB Medium     MP Biomedicals LLC  
         3002-031 
LB-Agar Medium    MP Biomedicals LLC  
         3002-231 
LS Columns     Miltenyi Biotec 130-042-401 
MeltiLex solid scintillator    Perkin Elmer  1450-441  
MS Columns     Miltenyi Biotec 130-042-201 
Nalgene® Mr. Frosty®   Thermo Scientific 5100-0001 
Parafilm     VWR International 291-1212 
PBS tablets     Oxoid   BR0014G 
PFA 4% in PBS    Insight Biotechnology Ltd  
         sc-281692 
Plate seals     Perkin Elmer  1450-462 
Propidium Iodide    Sigma-Aldrich P4170 
TALEN mRNA    Cellectis Bioresearch  
Terrific broth     Merck Chemicals 1.01629.0500 
Tris base     Fisher Scientific BPE152-5 
Trypan Blue solution   Sigma-Aldrich T8154  
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2.1.1.2 Molecular cloning enzymes, reagents and kits 
 
Hyperladder DNA ladder   Bioline Limited BIO-33026 
Murine Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) primer 
      Qiagen  QT01658692  
Nucleobond Midiprep kit   Thermo Scientific Abgene  
         NZ74041050 
Nucleospin Gel and PCR Clean up kit Thermo Scientific Abgene  
         NZ740609250 
Nucleospin Miniprep kit   Thermo Scientific Abgene  
         NZ740588250 
Oligo primers    Integrated DNA technologies (IDT)   
Phusion DNA polymerase   New England Biolabs UK Ltd 
         M0530L 
Platinum PCR SuperMix   Invitrogen  12532-016 
Restriction endonucleases & buffers  New England Biolabs UK Ltd 
         (various) 
TOPO TA cloning kit   Invitrogen  45-0641 
Qiagen Gel extraction kit   Qiagen  28706 
Qiagen Miniprep kit    Qiagen  27106 
QIAquick PCR purification kit   Qiagen   28104 
Quick Ligation kit    New England Biolabs UK Ltd 
         M2200L 
 
2.1.1.3 Bacteria 
 
New England Biolabs (NEB) 5-α Competent E. coli (High Efficiency) 
       New England Biolabs UK Ltd 
         C2987H  
NEB 5-α Competent E. coli (Subcloning Efficiency)  
       New England Biolabs UK Ltd  
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         C2988J 
 
2.1.1.4 Tissue culture plastic-ware 
 
0.2μM pore syringe filter   Sartorius  16532K 
0.45μM pore syringe filter   Sartorius  16537K  
100mm tissue culture (TC) dishes Corning  430167 
6 Well plate TC treated   Corning  3506 
12 Well plate TC treated   Corning  3513 
24 Well plate TC treated   Corning  3524 
24 Well plate non-TC treated  BD Biosciences 351147 
48 Well plate TC treated   Corning  3548 
96 Well plate flat bottom   Corning  3596 
96 Well plate V-bottom   Greiner Bio-One 650-180 
96 Well plate round-bottom  Corning  3799 
15ml Falcon tubes    Corning   430791 
50ml Falcon tubes    Corning  430829 
250ml centrifuge tubes   Corning  430776 
6.5mm Transwell, 0.4μM pore  Corning  3470  
Flask Ez Nunclon 175cm   Thermo Electron 159910 
Flask Ez Nunclon 75cm   Thermo Electron 156499 
Flask Ez Nunclon 25cm   Thermo Electron 156367 
 
2.1.1.5 Tissue culture medium and supplements 
 
Anti-CD28 antibody good manufacturing practice (GMP) pure  
      Miltenyi  170-076-117  
Anti-CD3 (OKT3) GMP pure  Miltenyi  170-076-124 
Anti-CD34 microbeads (human)  Miltenyi Biotec 130-046-702 
Anti-CD56 microbeads (human)  Miltenyi Biotec 130-050-401 
Cell dissociation medium   Sigma-Aldrich C5914 
Cryopreservation Medium   Lonza Bio Science Ltd  
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         US12-132A 
Cytoporation medium T buffer   BTX    47-0002 
Dimethyl sulfoxide (DMSO)  Sigma-Aldrich D2650 
Dulbecco’s PBS (DPBS) solution  Invitrogen Life Technologies 
         14190169 
Dynabeads - Human CD3/CD28   Life Technologies  11131D 
EDTA solution (0.5M)   Sigma-Aldrich E7889 
Foetal calf serum (FCS)   Biosera  S1900/500 
Ficoll-Paque     GE Healthcare Life sciences 
         17-1440-03 
Genejuice     Merck Chemicals Ltd  
         70967-3 
GlutaMAX     Invitrogen Life Technologies 
         35050087 
IL-2 Recombinant human   Genscript  Z00368 
Iscove's Modified Dulbecco's Media (IMDM)     
      Lonza Bio Science Ltd  
          BE12-726F 
Normocin     InvivoGen  ant-nr-1 
Phytohaemagglutinin (PHA)  Sigma-Aldrich L9017 
Polybrene     Millipore  TR-1003-G 
Retronectin     Lonza Bio Science Ltd  
         T100B 
Roswell Park Memorial Institute (RPMI) Lonza Bio Science Ltd  
         BE12-167F 
Trypsin-EDTA solution   Sigma-Aldrich T4049 
 
2.1.2 Buffers and solutions 
 
All buffers and solutions, unless otherwise stated, were prepared in deionised, 
reverse osmosis filtered laboratory grade water. They were also either 
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sterilised in an autoclave at 121oC for 15minutes or sterile filtered through a 
0.22µM filter using a vacuum. Recipes for buffers are below: 
Table 2 – Buffer composition, ingredients and recipes 
Buffer Composition and ingredients 
Flow cytometry fixing buffer 
(FACS fixing buffer) 
FACS buffer + 0.5% Paraformaldehyde 
(PFA) (Insight) 
Luria-Bertani (LB) broth 
LB tablets/powder were dissolved in 
deionised laboratory grade water according 
to manufacturer’s recipe (MP Biomedicals 
LLC) 
MACS/FACS buffer 1% FCS in PBS 
Phosphate buffered saline 
(PBS) (PAA Laboratories 
Ltd H15-002) 
PBS tablets (Oxoid) were dissolved into 1L 
of deionised laboratory grade water 
Propidium iodide (PI) stock 
solution 
25mg PI (Sigma) was suspended into 10ml 
of deionised laboratory grade water to 
establish a 2.5mg/ml stock solution 
Terrific Broth (TB) 
Terrific broth tablets/powder (Merck) were 
dissolved in deionised laboratory grade 
water, with glycerol (Sigma-Aldrich) added 
as required 
Tris/Borate/EDTA buffer 
(TBE) (x10) 
9.3g of EDTA, 55g of Boric Acid and 108g of 
Tris-base was dissolved into 1L of deionised 
laboratory grade water 
 
2.1.3 Antibodies 
 
The following antibodies were used during FACS analysis and in blocking 
assays: 
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2.1.3.1 General conjugates 
 
Streptavidin-APC    AbD Serotec  STAR119 
Streptavidin- Phycoerythrin (PE)  eBioscience  12-4317-87 
Streptavidin-PE-Cyanine-7 (Cy7)  eBioscience  25-4317-82 
Streptavidin- Peridinin chlorophyll (PerCP)     
       BD Biosciences  554064 
 
2.1.3.2 Human antibodies 
 
Dilutions used according to manufacturers’ guidelines 
CD33-APC     eBioscience  17-0338 
CD34-(581)-APC    BD Biosciences 555824 
CD34-(QBEnd10)    Dako UK  M7165 
CD34-(QBEnd10)-Biotin   AbD Serotec  MCA547B 
CD34-(QBEnd10)-PE   Abcam  ab30377  
CD3-APC     BD Biosciences 555335 
CD3-PE     Beckman Coulter PN IM1282 
CD3-PerCP     BD Biosciences 552851 
Goat-anti-human-Fc-Dylight488  Jackson ImmunoResearch  
         109-485-098 
Goat-anti-human-Fc-DyLight649   Jackson ImmunoResearch  
         109-496-127 
HLA-A/B/C-APC    BD Biosciences 555555 
HLA-A2-Fluorescein isothiocyanate (FITC)   
       BD Biosciences 551285 
HLA-DR-APC    BD Biosciences 559868 
HLA-G-PE     eBioscience  12-9957-41 
HLA-G-PerCP    eBioscience  46-9957-41 
IFNγ-FITC      eBioscience  11-7319 
TCR-Biotin     eBioscience  13-9986 
TCR-FITC     BD Biosciences 555547 
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TCR-PE     BD Biosciences 555548  
 
BD Cytofix/Cytoperm Fixation/Permeabilisation solution kit with BD 
GolgiStop      BD Biosciences 554715 
Paraformaldehyde (PFA)   Insight  10351641 
 
2.1.3.3 Blocking antibodies 
 
HLA-Class I (W6/32 Hybridoma)  Dako   M073601-2 
HLA-Class II (CR3/43 Hybridoma) Dako   M077501-2 
 
2.1.4 Cell lines 
 
293T  Human embryonic kidney (HEK) cell line – European 
collection of cell cultures (ECACC)-05/B/013). 
Jurkat  Human acute lymphoblastic leukaemia T cell line derived 
from non-Hodgkin lymphoma patient. Kind gift from Dr 
Cliona Rooney, Centre for Cell and Gene Therapy, 
Houston, TX, USA. 
TCRko Jurkat Derived from a patient with T cell leukaemia, 
demonstrated to lack endogenous TCR expression of 
both chains. Obtained as a kind donation from Prof Hans 
Stauss, Royal Free Hospital, London, NW3 2PF. 
SupT1 T lymphoblast cell line derived from a patient with T cell 
lymphoblastic leukaemia (Baylor College of Medicine). 
K562 Undifferentiated granulocytic cell line derived from a 
patient with chronic myelogenous leukaemia (ECACC). 
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BBM.1 (HB-28) Murine hybridoma cell line derived from mouse spleen 
cells and P3X63Ag8 myeloma cells (ATCC HB-28) 
 
2.1.5 Media recipes  
 
Table 3 – Tissue culture medium recipes 
 
2.1.6 Equipment 
 
AGO HS MP-1    X-ray irradiator  
BD Biosciences    LSR Fortessa cell analyser  
BD Biosciences   FACSVerse flow cytometer 
Beckman Coulter    CyAn ADP flow cytometer 
BioRad    Peltier Thermal Cycler 
LKB Wallac     1282 Compugamma Gamma Counter 
Nanodrop®     ND-1000 Spectrophotometer 
Perkin Elmer    1450 MicroBeta TriLux Microplate    
Medium  Recipe 
Complete IMDM 
(Lonza BE12-726F) 
10% FCS (Biosera), 1% GlutaMAX 
(Invitrogen) 
Complete RPMI 
(Lonza BE12-167F)  
10% FCS (Biosera), 1% GlutaMAX 
(Invitrogen) 
Freezing media with  15% DMSO 
(Lonza 12-132A)  
18ml of FCS (Biosera) was added to 
this medium to generate a solution 
with 15% FCS and 13% DMSO 
PBMC assay medium 
Complete RPMI as above, 
supplemented with 50 I.U/ml of 
recombinant human IL-2 (Genscript) 
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      Scintillation and Luminescence Counter 
 
2.2 Methods 
2.2.1 Molecular Biology 
 
2.2.1.1 Small scale DNA preparation 
 
Small scale (miniprep) DNA preparation was as follows: Single colonies were 
picked from an agar plate and grown overnight in 14ml Falcon tubes at 37oC 
with 200-250rpm shaking, in 4-5ml LB supplemented with 100µg/ml 
Carbenicillin. The Qiagen or Macherey-Nagel miniprep kit was used to isolate 
plasmid DNA according to the manufacturer’s instructions. Constructs were 
verified by restriction digest followed by agarose gel analysis and/or DNA 
sequencing. 
 
2.2.1.2 Large scale DNA preparation 
 
Large scale (midiprep) DNA preparation was performed as follows: 50-100ml 
of TB, supplemented with 100µg/ml of Carbenicillin, was inoculated with a 5ml 
bacterial culture and grown overnight at 37oC with 200-250rpm shaking. The 
Qiagen or Macherey-Nagel midiprep kit was used to extract plasmid DNA from 
the resulting bacterial prep, following the manufacturer’s instructions. Midiprep 
DNA was verified by multiple restriction digests to provide a clearly identifiable 
band pattern on an agarose gel. 
 
2.2.1.3 Measurement of DNA concentration 
 
DNA concentration was calculated by measuring the absorbance of light with 
a wavelength of 260 nm (A260) using a NanoDrop ND-1000 
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spectrophotometer with a 0.2mm pathlength; at this wavelength 50μg/ml of 
double-stranded DNA has an absorbance of 1. The ratio of absorbance at 
260nm:280nm can be used to establish DNA purity. A ratio of 1.8 indicates a 
high level of DNA purity with little or low levels of RNA and/or protein 
contamination. 
 
2.2.1.4 Splicing of DNA fragments by overlapping extension PCR 
 
Transgenes for cloning into expression vectors were generated by overlapping 
extension PCR. Transgenes were designed into multiple fragments with an 
NcoI restriction endonuclease site designed in the 5’ end of the N-terminal 
fragment, along with a signal peptide, and a MluI restriction endonuclease site 
designed into the 3’ end of the C-terminal fragment. Oligonucleotides, 
complimentary to the fragment being amplified, were used to generate the 
genes and assembled by overlapping PCR as follows: Oligonucleotide stocks 
were diluted to 25μM before being added to PCR tubes containing dH2O, HF 
Buffer, deoxyribonucleotide triphosphates (dNTPs), and Phusion Hot-Start II 
Polymerase (Finnzymes 2013). The primary PCR was used to amplify the 
fragments and was run on a Peltier Thermal Cycler (BioRad) as follows: 98oC 
for 2 minutes, 98oC for 40 seconds, 65oC for 40 seconds, 72oC for 1minute per 
kb of amplification, cycled back to the second step 35 times and then 72oC for 
a final 10 minutes before the reaction was complete. Each reaction was run in 
a separate lane by gel electrophoresis, as described in 2.2.1.6 Gel 
electrophoresis, and extracted into 30μl of dH2O using a Qiagen gel extraction 
kit as described in 2.2.1.7 Gel extraction. For the secondary PCR, 3.5μl of each 
primary PCR reaction was added to the same mix as the primary PCR, with a 
3x volume. The PCR was repeated as above on the thermal cycler, with an 
increased time for extension according to the length of the DNA being fused. 
The PCR products were run on an agarose gel and desired bands were 
extracted into 80μl of dH2O using the Qiagen gel extraction kit. This product 
was then digested with the appropriate restriction enzymes (2.2.1.9 Restriction 
endonuclease digestion), ligated into the relevant linearised vector (2.2.1.10 
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Ligation) and transformed into competent E.coli (2.2.2.2 Bacterial 
transformation). Verification restriction enzyme digests were performed and run 
on an agarose gel to select clones to be sent for capillary sequencing by 
Scientific Support Services (in-house). 
 
2.2.1.5 Site-directed mutagenesis using oligonucleotide primers 
 
In the instance of HLA-G extraction and cloning from genomic DNA, correct 
assembly of the gene was not completely successful. As a result, there were 
some mutations in the sequence that would have prevented, or possibly 
hindered, optimal expression as a transgene. In order to rectify this, 
oligonucleotide primers were designed over the relevant mutations that would 
revert those mutations back to the original HLA-G sequence. Full length, 
mutated HLA-G was used as a template, and oligonucleotides were diluted to 
a concentration of 25µM before being used in a PCR reaction as described in 
the PCR set-up in 2.2.1.4 Splicing of DNA fragments by overlapping extension PCR 
 
2.2.1.6 Gel electrophoresis 
 
The size of PCR products and digested plasmids was confirmed by gel 
electrophoresis. 1% agarose gels were prepared in 1x TBE buffer by boiling in 
a microwave. Once melted, 0.5µg/ml ethidium bromide was added to allow 
DNA visualisation. DNA samples were mixed with loading buffer at a ratio of 
5:1 prior to addition to set agarose gels. Relevant DNA hyperladder was 
included to allow determination of DNA fragment size. Gels were 
electrophoresed at 50-120V and up to 150mA in 1x TBE buffer until adequate 
separation of bands was observed. Fragments were visualised by exposure to 
UV light using a UV gel documentation system. PCR fragments requiring 
further manipulation were visualised using a blue light box to prevent DNA 
damage as a result of ultraviolet (UV) light exposure. Relevant bands were 
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excised from the gel using a sterile scalpel before DNA gel extraction as 
described in 2.2.1.7 Gel extraction. 
 
2.2.1.7 Gel extraction 
 
Following identification of the correct bands by gel electrophoresis, the desired 
band was visualised using a blue light box and excised from the gel using a 
clean scalpel blade. Gel extraction was then performed using the Qiagen 
QIAquick or Macherey-Nagel gel extraction kit according to manufacturer’s 
instructions. 
 
2.2.1.8 PCR purification 
 
The product of PCR reactions was purified with the Qiagen QIAquick or 
Macherey-Nagel PCR clean-up kit according to the manufacturer’s 
instructions. A portion of the resultant product was examined by gel 
electrophoresis to confirm size and purity. Products were subsequently 
digested by restriction enzymes as described in 2.2.1.9 Restriction 
endonuclease digestion before downstream processing. 
 
2.2.1.9 Restriction endonuclease digestion 
 
A 20-fold over-digestion was performed to produce fragments for subsequent 
ligation or for confirmation of successful cloning. 0.4-5µg of plasmid DNA was 
digested in a final volume of 30-100µl. The manufacturer’s recommended 
buffer was used, diluted to 1x with ddH20 and 0.1mg/ml BSA was added when 
needed. The volume of enzyme varied according to concentration but never 
exceeded 10% (v/v) of the final reaction volume. Digestion was performed for 
2 hours at 37oC and verified by agarose gel electrophoresis as described in 
2.2.1.6 Gel electrophoresis. Double digestions were performed in parallel where 
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buffers were compatible or sequentially following clean-up of DNA where 
buffers were incompatible using the relevant clean-up kit. For digestion 
reactions that ran overnight, the heating block was programmed to heat-
inactivate an enzyme once completed, or to reduce the temperature to 4oC if 
the enzyme could not be heat-inactivated. To generate vector backbone, or 
vector derived insert fragments, 5µg of plasmid vector DNA was used. Genes 
generated as above were subcloned as ‘sticky-end’ fragments into the relevant 
vector backbone as described in 2.2.1.10 Ligation. 
 
2.2.1.10 Ligation 
 
Following restriction enzyme digestion of vector and insert, ligations were 
performed using 100ng of vector DNA at a vector:insert molar ratio of 1:4-1:8, 
depending on insert size and concentration. Ligations were performed at room 
temperature for 5 minutes using Quick Ligase (NEB) according to the 
manufacturer’s instructions. 2µl of the ligated DNA was transformed into high 
efficiency C2987 chemically competent E.coli bacteria as described in 2.2.2.2 
Bacterial transformation. 
 
2.2.1.11 Plasmids 
 
The retroviral SFG plasmid vector (Büeler & Mulligan 1996) was used for 
expression of all genes generated in this project. SFG is based on the murine 
Moloney Leukaemia Virus, with the transgene start codon at the start site of 
the deleted viral env gene. This is followed by an internal ribosomal entry site 
(IRES), allowing expression of the relevant downstream reporter gene (if 
included). Fragments were cloned in using a unique restriction enzyme site 
upstream of the transgene start site, and the unique restriction enzyme site 
immediately following the transgene termination codon. For constructs 
containing the ‘2A’ sequence, the dual construct was translated as a single 
peptide, with separation of the separate components achieved by the self-
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cleaving activity mediated by the TaV (Thosea asigna virus) 2A sequence 
resulting in theoretical equimolar expression of both transgenes. Constructs 
denoted SFGmR also include a scaffold attachment region to enhance 
transgene expression. 
 
2.2.1.12 Codon optimisation and gene synthesis by oligonucleotide assembly 
 
An optimal sequence was designed using pMol software written by Dr Martin 
Pule. This allowed gene design based on optimisation of human codon usage 
to allow for optimal gene expression, raising GC content to 70%, reducing local 
sequence repeats, local hairpins, to a minimum and avoiding splice signals. 
The sequence was assembled with ligation-by-PCR using Phusion 
polymerase from overlapping oligonucleotides. Overlapping oligonucleotides 
were designed to allow short sections of DNA to overlap as demonstrated in 
Figure 1. Using these oligonucleotides as templates, two rounds of DNA 
amplification were performed. The first round produced short sections of 
template DNA and the second round allowed for amplification of the desired 
sequence using the terminal oligonucleotides.  
 
 
 
2.2.1.13 Trizol®-based RNA isolation 
 
Figure 1 – Gene construction by oligonucleotide assembly. Overlapping 
oligonucleotides (in blue) are used to generate the full length gene shown by the 
nucleotide sequence. 
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Around 5x106 PBMCs isolated by Ficoll extraction were re-suspended in 1ml 
of Trizol® reagent, with pipette agitation to achieve generation of a single cell 
suspension to allow for effective cell lysis. Cells were incubated in Trizol® for 
5minutes at room temperature before being transferred to a sterile Eppendorf 
tube. 200µl of chloroform was added to the Trizol® lysate. This suspension 
was vigorously vortexed for 15seconds, incubated at room temperature for 
3minutes then centrifuged at 11,500G for 15minutes. The upper aqueous layer 
was removed and transferred to a fresh sterile Eppendorf tube. 500µl of 
isopropanol was added and inverted twice before incubation at room 
temperature for 10minutes. This sample was centrifuged at 11,000G for 
10minutes at 4oC. The supernatant was removed, and the pellet was washed 
twice with 1ml of 75% ethanol, each time the sample was re-pelleted by 
centrifugation at 7,000G for 5 minutes at 4oC. Following the second wash, the 
ethanol supernatant was aspirated by pipette and the Eppendorf tube was 
dried in a sterile hood for 20minutes. The RNA sample was then re-suspended 
in 40µl of molecular biology grade water and the concentration was assessed 
by spectrophotometric measurement by Nanodrop prior to cDNA generation. 
 
2.2.1.14 cDNA generation 
 
cDNA was generated from a cellular RNA sample by a two-step process. In 
the first step, a 20µl reaction mixture composed of 1µg of RNA, 2µl of Random 
Decamers, 4µl of 2mM dNTPs, with the remaining volume made up to 20µl by 
molecular biology grade water. This reaction was heated at 70oC for 3minutes 
before being transferred to ice for 1minute. 2µl of 10x reverse transcriptase 
buffer was then added to the above reaction mixture followed by 1µl of RNasin 
and 1µl of reverse transcriptase. This second reaction was then incubated for 
1 hour at 42oC, followed by a 5minute incubation at 95oC to deactivate the 
polymerase enzyme. Confirmation of successful cDNA generation was 
achieved by amplification of the GAPDH housekeeping gene. Forward and 
reverse primers for the human GAPDH sequence 
(GCCGAGCCACATCGCTCAGA, GAGGCATTGCTGATGATCTTG 
82 
 
82 
 
respectively) were kindly supplied by Prof. Rosemary Gale. Primers for murine 
GAPDH amplification (Qiagen) were generously supplied by Dr. Jenny 
McIntosh. 
 
2.2.1.15 Isolation of heavy and light chains from hybridoma 
 
Following successful RNA extraction and cDNA generation from hybridoma 
cells, primers for heavy and light chain amplification were obtained from IDT 
according to the protocol by Toleikis et al. (2004) and amplified using the 
platinum PCR SuperMix high fidelity kit (Invitrogen) which employs Taq 
polymerase for amplification, selected to facilitate our subsequent TOPO-TA 
cloning strategy. Agarose gel electrophoresis was performed to determine 
successful heavy and light chain amplification. These were then TOPO-TA 
cloned as per manufacturer’s instructions (Invitrogen). 
 
2.2.1.16 TOPO-TA cloning 
 
To facilitate screening of putative hybridoma cDNA fragments, a TOPO-TA 
(Invitrogen) cloning strategy was used to identify successful isolates. The 
supplied TOPO plasmid vector is supplied in a linearized format possessing a 
single 3’-thymidine (T) overhang with the Topoisomerase I enzyme covalently 
linked to the vector. As the Taq polymerase demonstrates a non-template-
dependent terminal transferase activity, Taq-enzyme PCR amplicons possess 
a 3’-terminal deoxyadenosine (A) overhang. The presence of the 
corresponding T-A overhangs and the Topoisomerase I enzyme facilitates 
efficient ligation of Taq-amplified PCR products into the linearized vector as 
illustrated by Figure 2. Following ligation, high-efficiency E. coli (NEB) were 
transformed with the TOPO vector and plated onto Carbenicillin infused agar 
plates pre-coated with 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-
gal). Further discrimination of successful vector integrants is achieved through 
the chromogenic identification facilitated by deletion of galactosidase enzyme 
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activity. X-gal is a lactose analogue which will form an indigo pigmented 
substrate due to dimerization of 5-bromo-4-chloro-3-hydroxyindole following 
galactosidase-mediated cleavage. Where the galactosidase enzyme 
sequence of the TOPO vector is interrupted by PCR ligation, enzymatic activity 
is ablated and resultant colonies will appear white on the agar plate. Following 
overnight culture, white colonies located proximal to indigo colonies were 
isolated for further analysis. 
 
  
2.2.2 Bacterial manipulation 
2.2.2.1 Growth and maintenance of E.coli 
 
E.coli were grown in liquid LB (miniprep) or TB (midiprep) media with 10mg/ml 
Carbenicillin (LB-Carb/TB-Carb) at 37oC with agitation at 200-250rpm, or 
streaked out on solid LB-Carb agar plates. For long term storage, bacterial 
Figure 2 – TOPO-TA cloning strategy. Illustration is taken from the Invitrogen 
TOPO-TA cloning manual 
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cultures grown from a single colony were stored in 20% volume for volume 
(v/v) glycerol and stored at -80oC. 
 
2.2.2.2 Bacterial transformation 
 
Competent DH5α E.coli were transformed by heat shock as follows: 25µl 
competent bacteria were thawed on wet ice. For DNA grow-up, C2988 E.coli 
were used; for ligations, C2987 E.coli were used. 1-10ng DNA or ligation 
reaction mix was added to the relevant E.coli and incubated on ice for 
30minutes. Bacteria were transferred to a 42oC water bath for 35 seconds then 
placed on ice for 2minutes. 250µl SOC media was added and the cells were 
incubated at 37oC with 200-250rpm shaking for 40-80minutes. The resulting 
culture was streaked onto an LB-Carb agar plate (100µg/ml) and incubated 
overnight at 37oC in a bacterial incubator.  
  
2.2.3 Cell culture 
 
2.2.3.1 Suspension cells 
 
Non-adherent suspension cell lines, including SupT1s, Jurkats and TCRko 
Jurkats were cultured in complete RPMI. K562s were cultured in complete 
IMDM. All of these cell lines were cultured in upright 75cm2 or 175cm2 tissue 
culture flasks at 37oC and 5% CO2. Cells were maintained at a density of 0.2-
2x106/ml; when confluent they were passaged at a dilution of 1:8-1:20 by 
removal of cells and old media followed by addition of fresh complete media. 
Discolouration of the phenol red indicator was used to visualise cell 
confluency. 
 
2.2.3.2 Adherent cells 
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Adherent cells, including 293T cells, were cultured in complete IMDM in 
175cm2 flasks at 37oC and 5% CO2. When the cells reached around 80% 
confluency, they were washed in 1x PBS before adding trypsin/EDTA solution. 
Following dissociation treatment, the cells were re-suspended in a single cell 
solution, centrifuged at 400G for 5minutes and the media was discarded. Cells 
were then re-suspended in fresh complete IMDM and re-plated in a fresh flask 
at a dilution of 1:8-1:12. 
 
2.2.3.3 Hybridoma cell lines 
 
BBM.1 hybridoma cells were ordered as a cryopreserved sample from 
American Type Culture Collection (ATCC) and were recovered upon delivery 
as described in section 2.2.3.4 Cryopreservation and recovery of cryopreserved 
cells. Cells were initially cultured at 37oC and 5% CO2 in complete RPMI at a 
density of 2x105/ml and subsequently maintained at 1x105-1x106 cells/ml as 
described in the culture instructions (LGC 2012).  
 
2.2.3.4 Cryopreservation and recovery of cryopreserved cells 
 
For long-term storage, where appropriate, cells were cryopreserved as 
follows: Cells were harvested whilst in optimal growth conditions and counted 
before being centrifuged. The media was removed and the cell pellet was left 
on ice for 10minutes. Cryopreservation tubes were also cooled on ice. Cells 
were then re-suspended at 5x106/ml in freezing media. 1ml of the freezing 
media-cell suspension was aliquoted to each cryopreservation tube. Cells 
were then transferred to -80oC in a cooled isopropanol freezing container (“Mr. 
Frosty” Nalgene), allowing for a controlled temperature decrease of around -
1oC per minute. The following day, cells were transferred to the vapour phase 
of liquid nitrogen for long term storage in a liquid nitrogen dewar. When 
required, cells were removed from liquid nitrogen, rapidly warmed to 37oC and 
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washed twice in warm complete media before being cultured as previously 
described for downstream applications. 
 
2.2.3.5 Isolation of PBMCs 
 
Consent was gained before obtaining any blood from healthy donors, with a 
trained medic performing the venesections. Donors were monitored before 
and after venesection to ensure safety at all times. No more than 100ml was 
taken from any donor at one time. Whole blood obtained by venesection and 
anti-coagulated with sterile EDTA was diluted 1:1 with plain RPMI and 25ml 
was layered onto 12.5ml Ficoll-Paque in 50ml centrifuge tubes. Tubes were 
centrifuged at 750G for 40 minutes at room temperature without brake. After 
centrifugation, the buffy coat at the Ficoll-plasma interface was removed using 
a sterile transfer pipette. The PBMCs were then washed twice; once in plain 
RPMI; the second time in complete RPMI, before being re-suspended in 
complete RPMI. Cells were then either cryopreserved (see section 2.2.3.4 
Cryopreservation and recovery of cryopreserved cells) or cultured at 1x106/ml in 
complete RPMI in 24-well tissue culture treated plates. For transduction 
experiments, PBMCs were stimulated on the day of isolation with 5µg/ml PHA, 
followed by 100IU/ml recombinant human IL-2 on day 2, ready for transduction 
24hours later. 
 
2.2.3.6 HLA Typing 
 
PBMCs were HLA-typed in one of two ways. Cells were either stained with the 
relevant subset(s) of anti-HLA antibodies (see 2.2.6 FACS analysis), or cells 
were submitted for HLA-typing to the Bone Marrow Transplant Office at Great 
Ormond Street Hospital, London, where PBMCs were analysed for HLA type 
by sequence-specific oligonucleotide primed PCR (PCR-SSO). 
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2.2.3.7 Alternative T cell stimulation  
 
The most commonly used method of stimulation of T cells was using the 
PHA/IL-2 protocol described above. For T cells that were to be electroporated 
with mRNA, alternative strategies were tested in order to try and optimise T 
cell stimulation. One method attempted was to use CD3 (OKT3) and CD28 
antibodies in place of PHA, but to still use IL-2 in the same way as described 
above. CD3/CD28 Dynabeads (Life Technologies) were as another option, 
which could then be removed by MACS columns if required, according to 
2.2.7.1 General magnetic bead selection protocol. 
 
2.2.3.8 Electroporation of mRNA into T cells  
 
T cells were stimulated in one of the ways described above for three days after 
Ficoll-Paque isolation from PBMCs. On day three, T cells were harvested and 
re-suspended in cytoporation medium T buffer (BTX) at a concentration of 
2.5x106/ml. 400µl of T cells were added to 2mm electroporation cuvettes 
(BTX), along with 5-10µg of mRNA. A control mRNA encoding the eGFP 
marker gene was included. T cells were electroporated according to the 
following protocol: 
Table 4 – Electroporation protocol for electroporation of human T cells with mRNA 
Pulse Group 1          Group 2 Group 3 
Amplitude (V) 1200          1200 130 
Duration (ms) 0.1 0.1 0.2 
Interval (ms) 0.2 100 2 
Number of pulses       1 1 4 
 
After electroporation, T cells were recovered into pre-warmed complete RPMI 
for 24-48hours at 37oC, 5% CO2 without cytokines. Cells were recovered in 
this way to prevent stimulation through the TCR, which would help TCR+ T 
cells to survive preferentially over the TCR- T cells. It also takes at least 
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24hours for the mRNA to be translated and expressed and for remaining TCRs 
on the cell surface to be internalised. Modified T cells were transduced with 
retroviral supernatant containing a CAR using the method described in section 
2.2.5 Retroviral transduction. 
 
2.2.4 Retroviral work 
 
2.2.4.1 Retronectin coating of TC plates 
 
Non-tissue culture treated 24-well plates were prepared by pre-coating plates 
with 500μl of PBS supplemented with 8μl of retronectin/ml at least 24hours 
prior to suspension cell transduction. Plates were wrapped in Parafilm and 
stored at 4oC until required. Retronectin supplemented PBS was reused up to 
twice by direct transfer to fresh plates and stored as above until required. 
 
2.2.4.2 Transient transfection for expression testing 
 
Transient transfections were performed in multi-well TC-treated dishes or 
plates as required with volumes of media, Genejuice and DNA as indicated by 
Table 5: 
Table 5 – Transfection calculation matrix 
Plate / dish Genejuice Plain media DNA 
100mm dish 30µl 470µl 12.5µg 
6-well plate 5µl 95µl 2µg 
12-well plate 2.5µl 47.5µl 1µl 
24-well plate 1.25µl 23.75µl 0.5µg 
 
2x106 HEK293T cells were plated into 6-well plates, 2ml cell culture/well, 
24hours prior to transfection. Cellular confluence was assessed by 
microscopic examination to ensure optimal density prior to transfection. 
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A bulk transfection mixture was prepared where 5µl of Genejuice (Merck) was 
added to 95µl of plain RPMI for each transfection condition to be tested. 
Genejuice is a lipid-based transfection reagent that complexes with DNA to 
facilitate transport of DNA into cells during transfection. Following a 5minute 
incubation to allow formation of Genejuice-micelles, 100µl of the transfection 
mixture was transferred to a separate well of a round-bottomed 96-well plate. 
2µg of plasmid DNA was used for each separate condition to be tested. 
Following a 15minute incubation of DNA, transfection was performed by drop-
wise addition of the transfection mixture over the 293T cell culture. 
 
2.2.4.3 Generation of retroviral supernatant 
 
1.5x106 293T were plated per 10cm tissue culture dish the day prior to 
transfection in 10ml complete IMDM. For retroviral supernatant production, 
RD114-pseudotyped transient retroviral supernatant was generated by triple 
transfection of 4.69µg Peq-Pam plasmid (Moloney GagPol), 3.125µg RDF 
plasmid (RD114 envelope), and 4.69µg SFG (or relevant) plasmid, per 10cm 
plate, into 293T cells using GeneJuice (Novagen). DNA was combined in 
470µl plain IMDM and 30µl Genejuice was added. Transfection mix was 
incubated for 15 minutes at room temperature, followed by drop-wise addition 
to cells. Supernatant was harvested at 48hours and stored at 4oC overnight. 
10ml of pre-warmed complete IMDM was added to the plates and a second 
harvest was collected at 72hours. The two harvests were combined before 
being snap frozen in a bath of dry ice and ethanol and stored at -80oC. 
 
2.2.5 Retroviral transduction 
 
Below is a general protocol followed for retroviral transduction. Modifications 
that were made depending on cell type are noted at the end. Pre-coated 
Retronectin plates were aspirated to remove the Retronectin before 250µl of 
retroviral supernatant was used to pre-coat the wells during cell harvest. This 
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retroviral supernatant was removed immediately prior to addition of 
suspension cells to be transduced.  
 
2.2.5.1 Retroviral transduction of suspension cells 
 
Cells were harvested and re-suspended at 6x105 cells/ml. 500µl of this cell 
suspension was added to each well of the Retronectin plate, along with 1.5-
2ml of retroviral supernatant. Plates were spun for 40minutes at 1000G and 
returned to the incubator at 37oC, 5% CO2 for two days before downstream 
processing.  
 
2.2.5.2 Retroviral transduction of adherent cells 
 
293T cells were transduced as follows: Cells were plated at 1x106 cells per 6-
well plate, with 2ml of medium plated in each well. The following day, plates 
were observed for confluence with the well selected for transduction based on 
confluence, growth and attachment profiles. Transduction was performed by 
removal of all media. This was replaced with 2ml of retroviral supernatant 
along with 20µg of polybrene. Cells were then returned to the 37oC, 5% CO2 
incubator overnight. The above transduction process was repeated daily until 
the 293T cells achieved confluence, when they were sub-cultured into a 
175cm2 flask. Cells were then processed downstream to determine transgene 
expression, and if appropriate, aliquots were cryopreserved and added to the 
group cell line bank. 
 
2.2.5.3 Retroviral transduction of human PBMCs 
 
Primary human PBMCs were isolated and stimulated as described in 2.2.3.5 
Isolation of PBMCs. PBMCs were then harvested, counted and re-suspended 
at a concentration of 6x105 cells/ml. The PBMC suspension was 
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supplemented with 400 I.U./ml of recombinant human IL-2 and 500µl of this 
cell suspension was transferred to each well of the retronectin coated plate. 
1.5ml of retroviral supernatant was added to each well and cells were spun at 
1000G for 40minutes at 37oC prior to return to the 37oC, 5% CO2 incubator for 
two days before downstream processing. 
 
2.2.6 FACS analysis 
2.2.6.1 Assessing transduction efficiency by FACS 
 
FACS analysis was performed to determine transduction efficiency. 
Transduced cells were harvested from retronectin-coated plates and either left 
to recover for 48-72hours or analysed straightaway, depending on the 
experimental requirement. If the construct used had a fluorescent marker gene 
included, cells were washed in 1x PBS buffer before being analysed on a CyAn 
(Dako), LSRFortessa or FACSVerse (both BD) flow cytometer. If the construct 
used had the RQR8 sort-suicide gene included, then transduction efficiency 
was analysed by CD34 expression, and therefore a relevant anti-CD34 
(QBend10) antibody was used, if necessary performing a two-step staining 
process. Cells were washed in-between staining steps with 1x PBS and 
analysed on the flow cytometers described above. In order to obtain target cell 
populations, gating was performed on the acquired cells to obtain a live 
population, based on forward scatter (FSC) and side scatter (SSC), followed 
by gating on combinations of marker genes and/or fluorescently-stained cell 
surface markers as required. 
 
2.2.6.2 General antibody staining protocol 
 
In order to analyse cell surface expression of various proteins, FACS analysis 
was used. Cells to be analysed were harvested into 5ml FACS tubes. Tubes 
were filled with 1x PBS and spun at 400G for 5 minutes. Supernatant was 
discarded, the FACS tubes were blotted on paper towel and the cell pellet was 
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re-suspended by vortexing. The relevant volume of antibody was added as per 
the manufacturer’s instructions and cells were vortexed briefly before being 
stored at room temperature in the dark for 15-30minutes. After staining, cells 
were again washed with 1x PBS and spun at 400G for 5minutes. Supernatant 
was discarded and the FACS tubes were blotted onto paper towel. Cells were 
then re-suspended in up to 500µl of 1x PBS and vortexed before being 
analysed on a flow cytometer. If multiple antibody staining steps were required, 
the staining cycle was repeated for each staining required, with a 1x PBS wash 
and spin performed between each step to remove any excess unbound 
antibody. FACS tubes were placed in wet ice pending flow cytometry analysis. 
Relevant non-transduced/non-stained/single-stained controls were included 
for benchmark comparison. 
 
2.2.6.3 PFA fixation protocol 
 
Where sample analysis was delayed overnight, following the final wash after 
antibody staining, samples were fixed by final re-suspension into 0.4% PFA-
PBS solution and stored at 4oC before flow cytometry analysis.  
 
2.2.6.4 Intracellular staining  
 
For intracellular IFNγ staining, the BD Cytofix/CytopermTM kit was used. Firstly, 
GolgiStopTM was incubated with the cells to be stained according to the 
manufacturer’s instructions to stop and further secretion of intracellular 
cytokines. After GolgiStopTM had been incubating with the cells for no longer 
than 12hours, cells were harvested and spun down at 400G for 5minutes. Cells 
were washed in 1x PBS as previously described, then stained with any 
relevant cell surface antibodies that were being included in the analysis. After 
staining for cell surface molecules, cells were washed in 1x PBS, then they 
were fixed and permeabilised using the solutions provided in the BD 
Cytofix/CytopermTM kit, for 20minutes at 4oC. Cells were then washed twice in 
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the BD Perm/WashTM buffer and centrifuged as before. Cells were re-
suspended in 50µl of BD Perm/Wash buffer and intracellular anti-IFNγ-FITC 
(eBioscience) antibody was added and incubated with cells at 4oC for 
15minutes. After intracellular staining, cells were washed twice in 1x PBS 
before being analysed by flow cytometry. 
 
2.2.6.5 Staining cells with secreted soluble antibody 
 
Secreted versions of some antibody transgenes were cloned into the SFG 
expression vector. The secreted versions contain a human Fc region, which 
can be targeted using an anti-human Fc antibody. By using secreted versions 
of antibodies, it is possible to determine whether they bind to their reported 
target of interest or not. These constructs are transfected into 293T cells as 
described in 2.2.4.2 Transient transfection for expression testing. After 
48hours, crude supernatant is removed and used to stain cells of interest. After 
cells of interest have been harvested into 5ml FACS tubes, up to 4ml of crude 
supernatant is added. Tubes are vortexed and incubated at room temperature 
for 15minutes in the dark. After 15minutes, cells are centrifuged at 400G for 
5mins and supernatant is discarded. Cells are then re-suspended in the 
remaining fluid and 2.5µl of the relevant anti-human-Fc-Dylight antibody is 
added. Cells are vortexed again and incubated for a further 15minutes at room 
temperature in the dark before being washed in 1x PBS. Cells are then treated 
as they would be for a regular flow cytometry analysis. Successful acquisition 
of the fluorophore in the analysis indicates that the secreted antibody is 
successfully binding to its target on the cell surface. 
 
2.2.6.6 FACS sorting of transduced cells 
 
Cells needing to be sorted to obtain a pure population were harvested and 
stained (if required) as described in section 2.2.6.2 General antibody staining 
protocol, with the exception of the process being carried out in sterile conditions 
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with capped FACS tubes. After cell preparation, cells were re-suspended in 1-
2ml of complete media. The machine used for FACS sorting was the MOFLO 
XDP (Beckman Coulter). Initially, a few cells were acquired and the relevant 
parameters were set on the software (Summit) to allow for sorting of the 
desired population. When parameters had been set, cells were run through 
the MOFLO XDP, and sorted cells were collected in a fresh FACS tube 
containing 1ml of FCS with 1mg/ml of antibiotic Normocin (Invivogen). After 
sorting, cells were removed from the MOFLO XDP, centrifuged and recovered 
into a 25cm2 or 75cm2 flask, also containing 1mg/ml Normocin. Cells were 
allowed to recover for 3-14 days and were regularly checked for any bacterial 
contamination. Once recovered, the cells were analysed by flow cytometry to 
verify their purity. 
 
2.2.7 In vitro magnetic cell selections 
 
When using the RQR8 sort-suicide gene as part of a multiple-construct 
expression vector, it was possible to perform cell selections using the MACS 
system (Miltenyi). This system was also used for TCR+/-, CD34+/- and CD56+/- 
selections. 
 
2.2.7.1 General magnetic bead selection protocol 
 
Magnetic bead selections were performed on both immortalised cell line and 
primary human T-cells when required. For cell lines, 20µl of beads were used 
to select <1.0x107 cells, separated using an MS column. For human primary 
T-cells, 100µl of beads were used to select <1.0x108 cells, separated using LS 
columns. Beads were added to cell suspensions and incubated for 15minutes 
at 4oC in the dark. Cells were then spun down at 400G for 5minutes and the 
supernatant was aspirated. Cells were re-suspended in MACS buffer before 
being run on the relevant column. For a positive selection, cells were added to 
LS or MS columns, run-through was discarded and bound cells were eluted 
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by addition of MACS buffer and using a plunger to wash off the bound fraction. 
Negative selections were performed using LD columns, with the unbound 
fraction kept and the bound fraction discarded. The required cells were then 
spun down at 400G for 5minutes. Supernatant was removed and cells were 
re-suspended in the relevant complete media. A cell count was performed and 
cells were cultured at appropriate densities as previously described. 
 
2.2.7.2 T cell magnetic bead selection 
 
As anti-TCR MACS beads were unavailable, a two-step protocol was used, 
where T cells were stained with aTCR-biotin antibody using the general 
antibody staining protocol (2.2.6.2 General antibody staining protocol). After 
washing in 1x PBS, cells were re-suspended in MACS buffer and streptavidin 
beads were used to bind to the biotin molecule on the aTCR antibody. Cells 
were then selected as described above on the relevant column. 
 
2.2.7.3 NK cell magnetic bead selection 
 
To exclude residual NK cells and potential lymphokine-activated killer cells 
prior to 3H assays, samples were depleted of CD56-expressing effector cells. 
For negative depletions, 20µl of beads were used to select <1.0x107 cells, 
separated using LD columns. Where required, multiple separations were 
performed in tandem. 
 
2.2.8 Cell-based assays 
 
Several cell-based assays were performed to determine cell function, 
expression and interaction. These are described below: 
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2.2.8.1 T cell incubation assays 
 
In order to determine the mechanism of apparent TCR knockdown achieved 
by the ER retention strategy (5.4.3 Knockdown of TCR by aTCR-SEKDEL 
constructs in donor PBMCstransduced and non-transduced autologous T cells 
were co-cultured together in various ways. Firstly, both sets of T cells were 
incubated together in a tissue culture-treated 24well plate at a 1:1 ratio for two 
days, followed by flow cytometry analysis as described in 2.2.6 FACS analysis. 
A repeat of this experiment using the same set-up was performed using a 
6.5mm 0.4µM pore transwell (Corning) insert in several wells of a 24well tissue 
culture-treated plate to separate the non-transduced and the transduced T cell 
populations. After two days of co-culture, non-transduced T cells were 
removed and stained as previously described, followed by flow cytometry 
analysis. 
 
2.2.8.2 3H-thymidine uptake proliferation assay 
 
To perform this functional assay, 105 effector cells were plated in triplicate in 
U-bottomed 96 well plates with various ratios (16:1 to 1:1) of allogeneic 
irradiated transduced cells. For T cell irradiation, 30Gray of X-ray was used; 
for cell lines, 120Gray of X-ray was used. Irradiations were all performed using 
an AGO HS MP-1 X-ray irradiator. After 5 days of co-culture at 37oC and 5% 
CO2, wells were pulsed with 1µl (37Bq) 3H-thymidine and incubated at 37oC, 
5% CO2 for a further 20 hours. Cells were then cells were harvested to a filter 
mat using a Tomtec MachIIIM Harvester 96. MeltiLex wax scintillation was 
applied, and thymidine incorporation measured using a Wallac 1450 
MicroBeta trilux beta-counter (Perkin Elmer). Specific proliferation was 
calculated by subtracting mean counts per minute (cpm) of effector and target 
alone control wells from those containing effector cells stimulated with target 
cells. 
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2.2.8.3 51Chromium release assay 
 
Functional demonstration of the effector capability of donor PBMCs and NK 
cells was measured by chromium release assays performed against K562 
cells expressing HLA molecules. 
 
Chromium release was calculated as follows: 
Chromium release = [(Experimental release – background release)*100] / 
(Maximum release – background release) 
K562 cells were loaded with 51Chromium as follows: approximately 1x106 
target cells were isolated for each target. Cells were harvested by 
centrifugation, supernatant was discarded and the residual cell pellet was 
gently re-suspended. 3.7MBq of 51Cr labelled sodium chromate (Perkin Elmer) 
was added to each tube of targets. Cells were incubated for 1hour and gently 
agitated every 15minutes. Following loading, residual chromium was removed 
by five consecutive complete media washes, before the cells were re-
suspended in media ready for use in the assay. 
The K562 cell line was transduced with either the SFG.HLA-A2.eGFP or 
SFG.HLA-G.eBFP2 construct. Following transduction, cells were purified by 
MOFLO cell sorting according to fluorescent gene expression. Cells were 
allowed to recover for 24hours before they were used in the assay. Target 
cells were then combined with PBMCs or NK cells (both derived from the same 
donor). Effector cells were then incubated with the relevant target cell line for 
2hours before obtaining a readout using a gamma counter. 
 
2.2.9 Statistical Analysis 
 
Statistical analysis was performed where indicated, using either Graphpad 
Prism software or Microsoft Excel to calculate averages, means, standard 
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deviation (SD) or standard error of the mean (SEM). Relevant statistical 
analyses were performed on data where appropriate in order to gain insight 
into the significance of results. For data presented in column format, values 
were calculated using one-way ANOVA analyses.  
Where indicated: 
‘*’  - p≤0.05 
‘**’  - p≤0.01 
‘***’  - p≤0.001 
‘****’ - p≤0.0001 
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Chapter Three: HLA 
Class I knockdown 
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3.0 Aims 
 
 To investigate various strategies that could result in the knockdown of 
HLA Class I from a cell surface. 
 To determine which strategy is the most successful in achieving HLA 
Class I knockdown. 
 To analyse the functional effect of the HLA Class I knockdown. 
 
3.1 Introduction 
 
HLA is expressed on the surface of most human cells. Its major function is in 
immunity, as HLA molecules are the mechanism by which peptides are 
presented on the cell surface to either activate or prevent an immune 
response. The majority of HLA molecules come under the classical Class I 
(HLA-A, -B and -C) or non-classical Class II (HLA-E, -F and -G) categories. 
These are all transmembrane glycoproteins that comprise a heterodimer of a 
polymorphic 45-kilodalton (kDa) chain and a non-polymorphic 12kDa beta-2-
microglobulin (β2m) chain (Bjorkman & Parham 1990; Shawar et al. 1994). 
When cells are infected by virus, or are transformed into cancerous cells, HLA 
expression is often down-regulated in order to bypass the immune surveillance 
that would otherwise eliminate the unhealthy cells (Hicklin et al. 1999). From 
immunohistochemical analysis of surgically excised tumours, multiple HLA 
expression phenotypes have been noted, including complete HLA Class I 
down-regulation, selective loss of a HLA Class I haplotype, selective down-
regulation of a HLA locus, selective loss or down-regulation of a HLA allele, 
and a combination of the above to create a complex phenotype (Ferrone & 
Marincola 1995; Garrido et al. 1997). Several of these phenotypes have been 
displayed in one tumour sample, demonstrating the ability of cancerous cells 
to modulate HLA Class I expression to ascertain the optimal method of 
preventing an immune response. 
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The molecular basis of these phenotypes is often due to mutations in key 
genes, with ‘hot spots’ of mutations localised to the β2m gene, frequently 
reported as being responsible for complete HLA Class I loss in colon 
carcinoma and melanoma cells (Bicknell et al. 1994; Hicklin et al. 1998). Other 
mutations modulate the ability of cells to process antigen and fold HLA 
molecules. Genes including latent membrane protein (LMP)-2, LMP7, TAP1 
and TAP2 were found to be down-regulated in small cell lung carcinoma cell 
lines (Restifo et al. 1993). In a study investigating viral infection of cell lines by 
Human immunodeficiency virus (HIV), HLA Class I was shown to be down-
regulated a few days post-infection, and that peripheral CD4+ T cells affected 
by down-regulated HLA Class I were targeted less by allogeneic Class I-
restricted CTLs compared to uninfected cells (Kerkau et al. 1989).  
 
3.2 Approaches to HLA Class I Knockdown 
 
There are various ways in which proteins can be eradicated from a cell. They 
can be targeted at the genomic level by methods such as ZFNs (discussed in 
chapter five); at the mRNA level by siRNA or microRNA (miRNA); at protein 
level by retention sequences and antibodies (Pelham 1990; LGC 2012). As 
seen in the above section, transformed cells and viruses are able to modify 
the HLA Class I expression in various ways. The aim was to mimic some of 
these strategies to achieve HLA Class I knockdown in healthy, non-
transformed cells.  
To target mRNA, the most commonly used technology is siRNA, although 
miRNAs are becoming more popular as their mechanisms and targets are 
better elucidated. siRNA technology was discovered by Fire et al. (1991) and 
has subsequently been shown to be effective at knocking down mRNA in 
multiple model organisms. siRNA works by using small 20-25 nucleotide-
length RNAs which assemble into RNA-induced silencing complexes (RISCs), 
which are then able to cleave the target mRNA, leading to its degradation 
(Whitehead et al. 2009). The advantage of using siRNA as a knockdown 
strategy is that the molecule is very small and can target a specific sequence 
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of mRNA. Conversely though, siRNA may be recognised as foreign and 
destroyed and it may cause off-target interactions. It is also difficult to get 
complete knockdown due to the siRNA machinery which can get saturated 
and the recent ability to elucidate the function of microRNAs may mean that 
these have become the optimal method of RNA interference (Boudreau et al. 
2008; Meister et al. 2004).  
In order to obtain knockdown of a protein, one strategy that was used in this 
project was to combine the specificity of an antibody against a protein with a 
retention sequence to retain the protein within the cell and prevent its surface 
expression. Retention sequences were first characterised by Munro and 
Pelham (LGC 2012), who showed that an amino acid sequence of ‘KDEL’ 
which was present on the C-terminus of three luminal ER proteins was 
responsible for their retention in the ER. Following on from this, it was shown 
that this sequence, when attached to various proteins, could be used to retain 
them in the ER and other locations (Pelham 1990; Andres et al. 1990). To 
target a protein in a specific manner and retain it within the ER, the strategy in 
this study required a molecule attached to a retention sequence that would 
bind to the protein of interest. This approach allows for a specific targeting of 
a protein and for intracellular retention, but the drawback is that it might cause 
ER stress due to the large amount of protein being retained in the ER. This 
could cause the activation of the unfolded protein response (UPR) and would 
lead to up-regulation of ER stress proteins including inositol-requiring enzyme 
(IRE)-1, activating-transcription factor (ATF)-6 and protein kinase RNA-like 
endoplasmic reticulum kinase (PERK), leading to ER-associated degradation 
(ERAD), translational attenuation and possible apoptosis (Rutkowski & 
Kaufman 2004; Schröder & Kaufman 2005). Knockdown of HLA Class I 
molecules by using a protein targeting method was preferable to using DNA 
editing molecules as it removed the risk of mutations caused by non-
homologous end joining (NHEJ), making this project safer and more viable. It 
also allows the use of a viral packaging and delivery system and therefore can 
be combined with other strategies, reducing the number of selection stages to 
obtain a homogenous cell product. 
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3.3 Testing of constructs 
 
Several siRNA and protein based strategies were investigated to cause 
knockdown of HLA Class I, with the aim of identifying the optimal strategy to 
take forward in the overall project. Some of these strategies have been 
described by other investigators, and some are novel. The approaches can be 
categorised as: (i) viral proteins (ii) dominant-negative β2-microglobulin (iii) 
siRNA (iv) single chain Golgi retention molecules generated from BBM1 and 
BB7 hybridomas (scFvs).  
 
3.4 Viral proteins 
 
It has been shown that the use of viral transgenes results in a decrease in the 
ability to present antigens on the cell surface MHC Class I molecules by 
disrupting the CD8+ CTL response (Radosevich et al. 2003). The viral proteins 
used were herpes simplex virus (HSV) protein ICP47 and human 
cytomegalovirus (HMCV) protein unique short glycoprotein (US)-11. ICP47 is 
a small 88 amino acid protein that binds to transporter associated with antigen 
processing (TAP). This prevents peptide translocation and loading onto MHC 
Class I molecules in the ER, leading to the degradation of immature MHC 
Class I. US11 is a 215 amino acid protein which ubiquitinates MHC Class I 
molecules in the ER, leading to retrotranslocation to the cytosol and 
subsequent degradation by the proteasome. Both of these proteins were 
cloned using oligonucleotide assembly (Figure 3). After initial testing, both 
were shown to have promising effects, which prompted the step of cloning 
both proteins together in one construct, joined by a 2A peptide. In a similar 
study by Berger et al. (2000), ICP47 and US11 were both tested to determine 
their efficacy at preventing transgene expression by CD8+ T cells. The aim 
here was to attempt something similar but to determine whether the use of one 
or both viral proteins was sufficient to prevent a response, and also, when 
used with the sort-suicide gene RQR8, to demonstrate the ability to generate 
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a homogenous pool of modified cells instead of doing this by FACS as in the 
study above. 
 
 
3.5 Beta-2-microglobulin 
 
β-2-microglobulin (β2m) is a subunit of the MHC Class I molecule that has 
been shown to function as a chaperone for MHC Class I molecule folding (Fink 
1999) and is also a major subunit of the molecule itself (Bix & Raulet 1992; 
Seong et al. 1988; Zijlstra et al. 1990). A mutant β2m defective in binding to 
the α1 and α2 subunits of the MHC Class I molecule has been shown to block 
Figure 3 – Construct designs for the viral proteins ICP47 (top) and US11 (bottom). 
Blue arrows indicate oligonucleotides used to build genes through oligonucleotide 
assembly, multi-coloured blocks denote amino acid sequence. 
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the extracellular folding of MHC Class I molecules, thereby knocking down 
HLA from the cell surface (Hill et al. 2003). These β2m mutants were 
generated by using oligonucleotide assembly to create mutant forms of wild-
type β2m (Figure 4). We generated the same mutants as Hill et al. (2003), 
namely β2m with a D53K mutation, β2m with a W60A mutation and β2m with 
both the above mutants (D53K/W60A). 
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3.6 siRNA 
 
siRNA is a powerful tool that has been developed to knockdown specific 
targets. Vector strategies have been developed which allow continuous 
Figure 4 – Construct designs for mutant β-2-microglobulin molecules. From top to 
bottom, wild-type, D53K, W60A and D53K/W60A mutant designs. Blue arrows 
indicate oligonucleotide primers to amplify β2-microglobulin from the EST_5502428 
clone; multi-coloured blocks denote amino acid sequence. 
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delivery of siRNA from an integrated vector. This is another strategy that was 
used to cause HLA Class I knockdown by using two siRNAs targeting β2m, as 
previously described (Gonzalez et al. 2005; Haga et al. 2006). We also 
generated our own designs against β2m (Thermo Scientific 2011) (Figure 5). 
These were generated by single-pair oligonucleotide annealing and assembly 
before being cloned into the pSuperRetro.eGFP plasmid, which drives the 
production of siRNA using the RNA polymerase III promoter. 
 
 
3.7 scFvs derived from hybridomas 
 
The BBM1 hybridoma was obtained from ATCC (LGC 2012) and heavy and 
light chains were extracted and cloned together to create an scFv against β2m, 
using the Dubel primers (Toleikis et al. 2004) (Figure 6). A paper by Mhashilkar 
et al. (2002) showed knockdown of HLA expression using intrabodies derived 
from the BB7 hybridoma. Intrabodies are antibodies expressed in various 
intracellular compartments that are designed to modify or block target 
molecule function or expression. They work by either neutralising the target 
protein through direct binding to the functional domain, interfering with binding 
partners or by diversion of the target to a different subcellular compartment to 
prevent function (Cardinale & Biocca 2010). In the study by Mhashilkar et al. 
1. GATCCCCGGAGATCACACTGACCTGGCATTTGTGTAGTGCCAGGTCAGTGTGATCTCCTTTTTAAGCT 
   
2. GATCCCCGCTGTGGTGGTGCCTTCTGGTTCAAGAGACCAGAAGGCACCACCACAGCTTTTTAAGCT 
 
3. GATCCCCCTCCAAAGATTCAGGTTTATTCAAGAGATAAACCTGAATCTTTGGAGTTTTTAAGCT  
  
4. GATCCCCCAGAGAATGGAAAGTCAAATTCAAGAGATTTGACTTTCCATTCTCTGTTTTTAAGCT 
   
5. GATCCCCGCAGAGAATGGAAAGTCAATTCAAGAGATTGACTTTCCATTCTCTGCTTTTTAAGCT 
   
6. GATCCCCCCAAGATAGTTAAGTGGGATTCAAGAGATCCCACTTAACTATCTTGGTTTTTAAGCT 
  
7. GATCCCCGTGTGAACCATGTGACTTTTTCAAGAGAAAAGTCACATGGTTCACACTTTTTAAGCT 
Figure 5 – Sequences of siRNA used to target knockdown of β-2-microglobulin. Blue 
highlighted sequence shows sense and anti-sense DNA, green highlighted texts shows 
hairpin loop sequence. 1 – ‘Outside_01’; 2 – ‘Outside_02’; 3 – ‘Own_01’; 4 – ‘Own_02’; 
5 – ‘Own_03’; 6 – ‘Own_04’; 7 – ‘Own_05’. Sequences 3-7 were designed using 
siDesign-Center online software. 
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(2002), two scFvs against β2m were created that would knockdown 
expression of human MHC Class I molecules by retaining MHC Class I in the 
ER (Figure 7). This was achieved by linking the scFv to a Golgi retention signal. 
Complete cellular surface knockdown was achieved in Jurkat T cells stably 
expressing an ER-directed sFvhMHCI intrabody. This was then used in 
multiple human cell lines with down-regulation of MHC Class I expression, 
even under inflammatory conditions. This shows that it is possible to achieve 
a reduced level of MHC Class I expression on the cellular surface. The two 
scFvs from this study and one extracted from the BBM1 hybridoma were 
cloned into the SFG vector containing a marker gene. 
 
Figure 6 – Construct design for scFv extracted from the BBM1 hybridoma. Blue 
arrows indicate oligonucleotide primers used to amplify fragments of heavy and light 
chains from products extracted from the hybridoma using Dubel primers. Multi-
coloured blocks indicate amino acid sequence. 
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3.8 Transduction of constructs in cell lines 
 
Figure 7 – Construct design for oligonucleotide assembly of scFvs derived from 
Mhashilkar et al. 2002. sFvhMHC-5 (top design); sFvhMHC-8 (bottom design). Blue 
arrows indicate oligonucleotides; multi-coloured blocks indicate amino acid 
sequence. 
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After assembly of the various constructs, retroviral supernatant (RD114) was 
produced and each of the constructs was individually transduced into the 
SupT1 cell line to assess the efficacy of HLA Class I knockdown. Knockdown 
was assessed by HLA Class I cell surface expression, measured by anti-HLA-
A/B/C antibody staining (Figure 8 and Figure 9). The anti-HLA-A/B/C antibody 
is a mAb derived from the hybridoma clone G46-2.6 and binds to a 
monomorphic epitope on the alpha chain of the MHC Class I antigen (Barclay 
et al. 1997; BD Pharmingen 2011). 
 
 
Figure 8 – HLA knockdown in SupT1 cell line as measured by mean fluorescence 
intensity (MFI). Surface expression was measured using anti-HLA-A/B/C-APC (BD) 
(not titrated). Error bars show S.E.M. (NT – non-transduced; NoAb – No antibody 
used; Ab – antibody used). Experiment repeated three times. One-way ANOVA 
analysis performed to calculate significance. 
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From these results, it can be seen that the two viral proteins, ICP47 and US11, 
are the two most effective constructs at achieving HLA Class I knockdown. 
Both viral proteins act by targeting the HLA Class I molecule as opposed to 
targeting β2m, therefore it appears that this is the more effective method of 
disrupting HLA Class I expression.  
 
3.9 Expression of HLA in K562 cell line 
 
Figure 9 – FACS plots for HLA Class I knockdown in SupT1 cells (same as in Figure 
8). Axes show: x-axis – eBFP2 marker gene; y-axis – aHLA-A/B/C/APC antibody 
(BD). a) Unstained cells b) NT stained cells c) Cells transduced with ICP47 construct 
d) Cells transduced with WT β2m construct. NT – non-transduced. 
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3.9.1 Initial K562 cell line modification 
 
In order to further verify the knockdown achieved by the viral proteins, a HLA 
negative cell line was needed to act as a negative control. The K562 cell line 
is of an erythroleukaemia type and lacks expression of the necessary MHC 
molecules to prevent NK cell activation (Britten et al. 2002) (Figure 10). 
 
The K562 cell line was modified with a construct containing HLA-A*0201 linked 
to β2m with a serine-glycine linker. The vector backbone was SFG. Retroviral 
supernatant was generated and used to transduce the K562 cells (Figure 11).  
Figure 10 – Lack of HLA Class I expression in the K562 cell line. a) K562 cells with 
no antibody b) K562 cells with anti-HLA-A/B/C-APC antibody added. Repeated once. 
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This gene transfer seemed to have failed, leading to the conclusion that there 
may be something wrong with the HLA-A*0201 gene, and therefore the vector 
was sequenced. After sequencing, a non-conservative mutation was 
discovered, resulting in a serine to proline mutation (Figure 12). From 
searching the Immunogenetics (IMGT) database, this is not a recognised 
single-nucleotide polymorphism (SNP) or other polymorphism and was 
therefore determined to be the likely cause of the failure in HLA-A*0201 
expression in the K562 cell line. 
Figure 11 – HLA-A*0201 transduction in K562s. a) NT K562s without Ab b) NT 
K562s with anti-HLA-A/B/C-APC antibody added c) HLA-A*0201 transduced K562s 
with anti-HLA-A/B/C-APC antibody added. (NT – non-transduced). Repeated once. 
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3.9.2 Repair of β2m-L-HLA-A*0201 construct 
 
In order to repair the mutation in the HLA-A*0201 gene, oligonucleotide 
primers were designed by Dr Pule (Figure 13). In a PCR, the 5’ forward 
external primer and the internal reverse primer were used to amplify the first 
fragment using the original construct as the template. The internal forward 
primer and the 3’ reverse external primer were used to amplify the second 
fragment, again using the original construct as a template. These two ‘half’ 
fragments were fused together in the second reaction using the primers at the 
5’ and 3’ ends of the design (below).  
 
Figure 12 – Alignment of original HLA-A*0201 construct (top line of sequence) with 
reference sequence from IMGT database (bottom line of sequence). Serine to 
proline mutation shown in red. 
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It was also decided to create a construct that expressed HLA-A*0201 on its 
own. In order to do this, the β2m gene needed to be removed from the original 
β2m-L-HLA-A*0201 construct. This was again done using oligonucleotide 
primers designed by Dr Pule. This construct required three initial reactions 
before fusing the fragments together (Figure 14). A construct containing β2m 
on its own had previously been assembled, allowing for two strategies to be 
tested here – one of having β2m and HLA-A*0201 in one construct and the 
other of having the two molecules in separate constructs. Correct repair of 
HLA-A*0201 and removal of β2m was verified by DNA sequencing before the 
constructs were tested in K562 cells (Figure 15). 
Figure 13 – Design for repair of β2m-L-HLA-A*0201 construct. Blue arrows show 
oligonucleotides used (and primer orientation), beige boxes show restriction enzyme 
sites, red/orange/yellow boxes show amino acid sequence, plain text shows DNA 
sequence. 
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Figure 14 – Design for repair of HLA-A*0201 construct and removal of β2m. Blue 
arrows show oligonucleotides used (and primer orientation), beige boxes show 
restriction enzyme sites, red/orange/yellow boxes show amino acid sequence, plain 
text shows DNA sequence. 
117 
 
117 
 
 
 
 
3.9.3 HLA Class I transduction in K562 and Daudi cell lines 
 
These two constructs were then used to transduce the K562 cell line. As one 
construct did not have β2m included, a construct containing the β2m gene was 
also transduced into the K562 cell line. The transductions of HLA-A*0201 and 
β2m were done sequentially, not together. The construct containing both β2m 
and HLA-A*0201 failed to transduce successfully, but the doubly-transduced 
cells did express low levels of HLA-A*0201, with 6.22% of the cells being both 
eGFP and eBFP2 positive (Figure 16). Studies have shown that exogenous 
β2m has caused apoptosis in K562 cells and other cell lines (Wu et al. 2002; 
Gordon et al. 2003). As the doubly-transduced cells did express a low level of 
both molecules, this was not investigated further. 
In order to purify the double positive population, cells were put through the 
MOFLO XDP sorter to allow selection of transduced cells, based on eBFP2 
and eGFP co-expression (Figure 17). Cells were sorted to around 90% purity 
and maintained in culture for fourteen days. This was to allow them to recover 
and to ensure that no bacterial or microbial contamination had occurred during 
 
 
β2m-L-HLA-A*0201 Construct 
HLA-A*0201 Construct 
Figure 15 – Sequencing results from the repaired HLA-A*0201 constructs. Green 
boxes show codon for serine residue, correctly repaired from proline. 
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the sorting process. Cells maintained the levels of HLA Class I expression, 
allowing for their use to test the HLA knockdown viral proteins.  
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Figure 16 – Transduction of repaired HLA-A*0201 constructs into K562 cells. a) NT 
K562s with no antibody added b) NT K562 cells with anti-HLA-A/B/C-APC antibody 
added c) K562 cells transduced with β2m-L-HLA-A*0201 construct (eGFP marker 
gene) d) K562 cells transduced with separate HLA-A*0201 (eGFP) and β2m (eBFP2) 
constructs. Percentage shows proportion of double-positive cells. Left column shows 
HLA Class I expression, right column shows expression of marker genes. Repeated 
once. 
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3.9.4 Transduction of viral proteins into HLA-A*0201 expressing K562 
cells 
 
After FACS sorting and allowing the cells to recover, the HLA-A*0201 positive 
K562 cells were transduced, using retrovirus (RD114-pseudotyped), with the 
viral proteins US11 and ICP47 (Figure 18). As can be seen, the effect of the 
ICP47 viral protein was very minimal, but the effect of US11 was 
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distinguishable. As the result here was not conclusive, it was decided to 
proceed with the two viral proteins by testing them in primary cells. 
 
 
3.10 Testing of viral proteins in primary cells 
 
The next step was to take these two viral proteins forward and to test them in 
primary cells (PBMCs). One additional observation from these results was that 
Figure 18 – Transduction of viral proteins into HLA-A*0201 K562 cell line. Top row: 
a) NT HLA-A2*0201 K562 cells with no antibody added b) NT HLA-A2*0201 K562 
cells with aHLA-A/B/C-APC antibody added. Bottom row: HLA-A*0201 K562s 
transduced with c) ICP47 d) US11 (NT – non-transduced). Both constructs have 
eBFP2 marker gene; cells shown are eGFP-gated (HLA-A*0201 construct). 
Repeated once. 
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the anti-HLA-A/B/C-APC mean fluorescence intensity (MFI) was not very high 
for the non-transduced (NT) cells, so the antibody was titrated and the 
transduction was repeated in three donor PBMCs. Figure 19 shows a 
representation of FACS staining for one donor. The constructs used in this 
experiment were ones that contained US11, ICP47 and siRNA_Outside_01. 
The siRNA construct was used as a control. 
 
These results demonstrate that HLA Class I can be knocked down from 
primary cells with a high level of efficacy, and that the previous results obtained 
from the modified K562 cell line can be disregarded. PBMCs transduced with 
the ICP47 and US11 constructs show a high level of HLA Class I knockdown; 
both seeming to be similar in the level of knockdown. The siRNA construct 
was ineffective in the donors. Testing of constructs was repeated in PBMCs 
from eight donors, in order to demonstrate reproducibility regardless of the 
donor HLA haplotype. Data was collated by calculating percentage of HLA 
Class I expression relative to the non-transduced cells, before being averaged 
and presented in Figure 20. The reason for the lack of knockdown by the 
strategies targeting β2m is possibly due to the high levels of endogenous β2m 
present in the cell, meaning that the effect of the constructs was negligible in 
comparison to the amount of β2m. The β2m strategies are also competitive 
strategies, competing with the endogenous β2m present in the cell. The two 
viral proteins act by non-competitive mechanisms, with ICP47 acting as a 
physical block to peptide entry into the ER and US11 binding to immature MHC 
Class I molecules and ubiquitinating them, regardless of the presence of β2m.  
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These results show that it is possible to achieve knockdown of 87% with 
ICP47 and 90% with US11. It was unknown as to whether this level of 
knockdown was sufficient to prevent alloreactivity in an in vivo context. In 
order to achieve the highest level of HLA Class I knockdown possible, the 
next step was to combine these two proteins to determine if their co-
expression could increase HLA Class I knockdown further. In order to do 
this, the viral proteins were expressed in one construct, separated by the 2A 
proteinase (Figure 21).  
 
Figure 20 – Transduction of PBMCs with HLA Class I knockdown constructs, ICP47 
and US11. Graph shows percentage of HLA Class I expression when compared to 
NT cells with Ab – set as 100%. (NT – non-transduced; NoAb – No antibody used; 
Ab – antibody used). Ten donors shown, one-way ANOVA used to calculate 
statistical significance (p<0.0001). Error bars show S.E.M. 
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The 2A proteinase is derived from the foot-and-mouth disease virus (FMDV) 
and is able to ‘self-cleave’ at its own C terminus. In proteolytic processing, 
the primary 2A/2B cleavage of the aphthovirus and cardiovirus is used to 
Figure 21 – Design of double-viral protein transgenes. ICP47-2A-US11 (top) and 
US11-2A-ICP47 (bottom) transgenes shown. Blue arrows indicate oligonucleotide 
primers used to amplify fragments from template DNA. Multi-coloured blocks denote 
amino acid sequence. 
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cleave polyproteins (Donnelly et al. 1997). The 2A peptide is very short, 
around 18 amino acids long, and along with the proline residue located at the 
N terminus of the 2B protein, forms an element capable of autonomous 
cleavage  (Donnelly et al. 2001). There are multiple naturally occurring 
versions of the 2A peptide, mostly originating from viruses. The one used in 
this project was the ‘2A-like’ peptide derived from the insect virus TaV 
(Pringle et al. 1999). The advantage of using the TaV 2A-like peptide over 
the FMDV 2A peptide is that it is shorter, and also has a higher level of 
cleavage activity (>99% compared to ~90% for FMDV 2A) (Donnelly et al. 
2001). This peptide was cloned into an SFG vector, flanked by the two viral 
proteins. In one of the vectors, the orientation of viral proteins was reversed, 
resulting in the following vectors: SFG.ICP47-2A-US11 and SFG.US11-2A-
ICP47. Both vectors had eBFP2 as a marker gene with an internal ribosomal 
entry site (IRES) sequence. Correct assembly was confirmed by sequencing 
and retrovirus was generated for both constructs before transduction into 
PBMCs from two donors (Figure 22).  
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Although the transduction efficiency was low in the cells transduced with the 
ICP47-2A-US11 construct, it can clearly be seen that this construct is more 
effective at achieving HLA Class I knockdown compared to US11-2A-ICP47. 
This suggests that the N terminus of the 2A peptide is inhibiting the activity of 
the attached protein, but the C terminal proline residue does not have any 
effect on activity. The 2A peptide self-cleaves at the C terminus, thereby 
allowing separate expression of both proteins. As a result of the cleavage 
event, an extra proline residue is added to the N terminal of the viral protein at 
the C terminal end of the 2A peptide and nineteen residues are added to the 
C terminus of the first viral protein. This may have a detrimental effect on the 
expression of the US11 viral protein in the US11-2A-ICP47 construct. If further 
investigation was required, the inclusion of a Furin cleavage site at the N 
terminal end of the 2A peptide could be used. As the level of HLA Class I 
knockdown did not appear to be anymore significant than that previously seen 
with the individual constructs, only one viral protein was taken forward in this 
project. Due to US11 being slightly more effective at HLA Class I knockdown 
than ICP47, this protein was the one taken forward for further testing in cell 
lines and functional assays. 
 
3.11 Addition of sort-suicide gene into HLA Class I knockdown 
construct 
 
As the transduction of US11 and ICP47 as separate constructs was 
successful, the next step was to introduce a way of selecting the transduced 
cells. Traditionally, cell sorting has been done based on the expression of a 
fluorescent marker such as BFP or GFP. A member of Dr Pule’s group, Brian 
Philip, has created a novel sort-suicide gene that combines the minimal 
epitopes of the CD20 and CD34 antigens, resulting in a construct that is 
around 136 amino acids in length. This protein is expressed on the cell surface 
and comprises of two CD20 epitopes and one CD34 epitope, protruded from 
the cell surface by a CD8 stalk. The CD20 epitopes are recognised by the 
CD20 mAb, Rituximab, thereby providing a ‘suicide’ mechanism by which to 
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deplete the modified cells. The CD34 epitope is recognised by a CD34 
antibody (QBend10 clone). The expression of the CD34 epitope acts as a 
marker gene, allowing for magnetic selection of transduced cells using Miltenyi 
MACS aCD34 beads (Philip et al. 2014). 
 
3.11.1 Design for creating RQR8-2A-HLA_knockdown constructs 
 
The constructs were created using PCR as described previously, resulting in 
two constructs, SFG.RQR8-2A-ICP47 and SFG.RQR8-2A-US11 (Figure 23). 
Correct assembly was verified by restriction enzyme digest and sequencing. 
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Figure 23 – Construct design for RQR8 assembly with the HLA knockdown viral 
proteins. Top half shows design for SFG.RQR8-2A-US11; bottom half shows design 
for SFG.RQR8-2A-ICP47. Blue arrows indicate oligonucleotide primers used for 
amplification of fragments from template DNA; multi-coloured blocks denote amino 
acid sequence. 
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3.11.2 Transduction and MACS sorting of RQR8-2A-HLA_knockdown 
constructs into SupT1s 
 
After assembly of the above constructs, retroviral supernatant was generated 
and used to transduce SupT1s (Figure 24). The RQR8 sort-suicide gene was 
used as the marker gene in FACS analysis. SupT1s that had been transduced 
were also sorted on their expression of the RQR8 sort-suicide gene. aCD34 
MACS beads (Miltenyi) were used to magnetically sort transduced cells. As 
can be seen, the magnetic selection process is very efficient, giving purity of 
95% for the US11 construct and 99% for the ICP47 construct (Figure 25). It is 
also clear that while both proteins are able to knockdown MHC Class I 
expression on SupT1s and PBMCs by around 90%, US11 seems to be slightly 
more effective at this than ICP47. Therefore, the preferred construct to use 
would seem to be the one containing the US11 viral protein.  
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Figure 24 - Transduction of SupT1s with constructs containing HLA knockdown 
proteins and RQR8 sort-suicide gene. Graph shows percentage of HLA Class I 
expression when compared to NT cells with Ab – set as 100%. (NT – non-transduced; 
NoAb – No antibody used; Ab – antibody used). Eight repeats shown, one-way 
ANOVA used to calculate statistical significance (p<0.0001). Error bars show S.E.M. 
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Figure 25 - HLA knockdown constructs with RQR8 gene transduced into SupT1 
cells followed by a CD34-MACS bead sort. a) NT SupT1s (LHS – No Ab; RHS – 
with Ab). b) SupT1s with RQR8-US11 construct. c) SupT1s with RQR8-ICP47 
construct. For b) and c), LHS shows unsorted cells, RHS shows cells after MACS 
sort. NT – non-transduced; Ab – Antibody. Repeated once. 
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3.11.3 Transduction and MACS sorting of RQR8-2A-HLA_knockdown 
constructs into PBMCs 
 
Due to the success achieved in the SupT1 cell line, the experiment was 
repeated in primary cells (PBMCs) derived from healthy donors, using the 
RQR8 sort-suicide gene as the marker gene (Figure 26). Figure 27 shows 
collated data from four donors.  
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Figure 26 – Transduction of PBMCs with constructs containing HLA knockdown 
proteins and RQR8 sort-suicide gene a) NT PBMCs with no antibody added b) NT 
PBMCs with aHLA-A/B/C-APC and aCD34-PE antibodies added c) PBMCs 
transduced with SFG.RQR8-2A-US11 d) PBMCs transduced with SFG.RQR8-2A-
ICP47 (NT – non-transduced). 
137 
 
137 
 
 
It appears from this experiment that the 2A peptide is not adversely affecting 
expression of the two molecules. In a further repeat of this experiment, after 
transduction, the cells were sorted using aCD34 magnetic beads (Miltenyi) 
(Figure 28).   
Figure 27 – Transduction of RQR8 HLA knockdown constructs in PBMCs. Graph 
shows percentage of HLA Class I expression when compared to NT cells with Ab – set 
as 100%. (NT – non-transduced; NoAb – No antibody used; Ab – antibody used). Four 
donors shown, one-way ANOVA used to calculate statistical significance (p<0.0001). 
Error bars show S.E.M. 
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As can be seen, the magnetic selection enables the effective purification of the 
transduced cells to a high level of purity. This experiment was repeated in 
multiple donors, with FACS analyses performed on different flow cytometers 
(CyAn, LSRFortessa, FACSVerse), with similar results obtained from all 
donors. 
 
Figure 28 – Clinical grade sorting of donor PBMCs transduced with SFG.RQR8-2A-
US11 construct. Top row – NT PBMCs without (LHS) and with (RHS) antibody 
added; second row – SFG.RQR8-2A-US11 transduced PBMCs. LS shows pre-
sorted cells, RHS shows cells after aCD34 MACS bead sort. (NT – non-transduced). 
Repeated three times but statistical analysis not possible due to FACS analysis being 
performed on multiple machines with incompatible software. 
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3.12 Testing the function effect of viral HLA knockdown proteins 
using a mixed lymphocyte reaction 
 
It is clear that the two viral proteins are effective at achieving HLA Class I 
knockdown, and that they can be combined with the RQR8 sort-suicide gene, 
allowing for clinical grade selection of the transduced cells. Despite the high 
levels of knockdown (>90%), it is unknown whether this is sufficient to prevent 
an allogeneic response in an in vivo context. In order to attain an idea of this, 
an MLR was carried out, using PBMCs transduced with the SFG.RQR8-2A-
US11 construct as targets and allogeneic PBMCs as the effectors. As US11 
gave the higher levels of HLA Class I knockdown, this was the construct used 
in the MLR.  
The transgenic cells, containing the HLA Class I knockdown construct were 
positively sorted using aCD34 MACS beads (Miltenyi) (as seen in Figure 28), 
before being irradiated (30Gy) and plated at various effector:target ratios 
(0.5:1 to 8:1). Effector PBMCs were CD56 depleted in order to remove NK 
cells from the co-culture, which would otherwise increase the level of killing 
due to NK-mediated null cell killing. The CD56 depletion was carried out by a 
negative selection of CD56 positive cells using aCD56 MACS beads (Miltenyi). 
The cells were co-cultured for five days, with tritiated thymidine (3H) being 
added on the fourth day, allowing for 20hrs of uptake (Figure 29). 
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From this result, it can be seen that the US11 viral protein has reduced the 
proliferation of the mis-matched effector PBMCs compared to the non-
transduced PBMCs. What is also clear is that it does not completely prevent 
the proliferation of the effector PBMCs. What needed to be shown was how 
much of the proliferation of the effector PBMCs was due to incomplete HLA 
Class I knockdown and how much was due to HLA Class II. In order to do this, 
another MLR was carried out with the same donors used for the target and 
effector PBMCs as the MLR shown in the above figure. Additional controls 
were used, including the use of pan-anti-HLA Class I (derived from the W6/32 
hybridoma) and pan-anti-HLA Class II (derived from the CR3/43 hybridoma) 
blocking antibodies (Barnstable et al. 1978; Naiem et al. 1981). The target 
Figure 29 – MLR using two mis-matched donors. Either NT or US11-modified 
target cells were irradiated (30Gy) before being cultured with HLA mis-matched 
effector PBMCs at the indicated ratios. Chart legend shows targets – NT – non-
transduced donor PBMCs. US11 – donor PBMCs transduced with RQR8-2A-US11 
construct and positively sorted with aCD34 MACS beads. Effector PBMCs were 
negatively selected using aCD56 MACS beads. Cells were cultured for five days 
with 3H added on the fourth day for 20hrs. Performed once in triplicate. Error bars 
show S.E.M. 
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cells were incubated with the HLA blocking antibody/antibodies for 30minutes 
at room temperature in the dark before being irradiated (Figure 30). 
 
This result shows that the viral protein US11 reduces the effector cell 
proliferation by around half. The pan-anti-HLA Class I antibody used in this 
experiment show that there may be some reactivity due to the HLA Class I 
knockdown not being complete. 
 
3.13 Conclusions 
 
In conclusion, novel constructs have been generated that have been shown to 
knockdown the expression of HLA Class I from the surface of both cell lines 
and primary cells. Initially, fifteen different constructs were tested in the 
attempt to achieve knockdown of HLA Class I. These included targeting β2m 
Figure 30 – MLR using mis-matched donor PBMCs (same donors as in Figure 26). 
Legend shows target populations used. NT – non-transduced; US11 – SFG.RQR8-
2A-US11 construct used; Ab – antibody; Class I Ab – pan-anti-HLA-Class I antibody 
derived from W6/32 hybridoma; Class II Ab – pan-anti-HLA-Class II antibody  derived 
from CR3/43 hybridoma. Error bars show S.E.M. Performed once in triplicate. 
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at the mRNA level and protein level, as well as targeting the HLA Class I 
molecule at the protein level by trying to disrupt the trafficking of the HLA 
molecule to the cell surface. The two most successful strategies used were 
derived from HSV (ICP47) and HMCV (US11). These two viruses have 
adapted to avoid the immune surveillance of the host organisms that they 
infect, with one aspect being to down-regulate the HLA expression in infected 
cells to prevent recognition of foreign peptides by the host immune system. 
The ICP47 and US11 proteins are ones that are designed to carry out this 
function, and this is the most likely reason why they have been the most 
successful strategies, with knockdown of 88% and 91% respectively. 
Unfortunately, the modification of the K562 cell line to express HLA-A*0201, 
so that the model of HLA Class I knockdown in a cell line could be further 
verified, was unsuccessful as the level of HLA-A*0201 expression was minimal 
and transduction with the viral protein constructs did not provide any firm 
conclusions from an engineered cell line.  
Despite this, the two viral proteins were very successful at knockdown of HLA 
Class I in primary cells, replicating the knockdown shown in the SupT1 cell 
line. When combining both viral proteins into one construct, the cleavage of 
the FMDV 2A peptide left an additional nineteen residues on the N-terminal 
protein, which impeded the activity of US11 when the construct was orientated 
with US11 as the N terminal protein. The remaining proline residue left on the 
C terminal protein had no apparent effect on expression and activity. In the 
reverse orientation, with US11 as the C terminal protein and ICP47 as the N 
terminal protein, the activity of the two proteins together was no more 
increased than when using US11 on its own. These results suggest that while 
both proteins are capable of causing HLA Class I knockdown individually, 
combining the two proteins into one construct would be inefficient and would 
reduce the remaining vector capacity when introducing the other strategies. 
It was possible, though, to combine the viral proteins with the sort-suicide gene 
using the 2A peptide. The proline residue left on the N terminal protein, in this 
case, the RQR8 sort-suicide gene, had no apparent effect on expression, and 
therefore it was possible to have dual expression of both proteins using just 
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one construct. When transduced into the SupT1 cell line, it was clear that there 
was no reduction in effect of the viral proteins with the addition of the sort-
suicide gene. It was also demonstrated that it is possible to sort the transduced 
cells based on their expression of the RQR8 sort-suicide gene. The RQR8-
2A-HLA knockdown constructs were then taken forward into primary cells and 
shown to have a very similar activity to their activity in SupT1 cells. The RQR8-
2A-US11 construct was shown to cause a reduction in proliferation of effector 
cells in a mis-matched donor context, suggesting that it would be possible to 
use this construct as part of the overall strategy. Another experiment that may 
be valuable to perform would be to use CD8+ T cells as effectors to determine 
if HLA Class I negative cells avoid activating this population. 
 
3.14 Final conclusions 
 
 Successful testing of various strategies aimed at causing HLA Class I 
knockdown. 
 Two strategies clearly more successful than the other strategies tried – 
the HSV protein ICP47 and the HMCV protein US11. 
 Both ICP47 and US11 result in high levels of HLA Class I knockdown. 
 Combination of viral proteins with RQR8 sort-suicide gene allows for 
clinical grade sorting of modified cells by MACS sorting. This has been 
shown in a cell line and in primary cells. 
 Primary cells that have been transduced with US11 cause a reduction 
of proliferation of allogeneic effector cells as shown through MLR. 
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Chapter Four: HLA-G 
expression 
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4.0 Aims 
 
 To determine a method of allowing HLA Class I negative cells to avoid 
NK cell killing. 
 To extract HLA-G from genomic DNA to mimic HLA-G expression by 
trophoblasts. 
 To test the effect of HLA-G expression on NK cell function. 
 
4.1 Introduction 
 
In healthy human tissues, HLA-G gene transcription is present in most cells, 
but this is only translated in certain tissues, including the trophoblast, pancreas 
and thymus. In diseased tissues, HLA-G expression can be found in viral 
infections, malignancies and autoimmune diseases (Carosella et al. 2003). In 
diseased cells and tissues, HLA-G can be found to be expressed by both the 
unhealthy cells and also the infiltrating immune cells, suggesting that HLA-G 
has a role in immune responses and in stressed microenvironments (Carosella 
et al. 2008). 
As previously discussed, HLA-null cells are vulnerable to cell killing by NK 
cells. NK cells require recognition of self MHC class I molecules in order for 
the inhibition of the release of lytic granules from the immunological synapse 
(Bryceson et al. 2011). HLA molecules interact with inhibitory receptors on the 
NK cell, so without this interaction, NK cell activation is not inhibited. Despite 
this, there are some forms of cancer that are HLA class I negative, yet they 
avoid killing by NK cells (Menier et al. 2008). Studies have shown that cancers 
such as AML, ALL and B-cell CLL express HLA-G and avoid killing by NK cells 
(Nückel et al. 2005; Mizuno et al. 2000; Poláková et al. 2003). In pregnancy, 
various isoforms of HLA-G are used by trophoblasts, to prevent NK cell killing 
(Hunt & Langat 2009). There are seven isoforms of HLA-G. Isoforms one to 
four are membrane-bound; isoforms five to seven are soluble versions of 
isoforms one, two and four respectively. In comparison, as of the beginning of 
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2013, HLA-A has 2995 variants and HLA-C has 2553 variants on the 
IMGT/HLA database (Robinson et al. 2013). HLA-G1 and HLA-G5 are the 
most studied isoforms, with both having the same extracellular structure: a 
three domain heavy chain able to associate with β2m and a nonamer. The 
other isoforms have fewer globular heavy chains and therefore should not be 
able to associate with β2m. (Carosella et al. 2008). 
Whilst not reported to have significant immune stimulatory properties, HLA-G 
has been shown to have other functions other than the inhibition of NK cells. 
The immunoglobulin-like transcript (ILT)-2, ILT4 and KIR2DL4 receptors all 
bind to HLA-G. ILT2 is expressed on some B and T cells, all monocytes, and 
NK cells. ILT4 is expressed only on monocytes and dendritic cells (DCs), and 
KIR2DL4 is expressed on CD56bright NK cells. ILT2 and ILT4 are inhibitory 
receptors, whereas KIR2DL4 has both an ITIM in its cytoplasmic domain and 
a positively charged arginine residue in the TMD (Selvakumar et al. 1996; 
Yusa et al. 2002). In this project, it was the ability of HLA-G to inhibit NK cells 
that was investigated.  
 
4.2 Strategy to extract HLA-G from genomic DNA 
 
The aim was to replicate the inhibition of NK cells by HLA-G to avoid NK cell 
killing of the null T cells by introducing a membrane-bound isoform of HLA-G, 
HLA-G1, into the retroviral cassette. The aim was to pull out HLA-G from 
genomic DNA using primers designed by Dr Pule. The reference sequence for 
HLA-G was taken from the NCBI database - ENST00000360323 (NCBI 
2011a). Oligonucleotides were designed to bind to the exon junctions of the 
HLA-G sequence to enable it to be cloned from genomic DNA. One strategy 
was to have HLA-G on its own in one vector; the second was to have HLA-G 
joined by a peptide linker to β2m (Figure 31 – Figure 32). Figure 33 shows a 
pictorial representation of how the β2m-Linker-HLA-G construct might 
assemble and fold correctly upon expression. Genomic DNA was obtained 
from donor PBMCs and then used as the template for HLA-G. We already had 
a vector containing β2m which was used as a template. 
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4.2.1 Design of HLA-G constructs 
 
 
 
Figure 31 – Construct design for assembly of HLA-G into an SFG vector. Template 
DNA for HLA-G was derived from genomic DNA. 
Figure 32 - Construct design for assembly of β2m-L-HLA-G into an SFG vector. 
Template DNA for HLA-G was derived from genomic DNA. 
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4.2.2 HLA-G construct repair  
  
Unfortunately, after cloning of these two constructs, errors were found in the 
sequencing. In the HLA-G alone construct, there were multiple errors resulting 
in point mutations. In the β2m-L-HLA-G construct, there was one silent 
mutation which was discovered to be a SNP (NCBI 2011b) and a single 
nucleotide mutation, resulting in an amino acid substitution. In order to repair 
these constructs, it was decided to repair the amino acid mutation and to then 
use this as the template to clone out the HLA-G alone construct. Again, this 
strategy was carried out using oligonucleotide primers; correct repair and 
construction was verified by sequencing. Figure 34 shows the sequence 
obtained after extraction from genomic DNA and the subsequent repair. The 
only difference between the ENST00000360323 sequence and the cloned 
sequence was a G>A alteration in a Proline codon, resulting in no amino acid 
change. 
α1 
β2m α3 
α2 
 
Linker 
Figure 33 – Schematic of assembly of β2m-Linker-HLA-G construct. Linker (in yellow) 
is postulated to allow orientation and correct assembly of full construct, without 
reliance on the presence of endogenous β2m. 
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4.3 HLA-G expression in cell lines 
 
The HLA-G and β2m-HLA-G molecules were both cloned into SFG vectors 
containing the eBFP2 marker gene. Both the Jurkat cell line and PBMCs do 
not express HLA-G so the constructs were tested in these cells to determine 
levels of HLA-G expression achievable using these constructs (Figure 35). 
FACS analysis was performed, and demonstrated that HLA-G expression was 
possible in both cell lines. Interestingly, for both cell lines, there was a higher 
level of HLA-G expression after transduction of the HLA-G construct compared 
to the β2m-HLA-G construct. This may be as a result of the β2m molecule. 
The cell lines would normally produce β2m which associates with other HLA 
molecules. It is known that β2m associates with the HLA molecule inside the 
ER during folding and assembly, therefore having the β2m molecule linked to 
the HLA-G construct may result in inefficient folding and assembly in the ER 
(Marsh et al. 1999). Figure 35 shows expression results from Jurkat cells and 
PBMCs from one donor. One donor has been used as a representative of all 
donors as FACS data was acquired on three different machines with different 
ATGAGGTATTTCAGCGCCGCCGTGTCCCGGCCCGGCCGCGGGGAGCCCCGCTTCATCGCC
ATGGGCTACGTGGACGACACGCAGTTCGTGCGGTTCGACAGCGACTCGGCGTGTCCGAGG
ATGGAGCCGCGGGCGCCGTGGGTGGAGCAGGAGGGGCCAGAGTATTGGGAAGAGGAGACA
CGGAACACCAAGGCCCACGCACAGACTGACAGAATGAACCTGCAGACCCTGCGCGGCTAC
TACAACCAGAGCGAGGCCAGTTCTCACACCCTCCAGTGGATGATTGGCTGCGACCTGGGG
TCCGACGGACGCCTCCTCCGCGGGTATGAACAGTATGCCTACGATGGCAAGGATTACCTC
GCCCTGAACGAGGACCTGCGCTCCTGGACCGCAGCGGACACTGCGGCTCAGATCTCCAAG
CGCAAGTGTGAGGCGGCCAATGTGGCTGAACAAAGGAGAGCCTACCTGGAGGGCACGTGC
GTGGAGTGGCTCCACAGATACCTGGAGAACGGGAAGGAGATGCTGCAGCGCGCGGACCCC
CCCAAGACACACGTGACCCACCACCCTGTCTTTGACTATGAGGCCACCCTGAGGTGCTGG
GCCCTGGGCTTCTACCCTGCGGAGATCATACTGACCTGGCAGCGGGATGGGGAGGACCAG
ACCCAGGACGTGGAGCTCGTGGAGACCAGGCCTGCAGGGGATGGAACCTTCCAGAAGTGG
GCAGCTGTGGTGGTGCCTTCTGGAGAGGAGCAGAGATACACGTGCCATGTGCAGCATGAG
GGGCTGCCGGAGCCCCTCATGCTGAGATGGAAGCAGTCTTCCCTGCCCACCATCCCCATC
ATGGGTATCGTTGCTGGCCTGGTTGTCCTTGCAGCTGTAGTCACTGGAGCTGCGGTCGCT
GCTGTGCTGTGGAGAAAGAAGAGCTCAGATTGA 
Figure 34 – Final sequence coding for HLA-G extracted from genomic DNA and 
repaired as described. One base pair was different compared to the 
ENST00000360323 reference sequence (G>A), which is shown in red font. 
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fluorophores attached to the aHLA-G antibody, and therefore cannot be 
collated statistically.  
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Statistics were gathered for the Jurkat, K562 and SupT1 cell lines. As staining 
levels varied between cell lines, a gate was set to exclude any cells expressing 
HLA-G below an MFI of 10. A second gate was used for the remaining cells, 
and the percentage of cells that were HLA-G positive was recorded (Figure 
36). There were three replicates for the Jurkat and K562 cell lines and four 
replicates for the SupT1 cell line. Statistical significance can be seen in all cell 
lines transduced with the two HLA-G constructs when compared to the non-
transduced cells, except for PBMCs (Figure 37). 
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Figure 36 – Gating strategy to determine percentage of HLA-G positive cells. Gate 
R1 was gated onto the top right dot plot to remove debris and dead cells. R2 was 
used to exclude doublets and was gated onto the histogram in the bottom left 
panel. From this, cells with an MFI <10 were excluded (R3) and R4 was used to 
provide a value of HLA-G positive cells. Cells shown are Jurkat cells transduced 
with the HLA-G only construct. Representative of the gating strategy used for all 
cell types in Figure 37. 
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It can clearly be seen that the cell lines successfully express HLA-G, with the 
HLA-G alone construct giving slightly higher levels of expression (ns). HLA-G 
can also be expressed in PBMCs, but at a lower level in comparison to the cell 
lines. This will need to be optimised. 
 
4.4 Co-expression of HLA-G with HLA knockdown strategies 
 
One caveat that was thought of before proceeding with further functional work 
was to assess the stability of the HLA-G transgene expression when 
expressed with the HLAko constructs. As described previously, US11 causes 
HLA Class I knockdown by ubiquitination of the HLA Class I molecule in the 
ER, causing it to be retrotranslocated to the cytoplasm, where it is degraded 
in the proteasome. ICP47 functions by blocking peptide entry into the ER via 
the TAP protein. There is a possibility that both US11 and ICP47 may hinder 
Figure 37 – Percentage of cells stained as HLA-G positive by aHLA-G-PerCP 
(Jurkat, SupT1 cell lines and PBMCs) or aHLA-G-PE (K562 cell line). Columns  
coloured according to construct used. Both constructs showed significant (p<0.0001) 
effects on HLA-G expression in Jurkat, K562 and SupT1 cell lines, but no 
significance shown in the PBMCs. NT – non-transduced; Ab – antibody. Performed 
twice in PBMCs, three times in Jurkat and K562 cell lines, four times in SupT1 cell 
line. 
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the expression of HLA-G. Although HLA-G is a non-classical HLA molecule, it 
does have a similar globular structure, with three alpha domains and it requires 
association with β2m to be expressed on the cell surface. As it has a similar 
structure, HLA-G may therefore be recognised by US11 and cause it to be 
removed from the ER in the same way as classical HLA Class I molecules. 
Additionally, if HLA-G has any antigen presentation functions, or if it requires 
an associated peptide in order to be presented on the cell surface, then ICP47 
may also hinder peptide loading, resulting in low or poor HLA-G expression. 
Therefore, following expression of HLA-G in PBMCs, it was important to 
demonstrate that both the HLA knockdown strategies and the HLA-G 
molecules can be co-expressed. 
This experiment was carried out in SupT1 cells as they express HLA Class I 
positive and are HLA-G negative. SupT1 cells were transduced with one of the 
two RQR8-2A-HLA knockdown constructs (ICP47 or US11) and one of the two 
HLA-G constructs (with eBFP2 marker gene) 72-96hours later (Figure 38). To 
allow for the possibility of the first construct hindering the expression of the 
second construct, both orders of transduction were tested (i.e. HLA 
knockdown construct transduction then HLA-G construct transduction or HLA-
G transduction followed by HLA knockdown construct transduction). Cells 
were stained with the previously described antibodies, aHLA-A/B/C-APC and 
aHLA-G-PE. The aCD34 antibody was not included as the conjugates 
available at the time were unsuitable. 
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As can be seen, the HLA-G is well expressed in SupT1s. The issue with this 
experimental set up is that it appears that the aHLA-A/B/C antibody also binds 
to a common epitope on the HLA-G molecule, shown in Figure 38 by the slight 
shift to the right on the x-axis of the cells transduced only with the HLA-G or 
β2m-HLA-G constructs, where the aHLA-A/B/C staining is higher than in the 
non-transduced cells. From the cells not transduced with the HLA-G 
constructs, it can be seen that the aHLA-G antibody is specific to HLA-G and 
does not recognise classical HLA Class I molecules. In order to be able to 
discern between the expression of HLA Class I and HLA-G, it was decided to 
use aHLA-A2 antibody as a representative antibody for HLA Class I. HLA-G 
transduced K562s were used to show that the aHLA-A2 antibody used did not 
also bind to HLA-G (Figure 39).  
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Figure 39 – Demonstrating the lack of HLA-G expression detected by aHLA-A2 
antibody in HLA-G transduced K562 cells. Antibodies used were aHLA-G-PE and 
aHLA-A2-FITC. Both HLA-G constructs used eBFP2 as a marker gene. Top 
histogram shows aHLA-A2-FITC staining of PBMCs from a HLA-A2+ donor. NT – 
non-transduced; Ab – antibody. Performed once. 
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As this demonstrates that the HLA-G and HLA Class I molecules can now be 
distinguished, the experiment from Figure 38 was repeated in donor PBMCs 
with the new antibody panel (aHLA-A2-FITC, aHLA-G-PE, aCD34-APC, 
eBFP2) (Figure 40). 
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Figure 40 – HLA class I knockdown and HLA-G expression in donor PBMCs. Top row 
– NT – non-transduced donor PBMCs without antibody; second row – NT donor PBMCs 
with aHLA-G-PE and aHLA-A2-FITC antibodies; third row – donor PBMCs transduced 
with RQR8-2A-US11 construct alone; fourth row – donor PBMCs transduced with HLA-
G.I2.eBFP2 construct alone; fifth row – donor PBMCs transduced with both constructs. 
Fifth row gating (gates not shown): Left dot plot shows HLA-G positive cells only. Middle 
dot plot shows RQR8 positive cells only. Right dot plot shows HLA-G and RQR8 positive 
cells in pink (P11). RQR8 expression detected with aCD34 antibody (NT – non-
transduced). Performed once. 
161 
 
161 
 
As can be seen from the bottom panel in Figure 40, although there is 
autofluorescence, it is possible to obtain cells that are both HLA-G positive 
and HLA Class I negative. This can be seen clearly in the bottom right dot plot, 
where the pink P11 gated cells are HLA-G positive, RQR8 positive and HLA-
A2 negative, although this is a small proportion of the overall number of cells 
used in this experiment. Unfortunately, due to time constraints, it was not 
possible to perform replicates of this experiment, and this would be one of the 
key pieces of work to provide reliable data for if further work were able to be 
performed. If Figure 40 is taken as an indication of co-expression, it can be 
said that the three strategies of HLA Class I knockdown, RQR8 expression 
and HLA-G expression can be combined and expressed concurrently in 
PBMCs. Clearly this requires further investigation, firstly to verify and quantify 
this and then to determine whether it would subsequently be possible to select 
the cells that express all of the above strategies, and how viable these cells 
would be after two transductions and a cell sort. 
 
4.5 Effect of HLA-G on effector cell function 
 
In order to begin to understand the functional capability of the HLA-G 
construct, a chromium release assay was carried out using PBMCs or NK cells 
as effector cells against K562s that were either HLA-negative (wild-type), HLA-
A2-expressing or HLA-G-expressing. K562 cells had already been transduced 
with the SFG.HLA-A2.eGFP construct, so the generated SFG.HLA-G.eBFP2 
construct was transduced into unmodified K562 cells, with the results shown 
below (Figure 41). 
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The K562 target cells were incubated with 51Chromium and the release from 
cells was measured and quantified (Figure 42). From this initial assay, it is 
clear that NK cells are more effective at killing target cells compared to 
PBMCs. What is unclear is whether the HLA molecules have an effect on the 
activity of the effector cells. This experiment would need to be repeated with 
PBMCs obtained from multiple different donors in order to determine whether 
this is a donor-specific result or whether it is representative of all donors. 
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NT NoAb NT Ab HLA-G.eBFP2 
Figure 41 – HLA-G expression in K562 cells. Far right plot shows K562 cells 
transduced with HLA-G.I2.eBFP2 construct. NT NoAb – non-transduced K562 cells 
without antibody; NT Ab – non-transduced with aHLA-G-PE antibody. Performed 
once. 
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4.6 Conclusions 
 
In conclusion, it was possible to extract the HLA-G from genomic DNA and to 
clone it into an SFG vector with a marker gene. The two constructs cloned 
from the genomic HLA-G gene were used to transduce HLA-G in multiple cell 
lines, including Jurkat cells, PBMCs and SupT1s, demonstrating that it is 
possible to achieve detectable cell surface expression.  
Since expression was better using the construct containing HLA-G on its own, 
without β2m attached by a linker, this was the construct that was planned to 
be taken forward into functional experiments. To build on the 51Cr release 
assay (Figure 42), one planned experiment would be to test NK cell 
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Figure 42 – Chromium release assay of PBMC/NK effector cells against K562 cell 
line targets expressing HLA molecules. a) NT K562 targets b) HLA-A2-expressing 
K562 targets c) HLA-G-expressing K562 targets. NT – non-transduced, PBMC – 
Peripheral blood mononuclear cells, NK – Natural-killer cells. Repeated once in 
duplicate. 
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proliferation in a co-culture with HLA-G expressing cells. K562 cells are an 
ideal cell line to use as they are HLA Class I negative and would therefore 
normally be targeted by NK cells (Drew et al. 1977; Saksela et al. 1979). Once 
a protocol and efficacy is demonstrated using K562 cells, PBMCs would then 
be investigated. The various subsets of cells within the PBMC population 
would be interrogated to determine whether any of these have an impact on 
the functionality of NK cells. The impact of transduction on expression of NK 
ligands would also need to be examined, as if NKG2D ligands are increased 
as a result of transduction, this might overcome the effect of HLA-G. 
 
HLA-G was expressed in cells alongside RQR8 and US11, resulting in the 
discovery that the aHLA-A/B/C Class I antibody being used also recognised a 
common epitope on HLA-G. Despite the lack of functional data, it appears 
possible to co-express RQR8, US11 and HLA-G in donor PBMCs, meaning 
that this has the potential to be the platform on which the universal T cell could 
be built if these strategies were proven to be functionally effective.  
 
4.6 Final Conclusions 
 
 Two HLA-G constructs have been successfully cloned from genomic 
DNA and repaired where necessary. 
 Both HLA-G constructs have been shown to be expressed in Jurkat, 
K562 and SupT1 cell lines, as well as in PBMCs, with the construct 
containing HLA-G alone expressing more highly than the construct also 
containing β2m attached with a linker. 
 When attempting to express the HLA Class I knockdown constructs with 
the HLA-G constructs, the aHLA-A/B/C antibody was shown to also 
bind to an epitope on HLA-G, resulting in a need to alter the antibody 
panel being used. 
 The RQR8-2A-US11 construct and HLA-G construct can be co-
expressed in PBMCs, although only in a small proportion. This also 
165 
 
165 
 
needs further verification and quantification in order to make a reliable 
assessment. 
 K562 cells expressing HLA-A2 or HLA-G were killed by PBMCs and NK 
cells but it was not possible to determine whether there was any 
difference between the cell lines. It was determined that NK cells had a 
higher capability to kill target cells compared to PBMCs. 
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Chapter Five: TCR 
knockdown 
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5.0 Aims 
 
 To prevent or reduce effects of GvHD as a result of TCR signalling. 
 To investigate methods of TCR knockdown from the T cell surface. 
 To verify success of these methods of knockdown. 
 
5.1 Introduction 
 
TCRs are widely expressed on the cell surface of T cells. Their role is in 
antigen recognition of antigen presented to them by APCs, which then results 
in either anergy or activation depending on the immunogenicity of the antigen 
presented (Janeway Jr et al. 2001). If allogeneic T cells are used in therapy, 
then the TCRs expressed by the therapeutic cells can activate the CTL 
response when they encounter antigens from the recipient’s tissues, leading 
to GvHD. In adoptive immunotherapy, transfer of antigen-specific T cells is 
used in an attempt to minimise GvHD. TCR knockdown is a mechanism which 
might be useful in preventing the GvHD response. If a CAR is introduced, this 
would have the effect of promoting the GvL effect, and also prolonging the 
persistence and survival of adoptively transferred therapeutic T cells in vivo. 
 
5.2 Approaches used for TCR knockdown 
 
There are multiple methods that can be used to knock down expression of 
proteins from a cell. They can be targeted at the genomic level by methods 
such as ZFNs (discussed in chapter four); at the mRNA level by siRNA or 
miRNA (tested and discussed in chapter three); at protein level by retention 
sequences and intrabodies (Pelham 1990).  
As used previously in an attempt to achieve HLA Class I knockdown, one 
strategy that was used in this chapter was to combine the specificity of an 
antibody against a protein with a retention sequence to retain the protein within 
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the cell and prevent its surface expression. Retention sequences were 
characterised by Munro and Pelham (1986), who showed that an amino acid 
sequence of KDEL which was present on the C-terminus of three luminal ER 
proteins was responsible for their retention in the ER. It was subsequently 
shown that this sequence, could be used to retain proteins in the ER and other 
locations (Pelham 1990; Andres et al. 1990). To target a protein in a specific 
manner and retain it within the ER, the strategy in this study required a 
molecule attached to a retention sequence that would bind to the protein of 
interest. This approach allows for a specific targeting of a protein and for 
intracellular retention, but the drawback is that it might cause ER stress due to 
the large amount of protein being retained in the ER. This could cause the 
activation of the UPR and would lead to up-regulation of ER stress proteins 
including IRE1, ATF6 and PERK, leading to ERAD, translational attenuation 
and possible apoptosis (Rutkowski & Kaufman 2004; Schröder & Kaufman 
2005). Other ER retention sequences that were tested to obtain TCR 
knockdown were the ‘KKAA’ retention sequence and the E19 adenovirus 
protein sequence ‘KYKSRRSFIDEKKMP’ (Pelham 2000).  
Another similar strategy was tried, using the ‘SEKDEL’ ER retention sequence 
attached to a bacterial ‘superantigen’ to knockdown the TCR. Bacterial 
‘superantigens’ are a family of 40 protein toxins produced by Staphylococcus 
aureus and Streptococcus pyogenes that bind to the TCR and MHC class II in 
order to cause mass T cell stimulation, resulting in toxic shock syndrome 
(Fraser & Proft 2008; Proft et al. 2000). A relatively small amount of 
superantigen in a human can cause a sudden rise in cytokine levels, including 
IL-2, IFN-γ and TNFα (Jupin et al. 1988). However, at lower levels, during the 
early stages of infection, the effect of the superantigen is to induce a localised 
immunosuppressive effect in order to prevent clearance of the bacterium. 
Studies have shown that the superantigens have the ability to bind directly to 
MHC Class II and the TCR-Vβ chain outside of the normal paratope for 
peptide-MHC recognition (Scholl et al. 1989; Dellabona et al. 1990). There are 
numerous superantigens that have been described, with SMEZ-2 
(S.pyogenes) having a high potency and therefore likely to have the highest 
affinity for the TCR-Vβ (4.1 and 8.1) and MHC Class II. This was cloned with 
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a signal sequence and attached to the ER retention sequence ‘SEKDEL’ 
before being tested in donor PBMCs. 
The final strategy used to obtain TCR knockdown was TALENs. TALENs are 
a fusion of a transcription activator-like effector, derived from the plant 
pathogen Xanthomonas spp., with the FokI nuclease. They are genome-
editing molecules that are designed to induce a double strand break (DSB) in 
the targeted area of the genome. TALENs recognise a sequence of DNA 
through a series of repeated variable di-residues (RVDs). Each repeat is 33-
35 amino acids long, with two hypervariable amino acids at the 3’ end which 
dictate which DNA base is targeted (Christian et al. 2010; Li et al. 2012; 
Hockemeyer et al. 2011). Combinations of these repeats can be joined 
together to target a DNA sequence of 18-20bp. Attached to the end of this is 
the catalytic domain of the FokI nuclease. FokI requires dimerization for 
catalytic activity, so two TALENs are used, one binding to the ‘left’ of the target 
sequence, the other binds to the ‘right’ end of the target sequence (Miller et al. 
2011). 
Knockdown of the TCR by using a protein targeting method was preferable to 
using DNA editing molecules as it removed the risk of mutations caused by 
NHEJ, making this project safer and more viable. It also allows the use of a 
viral packaging and delivery system and therefore can be combined with other 
strategies, reducing the number of selection stages to obtain a homogenous 
cell product. 
 
5.3 Testing of constructs 
 
After constructs were cloned, testing was performed in multiple cell lines, 
including TCRαβ-negative SupT1 cells, Jurkat cells and TCRko Jurkat cells as 
well as donor PBMCs. TCRαβ-negative SupT1 cells were used as they could 
be engineered to express a TCR, thereby creating an engineered cell line that 
had an ideal negative control for expression tests. SupT1s (negative for TCR 
expression) were transduced with a codon optimised TCR specific for the 
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mHag HA1 (den Haan et al. 1998) (Figure 43). TCR negative Jurkat cells 
(patient-derived cell line lacking TCR α and β chains) were also obtained to be 
used as a negative control cell line (kindly provided by Hans Stauss, Royal 
Free) (Figure 44). It was these engineered cell lines that were initially used for 
testing the aTCR antibody constructs with the ER retention sequences 
attached. 
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5.4 Attempting to knockdown the TCR using aTCR antibodies 
attached to ER retention sequences 
 
5.4.1 Testing that aTCR antibodies bind to target 
 
The first strategy used for TCR knockdown was to attach retention sequences 
to antibodies which have a high affinity for the TCR and its surrounding 
components. Single chains of OKT3, BMA031 and truncated pre-T cell 
Figure 44 – TCR expression on wild-type (WT) and TCR negative (TCRko) 
Jurkat cells. Cells were stained with aTCR-PE antibody (Ab) and aCD3-APC 
antibody. Performed once. 
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receptor alpha (dPTCRA) with the ‘SEKDEL’ retention sequence had 
previously been cloned (Figure 45). The ‘SEKDEL’ ER retention sequence is 
one that has been demonstrated to achieve effective retention of target 
proteins in the ER (Pelham 1990). OKT3 and BMA031 are both antibodies that 
have been generated against the TCR-CD3 complex (Borst et al. 1990; 
Midtvedt et al. 2003), whilst PTCRA is involved in the development of 
immature αβ T cells (Fehling et al. 1995). A truncated form of PTCRA might 
bind to the TCR during assembly and prevent surface expression. To test that 
the OKT3 and BMA031 antibodies bound to the TCR, scFvs attached to a 
human Fc were generated in secreted format and transfected into 293T cells. 
Retroviral supernatants were harvested before being incubated with Jurkat 
cells, followed by the addition of anti-human-Fc antibody to confirm association 
of the secreted scFv to the Jurkat cells. An aGD2 scFv construct was used as 
a negative control (Figure 46).  
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BMA031 construct: 
METDTLLLWVLLLWVPGSTGEVQLQQSGPELVKPGASVKMSCKASGYKFTSYVMH
WVKQKPGQGLEWIGYINPYNDVTKYNEKFKGKATLTSDKSSSTAYMELSSLTSED
SAVHYCARGSYYDYDGFVYWGQGTLVTVSASGGGGSGGGGSGGGGSQIVLTQSPA
IMSASPGEKVTMTCSATSSVSYMHWYQQKSGTSPKRWIYDTSKLASGVPARFSGS
GSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGAGTKLELKRSDPSEKDEL 
 
OKT3 construct: 
METDTLLLWVLLLWVPGSTGQVQLQQSGAELARPGASVKMSCKASGYTFTRYTMH
WVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSED
SAVYYCARYYDDHYCLDYWGQGTTLTVSSSGGGGSGGGGSGGGGSQIVLTQSPAI
MSASPGEKVTMTCSASSSVSYMNWYQQKSGTSPKRWIYDTSKLASGVPAHFRGSG
SGTSYSLTISGMEAEDAATYYCQQWSSNPFTFGSGTKLEINRSDPSEKDEL 
 
PTCRA construct: 
MAGTWLLLLLALGCPALPTGVGGTPFPSLAPPIMLLVDGKQQMVVVCLVLDVAPP
GLDSPIWFSAGNGSALDAFTYGPSPATDGTWTNLAHLSLPSEELASWEPLVCHTG
PGAEGHSRSTQPMHLSGEASTARTCPQEPLRGTPGGALWLGVLRLLLFKLLLFDL
LLTCSCLCDPAGPLPSPATTTRLRALGSHRLHPATETGGREATSSPRPQPRDRRW
GDTPPGRKPGSPVWGEGSYLSSYPTCPAQAWCSRSALRAPSSSLGAFFAGDLPPP
LQAGAARSDPSEKDEL 
 
 
Figure 45 – Design and sequences of constructs targeted at TCR knockdown by ER 
retention. Top two constructs show amino acid sequence – signal peptide is in italics, 
heavy chain is highlighted yellow and light chain is highlighted in green. ‘SEKDEL’ ER 
retention sequence is highlighted in blue. Bottom construct shows amino acid 
sequence of the PTCRA construct. Signal peptide is in italics, protein sequence is 
highlighted in grey. 
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Figure 46 – Testing of anti-TCR antibody apecificity for the TCR. Supernatants 
containing secreted Abs were generated by transfection of 293Ts with the relevant 
constructs. Supernatants were used to stain cells, followed by anti-Human-Fc 
detection as follows: Rows one and two – wild-type Jurkat cells stained with 
secreted Abs; Rows three and four – TCRko Jurkat cells stained with secreted Abs. 
Ab – antibody; 293T – supernatant from NT 293Ts used followed by secondary 
aHuman-Fc-Dylight 488 antibody. Performed once. 
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5.4.2 Knockdown of TCR by aTCR-SEKDEL constructs in Jurkat cells 
 
TCR knockdown was first tested by transducing wild-type Jurkats with 
retroviral supernatant containing the various ‘SEKDEL’ constructs: native TCR 
(nTCR), aHuman-CTLA4-SEKDEL, OKT3-SEKDEL, BMA031-SEKDEL and 
dPTCRA-SEKDEL constructs. TCR knockout Jurkats (Figure 47). The 
construct that targeted CTLA-4 was used as it is expressed on the surface of 
T cells and acts as a control in this experiment. 
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As can be seen, this strategy looks to have been successful in knocking down 
the TCR expressed on wild-type Jurkat cells as a result of transduction with 
either the OKT3-SEKDEL or BMA031-SEKDEL construct. The dPTCRA-
SEKDEL construct failed to work, but will be carried forward as a negative 
control construct. 
 
5.4.3 Knockdown of TCR by aTCR-SEKDEL constructs in donor PBMCs 
 
Since two of the constructs appeared to be successful in knockdown of the 
TCR from Jurkat cells, the next rational step was to test the constructs in donor 
PBMCs (Figure 48). 
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From this data, there initially looked to have been successful, although partial, 
TCR knockdown by the OKT3-SEKDEL and BMA031-SEKDEL constructs. 
Unusually though, the non-transduced cells also appeared to have lost some 
of their TCR expression despite being eBFP2 negative. It might also be useful 
to quantify the level of TCR expression on the cell surface for future 
experiments. 
 
5.4.4 Investigation into TCR knockdown 
 
5.4.4.1 Cell line investigation 
 
In order to elucidate what was occurring to cause these unusual results, further 
investigation was required. Firstly, the aim was to discover why there was only 
partial knockdown of the TCR. To do this, the HA1-TCR SupT1 cell line (Figure 
43) was transduced with the aTCR-SEKDEL constructs to determine if there 
was a Golgi saturation event due to the expression of the native TCR being 
higher than the transgene expression (Figure 49). 
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Here, the OKT3-SEKDEL and BMA031-SEKDEL constructs clearly work 
effectively in knocking down the HA1-TCR from the cell surface. This suggests 
that the knockdown constructs are limited in their efficiency by their 
expression, leading to the conclusion that the levels of TCR expression on the 
T cell surface are too high to be completely removed as the transgene is 
unable to effectively retain all of the TCRs within the ER and Golgi. To verify 
this further and determine if Golgi saturation was occurring, with more protein 
being expressed than can be retained by the construct, donor PBMCs and 
SupT1s were transduced with a construct that contained a truncated CD33 
molecule along with the eGFP marker gene. Following this, those populations 
were then transduced with retroviral supernatant containing an aCD33-
SEKDEL.eBFP2 construct (Figure 50).  
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The average aCD33-APC MFI for the dCD33 transduced (eGFP-gated) 
PBMCs was 285.03 (S.D. 53.24), and the aCD33-APC MFI for the double-
transduced populations (both eBFP2 and eGFP positive) was an average of 
100.33 (S.D. 47.33), a reduction of 65%. In the SupT1s, there was a reduction 
in aCD33-APC MFI from 291.10 to 43.25, a drop of 85%. This pattern 
replicated what had been seen previously, indicating that Golgi saturation was 
not occurring as both the target and the effector genes were both transgenes 
and therefore would have been expressed at a ratio of around 1:1. It can be 
concluded therefore, that the partial knockdown is very likely to be as a result 
of levels of TCR expression being higher than transgene expression. 
 
5.4.4.2 Co-cultures 
 
Another aspect of the original FACS analysis from Figure 48 was that the NT 
cells also had a reduced level of TCR surface staining. To try to resolve this, 
PBMCs were transduced with the SEKDEL constructs and then added to NT 
PBMCs at a ratio of 1:1 and incubated together for 48hrs (Figure 51).  
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In this experiment, if the construct was being secreted, it would have been 
expected to see three populations – one of NT PBMCs that had normal levels 
of aTCR staining, one of NT PBMCs with reduced levels of aTCR staining and 
one of transduced PBMCs also with reduced levels of aTCR staining. As the 
NT PBMCs that were introduced also had reduced levels of aTCR staining 
after 48hrs incubation, this suggests that there is a cell to cell contact 
mechanism occurring, with several possible theories that could explain the 
results obtained. One theory is that the SEKDEL construct might be binding to 
the TCR, but not causing retention, leaving the construct bound to the TCR on 
the cell surface, possibly blocking antibody binding (or vice versa) and leading 
to the reduction in TCR staining seen previously. It is also possible that the 
TCRs on the NT PBMCs are binding to the SEKDEL construct bound to the 
surface of the transduced PBMCs, again, blocking antibody binding and 
leading to the reduction in staining. Another explanation for the reduction in 
staining seen on NT PBMCs is that the SEKDEL constructs might be secreted 
and that is the mechanism by which they are able to bind to the NT PBMCs 
and block antibody binding. Fluorescence microscopy might be one technique 
that would help in investigating these hypotheses. 
To further investigate whether the SEKDEL constructs were being secreted or 
whether there was a cell to cell contact process occurring, supernatant from 
the transduced PBMCs was used to stain NT PBMCs, followed by TCR-PE 
antibody (Figure 52). It has already been shown that the OKT3 and BMA031 
antibodies bind to the TCR (Figure 46) and, with comparison to Figure 52, this 
shows that there was no reduction in staining, leading to the conclusion that 
the constructs are not being secreted. 
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To further prove this, NT PBMCs and transduced PBMCs were incubated 1:1 
in transwells, preventing cell to cell contact, but allowing exchange of anything 
that might be secreted (Figure 53). Again, this showed that there was no 
reduction in TCR staining on the NT PBMCs, supporting the theory that the 
constructs are bound to the TCR expressed on the cell surface and are 
blocking antibody binding on the transduced and adjacent NT cells. This may 
suggest a novel mechanism for achieving cell surface receptor or molecule 
blocking. 
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5.4.5 Knockdown of TCR by aCD3 ER retention constructs 
 
Since the strategy of targeting the TCR complex for knockdown caused 
unwanted effects, including blocking the TCR of neighbouring T cells, it was 
decided that if the TCR could not be retained in the ER directly, then it might 
be possible to retain the TCR in the ER by retaining the CD3 molecule. CD3 
has multiple dimeric signalling domains, CD3δε, CD3γε and CD3ζζ (Figure 66). 
These non-covalently associate with the TCR as a result of specific residue 
interactions with one basic residue and a pair of acidic residues in the 
transmembrane domains of the CD3 components (Call & Wucherpfennig 
2007). Each of the subunits of the TCR-CD3 complex have ER retention or 
retrieval signals, and regulation of each of these is key to obtaining cell surface 
expression. CD3γ has been shown to have a retention signal, but CD3γε 
dimers have been shown to express on the cell surface after deletion of the 
CD3ε ER retention signal, suggesting that the ε signal is dominant (Delgado & 
Alarcón 2005). Therefore, if it is possible to increase the ER retention of one 
or multiple CD3 components, this could lead to TCR retention also. To achieve 
TCR retention in the ER, one strategy was to replace the endodomains from 
the CD3 subunits with the  ‘KYKSRRSFIDEKKMP’ peptide from the 
adenovirus E19 protein (Pelham 2000) (Figure 54 and Figure 55). The risk with 
using this as a retention signal is that the long endodomains of neighbouring 
CD3 components might prevent access to the coat protein I (COPI) complex 
coat proteins, although retention with COPI proteins has been suggested to 
occur during TCR assembly as a result of the CD3ε subunit (Mallabiabarrena 
et al. 1995). Another strategy was to clone the following amino acid sequence, 
comprising of a serine-glycine linker attached to the ‘KKAA’ ER retention 
sequence, resulting in the peptide ‘SGGGSKKAA’ being added to the full-
length endodomain of each of the CD3 components (Pelham 2000) (Figure 
56).  
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a) 
Figure 54 – Construct design for CD3 components cloned with E19 retention 
sequence. a) CD3ζ; b) CD3γ. Blue arrows indicate oligonucleotide primers used for 
fragment amplification, multi-coloured blocks denote amino acid sequence. 
b) 
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Figure 55 – Construct design for CD3 components cloned with E19 retention 
sequence. a) CD3ε; b) CD3δ. Blue arrows indicate oligonucleotide primers used for 
fragment amplification, multi-coloured blocks denote amino acid sequence. 
a) 
b) 
193 
 
193 
 
  
Figure 56 – Designs for CD3 constructs with the ‘KKAA’ retention sequence attached. 
From top to bottom, CD3ζ, CD3γ, CD3ε, CD3δ. Blue arrows indicate oligonucleotide 
primers used to amplify CD3 components from template DNA. Multi-coloured blocks 
denote amino acid sequence. 
a) 
b) 
c) 
d) 
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These retention sequences were assembled with each of the individual CD3 
subunits as shown, before retroviral supernatant was generated, which was 
the used to transduce donor PBMCs. The OKT3-SEKDEL construct was used 
as a control for comparison, and as before, a slight drop in TCR expression 
was seen, along with a slight drop in CD3 expression (Figure 57).  
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This data is summarised in Figure 58, which shows the MFI of the cells that 
expressed high levels of eBFP2. From this, there looks to have been a small 
Figure 57 – Testing CD3-ER retention constructs in donor PBMCs. a) controls. b) 
CD3 constructs with E19 retention sequences. c) CD3 constructs with KKAA retention 
sequences. Cells were stained with aCD3-APC and aTCR-PE with eBFP2 marker 
gene. NT – non-transduced, Ab – antibody. 
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level of retention caused by the CD3ε subunit attached to the E19 retention 
sequence, but this was minimal and it was concluded that it was not sufficient 
enough to take this strategy further. Again, as with the TCR ER retention, it is 
probably due to levels of CD3 subunit expression far exceeding that of the 
transgene expression. What is supporting this conclusion is that both CD3 and 
TCR expression follow each other. Two alternative explanations may be that 
the CD3 constructs were unable to be incorporated into the TCR-CD3 complex 
before assembly, or that they did incorporate into the TCR-CD3 complex, but 
did not affected cell surface expression. 
 
 
5.4.5 Inhibition of TCR expression by expression of TCR constant chains 
 
Since the retention strategies did not have much success, it was decided to 
try another approach by disrupting the TCR assembly. There was a possibility 
that if expression of the TCR constant chain ectodomains was achieved, then 
these might pair with the relevant TCR alpha or beta chain, preventing correct 
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Figure 58 – MFI of high-expressing eBFP2 cells transduced with various constructs. 
Left hand x-axis – CD3-APC MFI (black squares); right-hand axis – TCR-PE MFI 
(black open diamonds). NT – non-transduced. Repeated once. 
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pairing with the TCR alpha and beta chains and subsequent cell surface 
expression. Although not complete, some retention had previously been seen 
with the ‘SEKDEL’ sequence, so constructs were made containing the TCR 
alpha (TRAC) and TCR beta (TRBC) constant regions alone and constructs 
were designed that contained the constant region and the ‘SEKDEL’ sequence 
(Figure 59-Figure 61).  
 
a) 
b) 
Figure 59 – Designs for TRAC constructs. a) TRAC construct on its own; b) TRAC 
construct linked to the ‘SEKDEL’ ER retention sequence. Blue arrows indicate 
oligonucleotide primers used to amplify DNA fragments, multi-coloured blocks denote 
amino acid sequence. 
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Figure 60 – Designs for TRAC constructs. a) TRBC construct on its own, b) TRBC 
construct linked to the ‘SEKDEL’ ER retention sequence. Blue arrows indicate 
oligonucleotide primers used to amplify DNA fragments, multi-coloured blocks denote 
amino acid sequence. 
a) 
b) 
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It has also been suggested that a splice variant of the PTCRA may, as a 
heterodimer, be degraded by the ER. This splice variant is expressed without 
the extracellular Ig-like domain (von Boehmer 2005). If this pairs with the TCRβ 
chain, then this splice variant might promote TCR degradation as a result if 
expressed more highly. Therefore, another strategy was to express a splice 
variant of the invariable chain on its own (Figure 62). These constructs were 
all assembled and transduced into Jurkat cells to determine efficacy (Figure 
63).  
  
  
TCRβ 
pTCRα 
Constant 
(TRAC) 
TCRβ 
pTCRα 
Constant 
(TRAC) 
  
  
pTCRβ 
Constant 
(TRBC) 
TCRα TCRα 
pTCRβ 
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a) b) c) d) 
Figure 61 – Depiction of how the constant chains of the TCR might bind to the 
corresponding TCR chain and retain them in the ER. a) TCRα constant region 
binding to TCRβ chain. b) as a), but with ‘SEKDEL’ sequence attached. c) TCRβ 
constant chain binding to TCRα chain. d) as c), but with ‘SEKDEL’ sequence 
attached. 
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Figure 62 – Gene assembly design for PTCRA-203 splice variant. Blue arrows 
indicate oligonucleotides used for assembly; multi-coloured blocks denote amino acid 
sequence. 
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As with previous strategies, no clear effect was seen with these constructs. 
Again, the likelihood is that the levels of TCR expression are far exceeding 
those of the transgenes tested so far. The PTCRA molecule is involved in 
thymic development and therefore may not have a role in mature T 
lymphocytes. Regarding the constant chain constructs, these may not have 
worked either due to not having high enough expression to match TCR 
expression, or the proteins may not have been able to interact with the TCR 
before it has already assembled and folded with the relevant chain.  
 
5.4.6 Knockdown of the TCR by expression of a bacterial superantigen 
 
A different strategy was to use a bacterial superantigen to knockdown the 
TCR. Bacterial superantigens are protein toxins that cross-link to the TCR and 
HLA class II in order to cause T cell stimulation, resulting in toxic shock 
syndrome (TSS) (Proft et al. 2000). There are numerous superantigens that 
have been described, most of which are derived from either Staphylococcus 
aureus or Streptococcus pyogenes. SMEZ-2 is found in S.pyogenes and has 
one of the highest potencies characterised. (Fraser & Proft 2008). Since 
superantigens bind to both the TCR and to HLA Class II, it was thought that 
using this molecule with a retention signal may lead to knockdown of the TCR. 
Therefore, SMEZ-2 was assembled with the ‘SEKDEL’ ER retention sequence 
and cloned into a SFG vector containing the eGFP marker gene (Figure 64). 
These constructs were transduced into donor PBMCs along with a control 
HLA-A2 construct, also with the eGFP marker gene (Figure 65). There are 
possible limitations to this strategy, including immunogenicity and inducing 
TSS upon T cell death, which would have to be taken into consideration. 
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Figure 64 – Gene assembly design of SMEZ-2 construct cloned with ‘SEKDEL’ ER 
retention sequence. Blue arrows indicate oligonucleotides used in gene assembly; 
multi-coloured blocks denote amino acid sequence. 
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As can be seen, there is little to no effect on TCR expression and HLA Class 
II expression (represented by aHLA-DR antibody staining). There appears to 
be a slight shift downwards of TCR expression, but this is negligible. Even if 
this strategy had been successful, there would have been the obstacle of 
avoiding the possibility of TSS when using this in in vivo model experiments. 
As this strategy failed, it was decided to try another strategy. 
Figure 65 – Testing knockdown of TCR and HLA class II knockdown in donor 
PBMCs using a bacterial superantigen, SMEZ-2. Cells were stained with aTCR-PE 
and aHLA-DR-Pacific-Blue antibodies. NT – non-transduced; Ab - antibody. 
Constructs used were HLA-A2.I2.eGFP and SMEZ_2-SEKDEL.I2.eGFP. No 
difference seen between GFP positive and negative cells for the SMEZ-2 construct. 
Repeated once. 
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5.5 Inhibition of TCR signalling by a null CD3 
 
As targeting the TCR directly did not prove to be effective, it was decided to 
target TCR signalling. CD3 had been previously modified by attaching ER 
retention sequences to the various components; this strategy was aimed at 
preventing the initiation of the signalling cascade triggered upon TCR-CD3 
activation. The CD3 components contain an extracellular domain linked by a 
transmembrane domain to an ITAM. These components associate with the 
TCR through specific amino acid residue interactions present in the 
transmembrane domain (Figure 66). Therefore, the plan was to introduce a 
transgene that contained both the extracellular and transmembrane domains, 
thereby allowing for TCR-CD3 assembly, but without the ITAMs attached, 
meaning that if the transgenic CD3 components associated with the TCR, 
upon activation, there would be no initiation of the signalling cascade. The 
construct was designed to contain all four components of the CD3 molecule 
(δ, ε, γ, ζ) separated by the FMDV 2A self-cleaving peptide, with a truncated 
CD34 molecule used as the marker gene (Figure 67). 
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Figure 66 – Association of dimeric CD3 components with the TCR. Top diagram shows 
residue-specific interactions between transmembrane regions of the various 
components. Orange circles show basic residues; green show acidic residues. Bottom 
diagram shows 2D representation of top diagram with residue annotation. Adapted from 
Call & Wucherpfennig (2007). 
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This construct was successfully assembled and correct sequencing was 
verified, but was not able to be shown to be functional within the time frame 
possible. This would be revisited in the future. 
 
5.6 Knockdown of the TCR by gene-editing TALENs  
 
5.6.1 Ways of modifying the genome of a cell 
  
Since the approach of targeting the TCR at the protein level has not been 
successful, it was decided to try and achieve knockdown of the TCR by 
targeting it at the gene level. There are several strategies that have been 
demonstrated to have the ability to edit the genome of a cell, including ZFNs, 
MNs and TALENs. These three methods of genome-editing are based on 
nuclease-mediated activity. Parts of the molecules direct the nucleases to the 
target site and the nuclease domain(s) cause a DSB in the DNA; this can be 
used to either remove sections of DNA or to insert a gene into the genome 
(Alwin et al. 2005; Rouet et al. 1994). A DSB stimulates the cellular machinery 
to induce homologous recombination (HR) to repair the DSB.  
Zinc fingers are a family of DNA-binding molecules that bind to a specific DNA 
sequence around 9bp in length. These have been fused to the endonuclease 
domain of the FokI restriction enzyme, giving rise to ZFNs, which have been 
demonstrated to cleave DNA at a specific site both in vitro and in vivo (Bibikova 
et al. 2003; Urnov et al. 2005). These chimeric ZFNs have also been designed 
to act in pairs and will not induce a DSB without dimerising with the other ZFN 
of the pair present. This is achieved by using a nuclease that requires 
dimerization for cleavage activity to be initiated (Vanamee et al. 2001). This 
technology allows for specific sites to be targeted, but it does have the 
drawback of relying upon using zinc fingers that are already in existence in 
nature and have been characterised. Unlike MNs and TALENs, these 
molecules cannot be modified to target any sequence of DNA. 
210 
 
210 
 
MNs are yeast-derived molecules that can induce homologous recombination 
(HR) at up to 1000-fold in cultured cells. They are highly-specific and provide 
a scaffold upon which gene-editing can be built. Based on sequence and 
structural motifs, MNs can be divided into five main families, LAGLIDADG, 
GIY-YIG, HNH, His-Cys box and PD-(D/E)XK (Orlowski et al. 2007; Zhao et 
al. 2007). MNs are able to target a region of DNA 14-40bp in length, and then 
subsequently create a DSB in that region. Since the recognition sequence is 
so long, the MNs can usually tolerate polymorphisms in the site with little or no 
loss in the cleavage activity (Arnould et al. 2011). MNs can also be modified 
to target different DNA sequences. Mutations of certain residues has resulted 
in modification of target site cleavage without loss of cleavage activity, but the 
amount of modification without cleavage activity loss is still limited (Seligman 
et al. 2002; Sussman et al. 2004; Doyon et al. 2006).  
TALENs are transcription activator-like effector molecules, derived from the 
plant pathogen Xanthomonas, fused to the FokI endonuclease. Each TALE 
molecule has repeats of highly conserved regions, which are usually 33-35 
amino acids long. These repeats are responsible for DNA binding; one repeat 
unit binds to one DNA nucleotide. The unique feature of these molecules 
compared to MNs and ZFNs is that they are customisable by modification of 
the polymorphic amino acids. Within each repeat, the two residues at positions 
12 and 13 are the variable residues determining specificity, and are called 
RVDs. These repeat units allow for a DNA sequence of 15-30 nucleotides to 
be recognised as the DNA binding domain of each TALE. Two TALEN 
molecules are required in order for dimerization of the FokI nuclease in order 
for cleavage activity to be activated (Miller et al. 2011; Moscou & Bogdanove 
2009; Boch et al. 2009; Morbitzer et al. 2010; Mussolino et al. 2011). Cellectis 
Bioresearch kindly allowed the use of their TRAC-targeted TALEN molecules 
in order to investigate this method for achieving TCR knockdown.  
 
5.6.2 TCR knockdown by TRAC TALENs 
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Cellectis Bioresearch provided mRNA containing engineered TALENs 
directed against the TCR alpha chain. Donor PBMCs were stimulated with 
CD3/CD28 Dynabeads for 48hrs before the TCR alpha chain TCRko TALEN 
mRNA was introduced by electroporation. Cells were recovered before being 
stained to determine the level of TCR knockdown at 24hrs (no effect seen) 
and 48hrs (Figure 68). 
 
Figure 68 – Donor PBMCs electroporated with TRAC TCRko mRNA. Cells were 
stimulated with CD3/CD28 Dynabeads before electroporation with GFP control 
mRNA or TRAC TCRko TALEN mRNA, followed by recovery in cRPMI without 
cytokines. Cells were stained with aTCR-PE antibody 48hrs after electroporation 
before FACS analysis. NT – non-treated cells; Ab – antibody. Repeated once. 
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As can clearly be seen, some knockdown of the TCR has been achieved. In 
order to get a clearer picture on the level and amount of knockdown achieved, 
it is easier to look at the histograms derived from Figure 68 (Figure 69). 
  
As can be seen, the proportion of cells in R10 increases from 14.39% in the 
aTCR-PE stained NT PBMCs, to 39.00% in the TRAC TALEN electroporated 
PBMCs, an increase of around 25%. The overall MFI also drops from 294.01 
to 169.10. This shows that it is possible to reduce TCR expression on T cells, 
although not fully. 
 
5.6.3 Introduction of a CAR to TCRlo cells 
 
It was possible to cause a reduction in TCR expression following treatment 
with TRAC-targeted TALENs. If these T cells were left in culture though, the 
TCRlo T cells would most likely die as a result of a lack of stimulation through 
the remaining TCRs expressed on the T cell surface. These TCRlo T cells need 
Figure 69 – Histograms with statistics taken from Figure 68, showing level of TCR 
knockdown as a result of treatment with TRAC TALEN mRNA. NT – non-transduced; 
Ab – antibody. Repeated once. 
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a signal to induce proliferation and survival. Therefore, it was decided to see 
if it was possible to subsequently transduce TALENised T cells with an aCD19 
CAR. PBMCs were isolated from a healthy donor and stimulated with aCD3 
and aCD28 Dynabeads for 48hrs before electroporation with TRAC TALEN 
mRNA. Immediately after electroporation, the cells were transduced with an 
aCD19-CAR (with RQR8 sort-suicide gene used as a marker). Cells were left 
to recover for 48hrs after electroporation and transduction before being 
analysed by FACS (Figure 70). 
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Figure 70 – Donor PBMCs electroporated with TRAC TALEN mRNA and 
transduced with an RQR8-aCD19-CAR. Before modification, PBMCs were 
stimulated with aCD3 and aCD28 Dynabeads for 48hrs. After treatment, PBMCs 
were recovered for 48hrs before FACS analysis using aTCR-PE and aCD34-APC 
antibodies. NT – non-transduced; Ab – antibody. Repeated once. 
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From this experiment, it is clearly possible to obtain T cells that have reduced 
levels of TCR expression alongside CAR expression. Over 82% of the cells 
that have been treated with TALEN mRNA and aCD19-CAR are CD34 
positive. Of that 82%, 32.58% are in R9 (lower right quadrant). These cells 
make up over 15% of the total number of cells analysed in this FACS analysis 
sample.  
 
5.6.4 MACS sorting TCRlo T cells 
 
Following on from this, the next logical step was to try and sort the TCRlo T 
cells to obtain a pure homogenous population of T cells. There were two 
options in terms of ways to sort cells – either through using the MOFLO XDP 
(BeckmanCoulter), or by using MACS beads (Miltenyi). MOFLO XDP cell 
sorting uses FACS analysis as the basis for cell sorting, and therefore allows 
cells to be sorted based on various cell surface markers or fluorescent marker 
genes, but it is done in a non-sterile environment and therefore requires the 
use of antibiotics in order to try and prevent bacterial or fungal contamination 
during the cell sorting process.  
MACS sorting can be done in a sterile environment, such as a class II 
biological safety cabinet, and as the aim for these cells is for them to ultimately 
be used in patients, this method was deemed to be the most appropriate. 
Miltenyi did not have aTCR MACS beads available, so a two-step method was 
used where aTCRαβ-biotin antibody was used to bind the T cells, followed by 
incubation with streptavidin MACS beads. The bead-labelled cells were then 
run through a MACS column, with the positive and negative fractions being 
separated and recovered for 48hrs before they were analysed by FACS 
(Figure 71). 
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As can be seen, the viability of the cells is maintained in the TCR positive 
fraction, but the TCR negative fraction was very low, around 1% based on a 
FSC/SSC live/dead gate. Therefore it can be said that the MACS selection has 
worked, but the viability of the cells has been lost. 
Figure 71 – MACS sorting of TALENised T cells. Cells were stained with aTCRαβ-
biotin antibody before being incubated with Streptavidin MACS beads. Cells were 
then passed through a MACS column, with the flow-through fraction labelled as the 
TCR negative fraction and the bound fraction as the TCR positive fraction. NT – 
non-treated. Repeated once. 
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5.7 Conclusions 
 
In conclusion, after trying multiple methods, partial knockdown of the TCR was 
achieved. Several key discoveries were made during this process, which could 
lead to further investigation and further attempts to modify TCR and/or T cell 
signalling in order to provide alternative immunotherapeutic treatments. 
To begin with, aTCR antibodies were used to target the TCR. These aTCR 
antibodies were shown to bind to the TCR, and were then modified with an ER 
retention sequence attached to the C terminal end of the protein. This was 
aimed at causing the naïve TCR to be retained in the ER and prevent cell 
surface expression. What was seen was partial apparent knockdown of the 
TCR in both the transduced and non-transduced cells. After using techniques 
such as co-cultures and transwells, the most likely explanation for this 
phenomenon is that the aTCR-SEKDEL constructs were binding to the TCR 
but were not able to cause ER retention. When expressed on the cell surface, 
the TCR-aTCR-SEKDEL complex blocked the fluorescence-conjugated 
antibody from binding, therefore giving an apparent knockdown in cell surface 
expression of the TCR. It also appeared that the cell surface expressed aTCR-
SEKDEL constructs were able to bind TCRs on the cell surface of 
neighbouring T cells, resulting in the apparent knockdown of TCR on non-
transduced cells. The key discovery here was that this showed that the 
constructs had the possibility of being flexible enough to bind to TCRs in a 
paracrine and autocrine way, which could lead to further investigation. 
As the above strategy was not highly effective, and because there were other 
unexpected effects seen, the CD3 molecule was targeted next, using the 
‘KKAA’ and E19 adenoviral ER retention sequences attached to the various 
CD3 components. No effect was seen by any of these constructs except for 
the CD3ε constructs, which only gave a small hint of any TCR knockdown 
effect; less so than previously seen with the aTCR-SEKDEL constructs. As 
this strategy failed, a slightly different tact was taken for the next strategy, 
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which was to add an ER retention sequence to the constant regions of the 
TCRα and TCRβ chains, with the aim of disrupting correct folding and cell 
surface expression. Of the three main ER retention strategies tested, this was 
the least effective and did not show any signs of success. 
Still sticking with the strategy of targeting the TCR and its signalling 
components directly, a construct containing ‘null’ CD3 components was 
designed and created. The CD3 components all lacked their ITAMs, with the 
aim of these components binding to the TCR in a competitive manner, and 
preventing TCR signalling and activation of the T cell. Intracellular IFNγ was 
used as the readout for this strategy, but unfortunately no effect was seen as 
a result. 
The penultimate strategy attempted was to use something found in nature, a 
bacterial superantigen. This was cloned based on a sequence obtained from 
a previous study, and an ER retention sequence was attached to see if this 
could improve the efficacy of the construct further. Unfortunately, no effect on 
TCR surface expression was seen as a result of transduction with the bacterial 
superantigen construct, so this strategy was not pursued. 
Finally, the last strategy tried was gene-editing TALEN molecules. Fortunately, 
these were donated from Cellectis Bioresearch, and therefore had been 
previously shown to cause TCR knockdown from the cell surface. The 
challenge was to be able to replicate this for this study, and also to build on it 
by adding other aspects of the project in order to combine as many aspects 
as possible. The replication itself was not easy, as the process of 
electroporation is quite a crude one, and often results in high amounts of cell 
death, and requires protocol optimisation in order to be able to recover as 
many cells as possible for downstream use. Once TCR knockdown had been 
shown, the TCRlo cells were also transduced with an aCD19-CAR that had the 
RQR8 sort-suicide gene as a marker gene. Around 25% of the cells had 
reduced levels of TCR cell surface expression, with the MFI being reduced 
from 294 to 169 (a drop of nearly 50%). The aim was to try and optimise this 
process in order to obtain as many TCRlo CARhi cells as possible, but 
unfortunately, it was not possible to do so. It was also shown to be possible to 
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sort the TCRlo and TCRhi populations by using MACS technology, but again, 
the TCRlo cells had a very low viability and succumbed to cell death within 
48hrs. This does show some promise, however, and since performing these 
experiments, it has been shown that it is possible to use TALENs to 
knockdown expression of the endogenous TCR in Jurkat and primary T cells 
at levels of 40-50% (Berdien et al. 2014). 
Despite these setbacks, it has clearly been shown that it is possible to cause 
partial knockdown of the TCR from the cell surface, and that it is possible to 
transduce these cells with a CAR in order to re-direct the targeting moiety of 
the T cells. Work done by Torikai et al. (2012) has reversed the order of T cell 
modifications to introduce the CAR first, followed by the TCR knockdown 
strategy (in this case, ZFNs). This may be another way of overcoming issues 
associated with cell viability in vitro. This provides a firm foundation for further 
investigation into the development of a universal T cell that can be used in 
adoptive immunotherapy. 
 
5.8 Final Conclusions 
 
 The OKT3 and BMA031 antibodies are both able to bind to the TCR. 
 The ER retention sequences, ‘SEKDEL’ and ‘KKAA’ and the E19 
adenoviral retention sequence were ineffective in achieving TCR 
knockdown when attached to aTCR antibodies, CD3 components or the 
TCRα/β constant chains. 
 The aTCR-SEKDEL constructs caused an unusual effect of blocking 
TCRs on neighbouring non-transduced cells. 
 Removing the ITAMs from the various CD3 components was ineffective 
at causing TCR knockdown. 
 The bacterial superantigen SMEZ-2 was unable to cause TCR 
knockdown. 
 TALEN molecules directed towards the TCRα constant chain were 
effective at causing partial TCR knockdown in around 25% of treated 
cells. 
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 TALENised T cells could be transduced with a CAR. 
 TCRlo and TCRhi fractions were able to be separated by the use of 
MACS technology. 
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Chapter Six: 
Discussion 
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6.1 Study conclusions 
 
With the efficacy ‘ceiling’ drawing closer for traditional chemotherapeutic 
agents, there has been an increased use of adoptive immunotherapy to treat 
cancer in the past few years. It is becoming increasingly clear that the human 
body can be more effectively treated by modification of cells that are already 
present rather than by introducing external, foreign agents. What is also 
becoming clear is that there are two possible routes for the potential 
development of adoptive immunotherapy treatments. One is the highly 
personalised route, whereby treatments are designed and created based on 
the individual’s need, which could potentially result in more effective treatment 
of disease. The second route is the universal route, whereby one treatment is 
developed in order to treat a disease in multiple patients rather than on a case-
by-case basis. This is much quicker and cheaper, but has an increased risk of 
adverse events and unwanted side effects. That is not to say, though, that 
these two development routes are mutually exclusive. Ultimately, universal 
treatments will be modified, in terms of factors including dosage and time, in 
order that they may be as personal as possible. That is why many of the major 
pharmaceutical companies are currently investing in biological research 
programs as this is the new frontier where diseases, such as cancer, will be 
tackled in the coming years. 
Adoptive immunotherapy has already been shown to be effective in numerous 
settings, including GvL (Bonini et al. 1997; Casucci, Perna, et al. 2013), CMV 
(Riddell et al. 1992, Walter et al. 1995, Einsele et al. 2002, Peggs et al. 2003), 
to reconstitute EBV immunity in post-transplant lymphoproliferative disease 
(PTLD) (Heslop et al. 1994a, Rooney et al. 1995) and in the use of TILs for 
metastatic melanoma (Rosenberg et al. 2008). Clearly, there is rapid progress 
in the development of these therapies, but they do have their limitations. The 
current issue with these forms of adoptive immunotherapy is that they are 
mainly based on personalised therapies, where the patients’ own cells have 
been extracted and modified before reinfusion. As a result, the cells 
themselves may be unhealthy due to the ongoing treatment regimen and 
disease load on the patient, and the time and cost of extracting, modifying, 
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expanding and reinfusion of patient cells is significant. As such, development 
of a universal T cell could circumvent many of these issues and also 
significantly reduce the time taken from diagnosis to initiation of adoptive 
immunotherapy treatment. Once a diagnosis has been made, pre-engineered 
T cells could be thawed, expanded in vitro and then delivered to a patient 
within a couple of weeks. As a result, this study was initiated in order to 
investigate the genetic engineering and manipulation of cells required to 
develop a universal T cell. Various avenues of molecule knockdown have been 
tested in primary and secondary cell lines, with the results showing that it is 
possible to achieve surface expression knockdown of both HLA Class I and 
also the TCR, as well as increasing HLA-G and RQR8 expression. 
For the HLA Class I knockdown, 16 different constructs were cloned. The aim 
of achieving HLA Class I knockdown was to prevent the allogeneic responses 
triggered upon recognition of foreign HLA by the recipient. These constructs 
comprised various methods of achieving HLA Class I knockdown, including 
variants of a mutant β2m molecule, designed to interfere with the correct 
folding of naïve HLA Class I. A previous study has shown that, at high (µM) 
concentrations, a mutant β2m molecule was able to block HLA Class I 
molecule folding. Also demonstrated was the ability of the dominant negative 
β2m molecule to block T cell functional responses to peptide-loaded HLA 
Class I molecules (Hill et al. 2003). siRNA was also tested, two of which were 
replicated from previous studies (Gonzalez et al. 2005; Haga et al. 2006) and 
the rest which were designed using an online tool. Again, these were directed 
at β2m, with the aim of preventing HLA Class I assembly due to a lack of β2m 
in the cell. Antibodies directed to β2m were also cloned and attached to an ER 
retention sequence in order to prevent cell surface expression of HLA Class I. 
Two antibodies were replicated from a previous study (Mhashilkar et al. 2002) 
and one was extracted from the BBM1 hybridoma (LGC 2012). Finally, two 
viral proteins, US11 and ICP47 were cloned into the SFG backbone, with 
ICP47 previously shown to interfere with peptide loading  and US11 shown to 
cause degradation by the proteasome as a result of ubiquitination of the HLA 
Class I molecule (Radosevich et al. 2003). All 16 constructs, with the exception 
of the viral proteins, were targeted at the β2m molecule, which is seen as 
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essential to the expression of HLA Class I molecule, and key to allowing exit 
of the HLA Class I molecule from the ER and Golgi apparatus. As with the 
TCR, there may have been too much β2m expressed in a cell for the 
constructs to be successful at achieving HLA Class I knockdown. All 
constructs were tested in SupT1s, with the constructs giving the most 
knockdown being taken forward and tested in primary cells. The two viral 
proteins gave the highest levels of HLA Class I knockdown in primary cells, 
and US11 in particular seemed to be the more effective of the two constructs.  
These were tested in a functional proliferation assay in an allogeneic context, 
and showed evidence of a reduction in effector cell proliferation when 
compared to target cells that had not been modified with the viral proteins. 
Ideally, the results seen in the studies by Berger et al. (2000) and de la Garza-
Rodea et al. (2011) would have been replicated to fully demonstrate the 
reduction in CD8+ T cell response to HLA Class I negative cells as a result of 
the use of viral proteins, and this is something that would need to be worked 
on further. The populations of target cells used in this functional assay were 
homogenous as the HLA Class I knockdown strategies had been combined 
with the RQR8 sort-suicide gene, which allowed for sorting of HLA Class I 
negative cells using the Miltenyi MACS system. The HLA Class I knockdown 
aspect of the study was particularly pivotal as it was designed to prevent the 
therapeutic cells from being rejected by the recipient’s immune system (Li & 
Sykes 2012; Game & Lechler 2002). It is clear therefore, that HLA Class I 
knockdown is needed in order to progress with the development of a universal 
T cell. It is unclear how much effect HLA Class II molecules have upon effector 
cell proliferation, but it is likely that HLA Class I is responsible for the majority 
of the allorecognition by recipient cells, as it is shown to mainly interact with 
the CD8 molecule on T cells (Barclay et al. 1997; Britten et al. 2002). Inhibition 
of this CD8-HLA Class I interaction would therefore cause the greatest amount 
of reduction in allorecognition. Despite this, it is highly likely that the CD4-HLA 
Class II interaction is also responsible for a proportion of the allorecognition. 
Molecules such as Class II-associated invariant chain peptide (CLIP) could be 
targeted, or the use of blocking antibodies could be investigated in order to 
interfere with HLA Class II expression and function. 
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To address the issue of NK-cell mediated killing of HLA Class I null cells, HLA-
G has also been introduced to primary and secondary cell lines, including 
Jurkats, SupT1 cells and PBMCs. The isoform chosen was HLA-G1, which 
contained the three membrane-bound α subunits, which would associate with 
the β2m subunit before progressing to cell-surface expression. HLA-G1 was 
cloned from genomic DNA and inserted into an SFG vector containing a 
marker gene. Generation of retroviral supernatant and subsequent 
transduction into cell lines resulted in HLA-G expression that was detectable 
by FACS analysis. Before attempting to determine the functional effect of this 
strategy, it was decided to combine the HLA-G expression with the HLA Class 
I knockdown strategy. One possible conflict between the two was that, if HLA-
G was a similarly structured molecule to HLA Class I, then the HLA Class I 
knockdown strategies may have impacted on HLA-G expression. From 
multiple tests in SupT1s and PBMCs, it appears that it is possible to co-
express these two strategies, but that it did appear that the HLA Class I 
knockdown did cause a reduction in HLA-G expression. This may have been 
due to the mechanism of ICP47 blocking peptide entry via the TAP molecule. 
If this is the case, then there may be a suggestion that HLA-G has some 
previously unknown antigen presenting properties, which would warrant 
further investigation outside of this project. With US11, this may have caused 
a reduction in HLA-G expression if it recognised a common epitope on a HLA 
Class I molecule on HLA-G, which, in terms of its structure, may well have 
been the case. The results seen here contrast with the study by Schust et al. 
(1998), which appear to demonstrate the efficacy of HLA-G, HLA-Cw*0401 
expressing JEG 3 cells at resisting rapid degradation associated with the 
presence of US11. There may be a difference in mechanisms between an 
immortalised cell line and primary cells that may account for this, but this would 
need to be investigated thoroughly. Again, due to the ambitious nature of this 
project, this was the limit of testing achieved for this strategy, but good 
progress has been made in investigating this aspect of universal T cell 
development. 
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Finally, TCR knockdown was investigated by numerous strategies, including 
ER retention, blocking of TCR/CD3 signalling and by genome-editing 
molecules. Unfortunately, all of these strategies, except for the TALEN 
molecules, failed to be successful at achieving TCR knockdown. Initially, the 
ER/Golgi retention strategy looked to have been working to some extent. On 
further evaluation, it seems as though the retention is not taking place despite 
the OKT3 and BMA031 scFvs binding to the TCR. One aspect of this that may 
be worth further investigation is the blocking of the TCR by the aTCR 
antibodies, which could effectively block TCR signalling. Another possibility 
could be to express these aTCR antibodies on the cell surface, protruded from 
the cell surface by a long flexible linker, which may allow the antibody to bind 
and block the TCR in an autocrine or paracrine manner. This may also be a 
way of blocking other cell surface signalling molecules, and it is worth 
investigating strategies such as adding a linker to an antibody in order to allow 
it to loop back and block ligand binding or signalling transduction of cell surface 
molecules. 
Trying to target other aspects of the TCR signalling complex, such as CD3, by 
the ER retention strategy was also ineffective. With the CD3 strategy, the CD3 
components may get retained too early in the assembly to be incorporated 
with the TCR, although one study does suggest that COPI retention in TCR 
assembly is caused by a region of the CD3 epsilon component, which is 
masked once assembly is complete (Mallabiabarrena et al. 1995). Despite 
slight effects seen by the CD3ε retention constructs, it seems as though this 
strategy did not work either. Subsequently, introducing a null CD3 construct, 
which lacked the individual component endodomains was tried in order to 
prevent TCR signalling. This was unsuccessful when analysed by intracellular 
cytokine staining. Many of these approaches may have been partially 
successful, but due to the high levels of TCR expression on the T cell, may 
have had a comparably negligible effect.  
The direct approach was to use TALENs to target the TCR at the genomic 
level. Although the efficiency of this process can vary, when compared to 
transgene expression methods, it is very effective at disrupting a gene locus. 
TALENs obtained from Cellectis Bioresearch were successful at achieving 
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TCR knockdown. This targeted the TCRα constant gene, resulting in a 
reduction of TCR expression. For the electroporations successfully achieved, 
partial knockdown was shown to be present. This may not have been complete 
knockdown as the knockdown of TCR would result in a loss of signal activation 
and the subsequent loss of some survival signals, leading to a reduction in 
TCRlo cell viability. In the timeframe of this project, unfortunately it was not 
possible to fully optimise the protocol needed in order to achieve repeatable 
and reliable electroporation that resulted in consistent levels of TCR 
knockdown, nor was it possible to develop a protocol that allowed for the 
selection of the TCRlo T cells using the Miltenyi MACS system. Subsequently 
it was not possible to elucidate the functional effect of the TCR knockdown 
that was achieved. 
Alongside the TCR knockdown, it was also shown to be possible to express a 
CAR in the T cells, which would re-direct the T cells that had lost TCR 
expression. In this way, it may be possible to prevent the unwanted GvHD 
effect, and also to target the T cells to a target of choice. The CAR would also 
provide the survival signals necessary for the T cells to survive and persist in 
vitro and in vivo. The CAR was able to be expressed in a small proportion of 
the TCRlo cells, and the CAR was combined with the RQR8 sort-suicide gene 
that could allow for selection of modified T cells once a protocol has been fully 
developed.  
CARs have now progressed to the third generation, with intracellular signalling 
domains becoming more robust in their activities, such as 4-1BBL, CD28 and 
OX40. Currently in the Pule group, the CD28 molecule is used as the 
endodomain, although a recent study has shown that using the 4-1BBL in the 
endodomain improves persistence of transduced cells in vivo (Song et al. 
2011), so this could be investigated further. As well as the endodomains, the 
CAR work could also look into the type of viral vector that could be used in a 
potential clinical setting. So far, a retroviral packaging cassette has been used, 
but the ability of lentivirus to transduce quiescent T cells may be preferential, 
as stimulated T cells will terminally differentiate and therefore persist less in 
vivo. The envelope used to make the lentivirus could also be investigated as 
a recent study suggested that the measles envelope proteins haemagglutinin 
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(H) and fusion (F) are more efficient at quiescent T cell transduction than the 
commonly used VSVg envelope (Frecha et al. 2008).  
 
6.2 Sort-suicide gene 
 
The RQR8 sort-suicide gene developed by Brian Philip has also been 
incorporated into some of the above strategies, including the HLA class I 
knockdown and the introduction of a CAR to the T cells. In this study, RQR8 
has been shown to be useful in cell sorting transduced from non-transduced 
populations, and in other work (Philip et al. 2014), has been demonstrated to 
be susceptible to Rituximab in in vitro and in vivo models. This has the dual 
function of being able to allow for clinical grade sorting of transduced cells, 
creating a homogenous population of therapeutic cells. The suicide gene also 
allows for rapid depletion of the therapeutic cells in case of a serious adverse 
event, such as the ones previously discussed. Depletion of therapeutic cells 
would prevent any further stimulation of the recipient’s immune system and 
may reduce the effects and consequences of severe adverse events.  
This study has included the RQR8 sort-suicide gene in combination other 
strategies, but the only function investigated in this study is the clinical grade 
sorting, which has proven to be effective. Analysis of efficacy as a suicide 
system would be needed for this project in order to determine which cancers 
would be amenable to this system. Currently, the suicide gene is a minimal 
CD20 epitope, recognised by the monoclonal antibody Rituximab. Rituximab 
recognises CD20, which is expressed on B cells, therefore use of this epitope 
as the suicide system would result in B cell depletion in the patient. It also 
prevents use of the therapeutic cells in any patient with B cell cancers and any 
patient already receiving Rituximab treatment. If it were possible to 
interchange the suicide gene epitope depending on the disease being treated, 
this would be a huge advantage over other suicide systems. 
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6.3 Additional obstacles of adoptive immunotherapy to overcome 
  
Adoptive immunotherapy is a vast area, and as it involves manipulating the 
immune system, there are many facets of this subject that need to be 
investigated. This study investigates some of them, but there are others that 
have been omitted due to practical and time constraints. Other aspects to 
consider include the role of minor histocompatibility antigens (mHags), 
persistence of therapeutic cells, ex vivo expansion of therapeutic cells, 
immunogenicity of transgenes and the functionality of this whole approach in 
solid tumours.  
 
6.3.1 Minor histocompatibility antigens 
 
During allograft transplantations, recipients and donors have their HLA types 
matched in order to reduce the risk of allograft rejections as much as possible. 
Despite this, allograft rejection occurs even when donors and recipients are 
matched by their six major HLA alleles. One of the reasons for this is mHags. 
mHags are disparities in molecules outside of the MHC antigens, and when 
expressed on recipient cells and not donor cells, results in the donor T cells 
being stimulated by these mHags, leading to GvHD. The two main categories 
of mHags are sex-linked and non-sex-linked. The sex-linked mHags are ones 
that are expressed on the Y chromosome in males, and not in females. One 
study, by Miklos et al. (2005), looked at this set of mHags on the Y 
chromosome (H-Y). Each of these H-Y genes has an X chromosome homolog, 
which is found to be between 91-99% identical at the amino acid level (Lahn 
& Page 1997). Males develop tolerance to these; female T cells are capable 
of being activated by H-Y derived antigens following transplantation into male 
recipients (Wang et al. 1995). The study by Miklos et al. (2005) found that  
male patients with female donors were found to have a significantly greater 
frequency of antibody response that male patients with male donors. This 
antibody response has also been further characterised and been shown to be 
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high-titre and potent due to the combined response of both B and T cells to 
the H-Y antigens (Zorn et al. 2004). 
One of the most commonly studied mHags involved in GvHD is HA-1. This 
mHag is recognised by HLA-A*0201 restricted CTLs and is present in around 
69% of the HLA-A*0201-positive population (den Haan et al. 1998). Data from 
a previous study has shown a significant correlation between the presence of 
a HA-1 mHag mismatch and the incidence of GvHD in adult recipients of bone 
marrow, from genotypically HLA-identical donors. Whenever a HA-1 positive 
recipient received an allograft from a HA-1 negative donor, grade II or higher 
GvHD developed (Goulmy et al. 1996). Clearly, this needs to be taken into 
consideration in adoptive immunotherapy and this project, as, although HLA 
Class I has been knocked down, at the moment, it would be unfeasible to 
remove all of the HLA and mHags from the cell surface. Matching donors with 
recipients needs to be based on more than the traditional HLA major allele 
matching, although matching will never be perfect, even between siblings. 
 
6.3.2 Persistence of therapeutic cells 
 
Persistence of therapeutic cells is a key factor that needs to be taken into 
consideration. If cells do not persist for long enough, then the chances of 
tumour elimination are lowered and there is a higher chance of relapse. Whilst 
CAR therapies have been shown to be successful in treating malignancies in 
certain settings, poor persistence of therapeutic cells has caused poor clinical 
trial results. A phase I clinical trial for the treatment of metastatic ovarian 
melanoma using CARs directed against α–folate receptor (aFR) did not cause 
tumour regression due to poor persistence of the CAR T cells, and the lack of 
localization to the tumour (Kershaw et al. 2006). One way of improving 
persistence has been to introduce CARs into antigen-specific T cells against 
viral infections including EBV and CMV. These EBV or CMV-reactive T cells 
will be stimulated by any latent infection in the recipient, allowing for another 
method of co-stimulation in vivo (Savoldo et al. 2007; Di Stasi et al. 2009). One 
way of using an aspect of this project could be to create a third party bank of 
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HLA Class I negative EBV-CTLs which could be used in PTLD. These cells 
would not cause GvHD as they would be EBV-specific (Haque et al. 2007). By 
introducing resistance to Tacrolimus through the use of a calcineurin mutant, 
these EBV-CTLs could also be used as a therapy for someone undergoing 
immunosuppressive therapy (Brewin et al. 2009). 
Enhanced in vivo persistence has been seen when therapeutic cells are 
expressing high levels of co-stimulatory receptors, suggesting that this is 
required for improved persistence (Powell et al. 2005; Zhou et al. 2005). As a 
result, subsequent generations of CARs have been designed with additional 
co-stimulatory domains, including CD28 intracellular domain, OX40 and 4-
1BB. This results in CAR stimulation being able to enhance cytokine secretion 
and anti-tumour efficacy (Carpenito et al. 2009; Imai et al. 2004; Moeller et al. 
2004). A study was carried out using various combinations of intracellular 
signalling domains for a CAR, where CD28, 41BB and CD3ζ were used. The 
CAR containing all three domains was found to be the strongest at promoting 
cytokine release, in vivo persistence and tumour elimination. Upon CAR 
stimulation, the strongest activation signals were obtained alongside the least 
induction of apoptosis in the therapeutic cells (Zhong et al. 2010; Kowolik et 
al. 2006). Therefore the design of the intracellular CAR signalling domains 
needs to be based on the best combination in order to elicit the optimal 
activation signals, driving the best tumour clearance possible and maintaining 
persistence in vivo. This can also be enhanced by performing codon 
optimisation to humanise any non-human domains to ensure immunogenicity 
risks are kept to a minimum. 
 
6.3.3 Ex vivo expansion of therapeutic cells  
 
Related to the obstacle of persistence, the ex vivo manipulation of the 
therapeutic cells needs to be determined also. When transducing T cells with 
viral supernatant containing transgenes, T cell stimulation needs to be used in 
order to stimulate proliferation, allowing for successful uptake of the relevant 
transgenes. Transduction efficiency needs to be as high as possible in order 
232 
 
232 
 
to retain as many viable modified T cells as possible; therefore the stimulation 
protocol needs to be optimised.  
Aspects to take into consideration include method of stimulation, duration of 
stimulation and type of viral preparation used in transduction. There are 
various protocols that have been used in the stimulation of T cells from 
PBMCs. Examples include performing cell selections to purify the T cells from 
PBMCs before providing cytokine stimulation, or adding cytokines that will 
stimulate T cells specifically from PBMCs. Both of these methods are then 
followed by transduction using viral supernatant containing the transgenes of 
interest. Currently, for autologous adoptive immunotherapy, it takes a few 
weeks for cells to be extracted, expanded, modified and prepared before they 
can be reinfused to the patient. In an allogeneic setting, it would be possible 
to have universal T cells ready to go, ‘off the shelf’, with the only delay being 
in the preparation of the cells for infusion, for example, thawing the cells from 
cryogenic storage.  
Instead of using soluble cytokines to stimulate T cells, recent research has 
focused on the use of artificial antigen presenting cells (aAPCs) as the method 
of T cell stimulation. Magnetic beads coated with anti-CD3 and anti-CD28 
antibodies were initially tested, which were found to stimulate long-term growth 
of CD4+ T cells, but were not found to be able to induce long-term growth of 
CD8+ T cells (Levine et al. 1997; Deeths et al. 1999). Co-stimulation was 
added by generating a K562 cell line that expressed CD32 and 41BB ligand 
(41BBL). These cells were also coated with anti-CD3 and anti-CD28 
antibodies, and this was found to enable the long-term growth of CTLs (Maus 
et al. 2002).   
The subset(s) of T cells being manipulated also needs to be taken into 
account. CD4+ T cells are most commonly involved in the development of 
memory, and therefore are less efficient at inducing cell death. CD8+ T cells 
are very adept at inducing cell death and eliminating target cells, but are less 
capable when it comes to developing a memory response. A balance of the 
two is needed if prolonged immune response to a particular cancer antigen is 
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required, so that the initial tumour can be targeted by CTLs, and so that 
persistence is maintained through the development of CD4+ memory. 
The differentiation of the T cells can also have an impact on persistence. If T 
cells have been kept in ex vivo culture for too long, then they may become 
terminally differentiated, resulting in a reduction in proliferative capability, and 
a subsequent reduction in long-term in vivo persistence when transferred into 
the patient. The more mature and differentiated the therapeutic cells are, the 
less they will be able to proliferate, and therefore persistence will be shorter. 
It has been shown that naïve or central memory T cells persist and engraft to 
a greater extent than terminally differentiated T cells (Berger et al. 2008; 
Hinrichs et al. 2009; Klebanoff et al. 2011). When transducing T cells, the type 
of viral supernatant affects how much stimulation the T cells receive during ex 
vivo manipulation. When using retrovirus, cells need to be actively proliferating 
in order to retrovirus to be taken up and for successful integration into the 
genome. Therefore, cytokine stimulation is required for efficient transduction. 
Retrovirus also tends to be associated with very low or undetectable levels of 
site-directed mutagenesis (Newrzela et al. 2008). Lentivirus is able to integrate 
into the host cell genome of quiescent cells, which provides an advantage if 
the aim is to minimise the amount of cell stimulation provided ex vivo (Cooray 
et al. 2012; Dufait et al. 2012). The drawback with lentivirus is that it is harder 
to achieve high levels of gene transfer, with typical ranges in clinical trials 
being between 5-23%, although protocol modifications are investigating 
whether the use of cytokines might improve this (Kalos et al. 2011; Gilham et 
al. 2012). 
 
6.3.4 Functionality of therapeutic cells in solid tumours 
 
Currently, CAR+ T cells have been used in lymphomas, leukaemias and 
melanomas with clear effects. The next area of development of T cell therapy 
is in targeting solid tumours. The main obstacle here is finding a target antigen 
that is stably and exclusively expressed on tumour cells. Initial studies for 
CAR+ T cells targeting carbonic anhydrase IX (CAIX) and aFR proved to be 
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unsuccessful in producing an effective outcome (Kershaw et al. 2006; Lamers 
et al. 2006).   
An example of a solid tumour target is GD2, a disialoganglioside that is highly 
overexpressed in melanoma, neuroblastoma and Ewing sarcoma (Kailayangiri 
et al. 2012; Han et al. 2013). An additional obstacle with solid tumours is the 
reduction in vasculature compared to haematological cancers, which are 
present in the circulation and bone marrow niche. 1cm3 of solid tumour can 
contain 109 cells, therefore high numbers of CAR+ T cells need to home to the 
site in order to elicit an effective response. CAR+ T cells also need to persist 
and function in this immunosuppressive environment, and a lack of co-
stimulatory molecule expression makes this a difficult issue to solve (Rossig 
2013; Pedrazzoli et al. 2012).  
 
6.4 Further work  
 
There is clearly plenty of remaining work to be done on this project – this thesis 
investigated the beginnings of several aspects needed to develop a universal 
T cell. Work remaining on these aspects and other aspects not yet investigated 
are discussed in the following sections. 
 
6.4.1 Validation of TCR knockdown 
 
The work done so far on knockdown of the TCR has resulted in the 
demonstration of cell surface knockdown in T cells caused by TALEN 
molecules directed against the TCR α chain. What has yet to be demonstrated 
is the effect that this has on the T cell function. Several key checkpoints need 
to be passed in order to determine whether this strategy is one that can be 
pursued further.  
The reason for investigation TCR knockdown is in order to prevent or reduce 
GvHD induced by donor therapeutic cells when given to the recipient. 
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Therefore, these TCRlo T cells need to show a reduction in GvHD in an 
allogeneic setting. It has also been shown that it is difficult to maintain cell 
viability of the TCRlo T cells, as keeping them in culture for a short amount of 
time results in large amounts of cell death when analysed by FACS (see 
Chapter Five). This could be due to a lack of survival signals that are normally 
received through the TCR, due to other cells, such as NK cells in the culture 
targeting the TCRlo T cells for cell death, or a combination of both.  
It is unlikely that it would be possible to demonstrate a reduction in GvHD if 
using just TCRlo T cells against an allogeneic donor. Simultaneous, or 
subsequent introduction of a CAR is required in order to maintain cell viability 
and allow for a demonstration of a lack of GvHD. Introducing a CAR, though 
requires the use of a target cell line that expresses the CAR target, and 
therefore means that an assay needs to be developed to assess a reduction 
in GvHD and the efficacy of the CAR against its target. One way to 
demonstrate this in vitro may be to use an engineered SupT1 cell line that 
expresses the CD19 molecule. In Dr Pule’s research group, this cell line 
already exists to validate CARs directed against CD19 for use in B cell 
malignancies. TCRlo aCD19-CAR+ T cells could be used against various cell 
lines, including CD19-SupT1s to demonstrate CAR efficacy against the CD19 
target, and also to demonstrate a lack of activity against the unmodified SupT1 
cell line. This could be done in the form of a 51Cr release assay, and 
unmodified T cells could be used as a positive control to demonstrate the usual 
levels of GvHD in this assay. Cell viability would also be assessed in order to 
determine if the CAR molecule was able to provide sufficient survival signalling 
for the TCRlo CAR+ T cells to persist over extended periods of time.  
A study performed since the conclusion of these experiments has 
demonstrated effective knockdown of the TCR by the use of TALENs directed 
against either the TCRα or the TCRβ chains. In particular, one TALEN directed 
against the TCR-α2, in three different donors and six experiments, increased 
the proportion of TCR-negative cells from 5.6% (+/-1.1%) in mock-transfected 
cells to 58.5% (+/-15%) in cells transfected with the TALEN-TCRα2 mRNA. 
This was further supported by sequencing of 17 clones, which demonstrated 
genomic deletions in the TCR-α2 locus in nine of these clones (53%). These 
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TCR negative cells then had a transgenic TCR introduced and were shown to 
be functional, secreting a significantly higher amount of IL-2 and IFNγ when 
stimulated with APCs bearing a Flu tetramer (Berdien et al. 2014). This 
demonstrates that it is possible to knockdown the endogenous TCR and to 
then subsequently redirect a cell’s specificity with a transgenic TCR. This 
study, amongst others, would form the basis for repeat experiments studying 
the effect of the TALENs used in this thesis. An aspect of the study by Berdien 
et al. (2014) that would need to be streamlined would be the protocol. In the 
study, the protocol involved TCRα knockdown, followed by the enrichment of 
TCR negative cells by CD3 depletion. These TCR negative cells were then 
transduced with the transgenic TCRα chain. Following this, TCR positive cells 
were selected by FACS sorting before being treated with TALENs against the 
TCRβ locus. TCR negative cells were enriched by a further CD3 depletion 
before these were transduced with the transgenic TCRβ chain. This created a 
population of T cells that were negative for endogenous TCR and positive for 
the transgenic TCR. A similar strategy was used by (Provasi et al. 2012) using 
ZFNs instead. It is a complex and lengthy process that could be improved with 
the use of CARs as the transgene instead. This would allow for knockdown of 
the TCR by targeting one chain, followed by a sort and transduction with the 
CAR transgene. There would not be the risk of the endogenous TCR pairing 
with the transgenic TCR that had to be circumvented by the above study, and 
would also mean that only one electroporation, depletion and transduction 
step would be needed; a protocol that could be completed in less than two 
weeks.  
Another approach that has been recently developed is the Clustered Regularly 
Interspaced Short Palindromic Repeats (CRISPR) and CRISPR Associated 
(Cas) systems. The CRISPR system in bacteria relies on the acquisition of 
foreign DNA fragments into CRISPR loci in the bacterial genome, which then 
undergo transcription and processing into CRISPR repeat-spacer arrays into 
short CRISPR RNAs (crRNAs). The crRNAs then anneal and become a trans-
activating crRNA (tracrRNA), which direct sequence-specific silencing of 
foreign nucleic acid by the mechanism of the associated Cas proteins (Hwang 
et al. 2013). Synthetic guide RNAs (gRNA) can be adapted from the system in 
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order to guide a nuclease to a specific DNA site and then cause a DSB. To 
date, some of the applications for this technology has involved screening for 
disease-related genes and generation of knockout models (Shalem et al. 
2014; Yang et al. 2014; Gaj et al. 2013; Li et al. 2013; Xiao et al. 2013). Clearly, 
the use of CRISPR in TCR knockdown is a strategy that needs investigating, 
as there is currently no literature published in this area. 
 
6.4.2 Functional validation of HLA-G transgene 
 
As with the work on TCR knockdown, the functionality of HLA-G has not been 
evaluated yet; therefore the next steps need to be the functional testing in 
MLRs and to test NK cell activity in response to HLA-G expressing cells. The 
K562 cell line is HLA Class I negative, as discussed earlier, therefore 
introducing the HLA-G transgene to these cells would allow for testing of the 
functional effect of HLA-G. A proliferation assay or a cytokine release assay 
would be suitable for assessing this.  
 
Although HLA-G is a non-classical HLA molecule, it does share similarities 
with HLA Class I molecules, and this was shown when attempting to co-
transduce the SupT1 cell line with the HLA Class I knockdown and HLA-G 
transgenes (Figure 40). When attempting to do this, the level of HLA-G 
expression was quite low, suggesting that the ubiquitination caused by the 
US11 transgene might also target HLA-G. Therefore, in case it proves to be 
unviable to co-express the HLA Class I knockdown and HLA-G transgenes in 
the same cell, alternative strategies need to be investigated, such as HLA-E, 
HLA-F and UL142. UL142 is a HCMV derived protein that is heavily 
glycosylated and is expressed during late stage infection. Knockdown of 
UL142 by siRNA in HCMV-infected cells resulted in an increase in vulnerability 
to NK cell killing, suggesting that this molecule has a role in inhibition of NK 
cell activation (Wills et al. 2005). If HLA-E and HLA-F also have structural 
similarities to HLA Class I, then UL142 may be a viable alternative for inhibition 
of NK cell lysis. Another option may be to use a genomic-targeting strategy, 
as was demonstrated by Torikai et al. (2013) in the use of ZFNs. 
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6.4.3 Combination of strategies 
 
The key to this project is the ability to combine the strategies that have been 
successfully tested. The initial aim was to have one viral cassette that 
contained all of the transgenes, separated by the FMD 2A self-cleaving 
sequence. This would have allowed for one transduction to be performed, 
followed by cell recovery and MACS-based cell sorting, resulting in a 
homogenous T cell product that could be used for adoptive immunotherapy. 
As this project has progressed, a slightly different approach has been 
developed, as not all strategies were successful at a protein level, so a single 
viral cassette is no longer possible. If the strategies tested were to be 
combined, then a viral cassette could be developed that contained the HLA 
Class I knockdown, HLA-G, CAR and sort-suicide transgenes. For the TCR 
knockdown, this would need to be done through the electroporation of RNA 
into the T cells; therefore a two-step protocol looks more likely.  
During the project, it has been possible to combine some of the strategies 
together and expression of them has been demonstrated, although 
functionality in these combinations has not necessarily been shown. HLA 
Class I knockdown strategies were combined with the RQR8 sort-suicide gene 
(Figure 25 and Figure 27), and the CAR was also combined with the RQR8 
sort-suicide gene (Figure 71). For these ‘double’ transgene constructs, 
expression of both elements was demonstrated, as well as the ability to use 
the RQR8 sort-suicide gene to sort the transduced cells to high levels of 
homogeneity. Although not in one viral cassette, it has been possible to co-
express the RQR8-2A-HLAko constructs alongside the HLA-G transgene, 
showing promise that these three have the potential to be combined. With 
more time to work on this project, the development of a construct that 
contained all these five transgenes would be a high priority once functional 
work had been performed on each of the strategies individually. For the RQR8 
sort-suicide gene, this has formed the basis of another project in the research 
group, which has clearly demonstrated that both the sorting and suicide 
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mechanisms are functional and effective in murine models (Philip et al. 2014). 
Once the strategies have been proved to be functional in vitro, individually and 
combined, the next step would be to test them in vivo, in a model organism, 
with the preferred model being a humanised SCID mouse model. This would 
allow for an allogeneic immune system to be developed in the mouse before 
the addition of tumour cells, followed by the therapeutic T cells, and would 
allow for a model that is humanised, preventing the need to optimise or modify 
transgenes for murine expression before testing.   
For each of the strategies, the following work needs to be done before they 
can be combined into a single viral construct. For the HLA Class I knockdown, 
the impact of the HLA knockdown needs to be fully quantified before 
introducing HLA-G to the HLA Class I negative T cells. MLRs can be 
performed with the HLA Class I negative T cells to determine the level of NK 
cell killing induced by the therapeutic T cells. This can be measured by cell 
viability analysis. Once this has been established, HLA Class I negative, HLA-
G-RQR8 positive T cells can then be used in an MLR with NK cells to 
demonstrate any reduction in NK cell killing activity. Further MLRs will also be 
used to test activation of the T cell effector population, which will have been 
transduced with the HLA knockdown and HLA-G transgenes, against target 
cells, to determine if a reduced response occurs as a result of the knockdown. 
NK cells will be depleted from these MLRs as they may skew results by killing 
the HLA knockdown cells, preventing quantification of T cell activation by the 
effector population.  
The RQR8-CAR construct will need to be tested in a 51Cr release assay to 
determine activity against the CAR targets. The effector cells will be sorted 
using the RQR8 sort-suicide gene before using them in the assay. The assay 
can also be performed in the presence, or absence of Rituximab in order to 
demonstrate lack of activity when the RQR8 suicide system is activated, and 
to demonstrate the successful killing of RQR8-CAR T cells in vitro. The 
TALENs directed against the TCR can then be incorporated into these assays, 
with there being an additional observation for the presence or absence of 
GvHD. RQR8-CAR+, TCRlo T cells can finally be tested in an allogeneic setting 
to demonstrate a lack of GvHD against the mis-matched cells, with activity only 
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present against CAR-targeted cells. Once the RQR8-HLAko-HLA-G construct 
and the RQR8-CAR construct have both been tested and shown to be fully 
functional in vitro, they will be combined to create one viral cassette. 
 
6.4.4 CD52 knockdown 
 
One additional aspect to this project was investigating the possibility of CD52 
knockdown from T cells. CD52 is a molecule expressed on lymphocyte cells 
and Campath-1H is a mAb used in the treatment of CLL amongst other 
malignancies (Domagała & Kurpisz 2001). It eradicates cells expressing 
CD52, both donor and recipient, treating the malignancy but leaves the patient 
vulnerable to infection (Ratzinger et al. 2003). If a patient, who is already 
receiving Campath-1H, is given therapeutic T cells, then they will be depleted 
by the Campath-1H treatment. By knocking down CD52 from the therapeutic 
cells, therapeutic T cells should persist in vivo.  
 
Multiple antibodies were found in a patent that bound to the twelve residue 
CD52 epitope (Roberts et al. 2010). Two of these antibodies were selected 
based on their recorded binding to the CD52 epitope – 7F11.1.9.7 recognises 
the first five residues of glycosylated CD52; 9D9.A2 recognises residues three 
to seven of the CD52 epitope, with no preferential binding to glycosylated or 
non-glycosylated CD52. Both of these antibodies were cloned, tested for 
binding affinity and then an ER retention sequence was attached to the C-
terminus. When retroviral supernatant was transduced into T cells, these two 
antibodies were unsuccessful at achieving CD52 knockdown. CD52 is 
normally expressed on the cell surface by a GPI anchor, therefore one other 
strategy tried was to attach the antibodies to a GPI anchor and aim to disrupt 
CD52 folding and assembly before reaching the cell surface. Again, this was 
unsuccessful. 
 
Despite this, there are TALENs targeted to CD52 that are able to achieve 
CD52 knockdown (Cellectis), so this now becomes a viable strategy to develop 
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therapeutic T cells that have a CAR, as well as being both TCR and CD52 
negative. These T cells would be able to be used to treat someone undergoing 
Campath-1H therapy, and could result in improved recovery rates and tumour 
clearance. 
 
6.5 Final conclusions 
 
Since beginning this project, there have been several studies done that have 
also investigated the development of T cells in adoptive immunotherapy, which 
need to be highlighted to show other approaches and strategies used to 
achieve similar aims to the ones that have been investigated here. A study by 
Torikai et al. (2012) looked at developing T cells that expressed an aCD19-
CAR and had endogenous TCR expression knocked down. The Sleeping-
Beauty (SB) transposon/transposase system was used to introduce ZFNs that 
targeted the TCR α or β chains. The aCD19-CAR was introduced using the 
SB system and the ZFNs were introduced by electroporation of RNA. 
Electroporation efficiency was up to 37%, and the CD3- T cells were enriched 
by multiple rounds of CD3+ depletion, resulting in populations of over 99% 
CD3- T cells. The engineered cells were demonstrated to have efficacy against 
CD19 expressing targets whilst remaining unresponsive to TCR stimulation. 
Propagation of these cells was also possible by using CD19+ aAPCs. This 
study was further built on by Torikai et al. (2013), which investigated the 
elimination of HLA Class I from the surface of T cells. Again, this was done 
using ZFNs, and resulted in an elimination of 52% HLA-A from the modified T 
cells. These HLA-A- CAR+ T cells were enriched to ~94% purity and could 
evade lysis by HLA-restricted CTLs, as well as maintaining their CAR activity. 
Inhibition of NK cell killing was also shown by expression of the non-classical 
HLA molecules, HLA-E and HLA-G, on HLA Class I negative 721.221 cells. 
These two studies show that there are major steps being made towards 
achieving the aim of developing a universal T cell for use in adoptive 
immunotherapy. The key difference between this project and these two studies 
is the method of achieving this aim. This project has aimed to combine as 
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many strategies as possible into one viral cassette, thus reducing the level of 
manipulation and complex protocol optimisation that is needed when using 
genome-editing nucleases such as ZFNs and TALENs. If the above two 
studies were to be combined, it would require multiple steps of electroporation, 
as well as multiple rounds of cell selections in order to obtain the desired cell 
population.  
 
Creation of a third party T cell would be a huge step forward as it would 
significantly reduce the costs and risks involved in adoptive cell therapy. HLA 
knockdown and TCR knockdown would reduce the risk of the alloreactions 
currently hindering allogeneic T cell therapies. Using a CAR allows re-direction 
of the T cell and a molecule such as HLA-G could ensure survival of the T cell 
by avoidance of NK cell killing in the recipient. Finally, a sort-suicide gene 
would allow clinical grade sorting of transduced cells and provides a 
mechanism to delete therapeutic T cells in the case of toxicity and/or adverse 
reactions. Combining these elements would provide the first steps towards the 
creation of a universal T cell and significantly reduce the time required for T 
cell engineering and provide an ‘off-the-shelf’ therapeutic for various 
malignancies. This project has investigated the first steps towards achieving 
this aim, and provides a body of work to help direct future developments. 
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